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iABSTRACT
Gastrointestinal (GI) nematodes are important helminth pathogens responsible for
severe losses to livestock industries and human health throughout the world. Control
of these infections relies primarily on chemotherapy; however there is rapid
development of resistance to all available classes of anthelmintic drugs, and therefore
new alternative treatments are urgently required.
Plant cysteine proteinases (CPs) from papaya latex, pineapple fruit and stem
extracts have been demonstrated to be effective against GI nematodes of rodents,
chickens, pigs and sheep. The current study extended evaluation of different plant
extracts and the factors affecting the efficacy of papaya latex supernatant (PLS) as an
anthelmintic against GI nematodes in a mouse model system and formulation and
delivery for use in ruminants.
The study started with purification and concentration of CPs in PLS using
different methods to determine which of them would provide high yield of CPs. It was
found that concentration by dialysis provided a high yield of active enzyme in PLS.
Storage of PLS at -20
0
C and -80
0
C retained more active enzymes for prolonged period
of time than at ambient temperature and 4
o
C. Motility assay conditions showed to
have no influence on enzyme activity. While the in vitro experiment results showed
significant detrimental effect of pineapple fruit extract, stem bromelain and little effect
of kiwi fruit extract against Heligmosomoides bakeri motility. In vivo experiments
showed less efficacy of these enzymes than expected when compared with PLS.
ii
The first factor to be assessed in this study was the effect of fasting on the
anthelmintic efficacy of PLS. The results showed that PLS was equally effective in
reducing worm burdens whether mice were fasted before treatment or not, and by
avoiding fasting the side effects of treatment were minimized. Comparison of efficacy
in a range of mouse strains indicated that efficacy varied between mice of different
genotype. At the dose used, the treatment was most effective in C3H mice ranging
from 90.5% to 99.3% in reducing worm burdens and less effective in NIHS, CD1 and
BALB/c strains (7.9%, 36.0% and 40.5% reduction respectively). However, host sex
and body size were shown not to have any influence on the anthelmintic efficacy of
PLS. Since CPs are particularly sensitive to pH, variation between mouse strains in
gut pH was investigated but no significant differences in pH were found along the GI
tract of the poor (BALB/c) and high responder mice (C3H) to PLS treatment and
concurrent administration of the antacid cimetidine also did not improve efficacy.
The study also explored the potential of formulation and delivery of PLS as an
anthelmintic drug for ruminants. In vitro studies involving both immediate and slow
release dosage formulations simulating the physiological conditions (pH, temperature
and peristaltic movement) in the GI tract of the animal were conducted. In the slow
release experiments, two hydrophilic matrices were tested, the xanthan gum and
hydroxypropyl methylcellulose (HPMC) (both Methocel-LVCR and Methocel-CR).
Methocel-CR provided better slow release results compared to the others. In the
immediate release experiments 3 disintegrants (Primojel, L-HPC and Ac-Di-sol) were
investigated and Ac-Di-Sol
®
was found to produce the faster immediate drug release
rate. Preliminary in vitro studies also showed that PLS was highly effective against
equine GI nematodes.
iii
Finally the empirical findings in this study provide useful information for
improvement of formulation and delivery of these naturally occurring plant-derived
enzymes for treatment of intestinal worm infections in humans and livestock, while
achieving maximum efficacy and minimal side-effects.
iv
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1CHAPTER 1: INTRODUCTION
1.0 Summary
Infections with Gastrointestinal (GI) nematodes have severe effects on human health
and cause serious economic losses in livestock farming. Cysteine proteinases (CPs)
from papaya latex have been demonstrated clearly to be powerful anthelmintics
against nematodes of rodents and sheep. Despite this finding, the enzymes have not
yet been developed to a market level for use as anthelmintic drugs. This chapter
provides a review of the importance of GI nematodes for human health and livestock
production and their life cycles, current methods available for their control and the
development of drug resistance. The chapter details the potential advantages of using
CPs as novel anthelmintics for humans and livestock and its formulation and delivery
system. It concludes with the objectives of the study which are:
1. To determine the best preparation method of PLS and storage conditions for long
term survival of the enzymes.
2. To evaluate the anthelmintic efficacy of CPs from sources other than papaya
latex including pineapple and kiwi extracts.
3. To assess the effect of fasting on the anthelmintic efficacy of papaya latex
supernatant (PLS).
4. To examine whether the efficacy of PLS treatment is host genotype dependent
and
5. To formulate and design an appropriate delivery system for CPs from papaya
latex for use in humans and livestock.
21.1 Background
Parasites are important pathogens worldwide causing severe effects on human health
and serious economic losses in the livestock industry. They are of 2 types, ecto- and
endoparasites. Endoparasites are mainly the protozoa and the helminths (May, 2007).
The protozoa are responsible for the majority of the mortality associated with
parasitic infections, while helminths generally are non-life threatening but produce
long-term (or chronic), debilitating diseases (Chan, 1997).
Among the helminths, GI nematodes are the most common parasites affecting
more than 50% of the human population worldwide particularly in the tropics (Chan,
1997) and cause significant economic losses to the livestock industry (Nieuwhof,
2005). However, their impact on human populations is often neglected by public
health authorities and authorities acting as sources of research funding, in contrast to
protozoans (Boatin et al., 2012). The major control method for limiting the extent of
infection with these parasites relies primarily on the use of chemotherapy (Behnke et
al., 2008).
1.2 GI Nematodes of medical importance
The most common GI nematode species that infect humans are Ascaris lumbricoides
(roundworm), Ancylostoma duodenale and Necator americanus (hookworms),
Trichuris trichiura (whipworm), Enterobius vermicularis (pinworm) and
Strongyloides stercoralis (threadworm) (Table 1). These species are referred to as
‘Soil Transmitted Helminths’ (STH). Most of them have direct life cycles (involved
single host) where all pre-parasitic stages are found free-living in the environment
3and their development may take place either inside the egg or after hatching. The
eggs or larvae of these nematodes, with the exception of E. vermicularis, require a
period of development in the soil to become infective before transmission to the
human host. It is very common to have multiple species infections for example A.
lumbricoides and T. trichiura species commonly co-occur in the same host (Booth &
Bundy 1992).
Table 1.1: Human GI nematode parasites of worldwide importance
GI Nematode
species
Group
name
Number
infected
Distribution Transmission
Ancylostoma
duodenale &
Necator
americanus
Hookworm 1.3
billion
Worldwide,
mainly in tropical
regions
Skin contact with
contaminated soil
Ascaris
lumbricoides
Roundworm 1.3
billion
Worldwide,
mainly in tropical
regions
Ingestion of eggs
Trichuris
trichiura
Whipworm 1.05
billion
Worldwide,
mainly in tropical
regions
Ingestion of eggs
Enterobius
vermicularis
Pinworm 209
million
Worldwide Ingestion of eggs;
occasionally
inhaled
Strongyloides
stercoralis
Threadworm 30
million
Worldwide,
mainly in tropical
regions
Skin contact with
contaminated
soil;
autoinfection
Source: Stepek et al, 2006
Their life cycle starts by the female worms producing and releasing eggs into
the intestine which then pass into the external environment via the host faeces. In
most cases the first larval stage develops (L1) within the eggs. After hatching the L1
develops through four further stages (L2, L3, L4 and pre-adults) with each stage
4preceded by a cuticular moult with an increase in size of the worm, until finally they
develop into adult worms. The major routes of infections of STH are through oral
ingestion of eggs, or skin penetration of larvae usually between the toes and fingers
in case of hookworm. The larval stage L3 is the main infective stage in most species.
GI nematode infections are associated with many physical and mental
symptoms of disease. These include anaemia, wasting, stunting, cognitive
impairment and lowered educational achievement, all of which can significantly
reduce the productivity and wage-earning capacity of adults (Guyatt, 2000). Chan
(1997) estimated that the disease burden caused by the 3 most important GI
nematode infections (hookworm, Ascaris lumbricoides and Trichuris trichiura)
resulted in 39 million disability-adjusted life years (DALYs) being lost due to these
parasites compared with 35.7 million lost due to malaria. These figures explain why
it is necessary for the health care services to commit their scarce resources for
controlling intestinal nematode infections (Stephenson et al., 2000).
Anaemia
Anaemia occurs when the adult worms (hookworms in particular) attach to the villi
of the small intestine, drawing blood into their intestines to obtain oxygen and food,
causing abdominal discomfort, diarrhoea and cramps, anorexia, weight loss and
ultimately anaemia (Muller, 2001). A study by Georgiev (1999) reported that
hookworm infections in humans, especially in children, are one of the leading causes
of iron-deficiency anaemia. It has been also observed that iron-deficiency anaemia is
more serious in pregnant women infected with hookworms, than non-pregnant
5infected women (Dreyfuss, 2000). Thus poor iron status and iron deficiency anaemia
are characteristics of hookworm disease (Crompton and Nesheim, 2002).
Malnutrition
Ascaris, trichuris and hookworm disease are associated with malnutrition caused by
reduced food intake, impaired digestion, diarrhoea, abdominal pain, malabsorption,
and poor growth rate (Bethony et al., 2006). Malnutrition is exacerbated by infection
because the nematodes damage the intestinal mucosal epithelial cells whilst feeding,
resulting in the prevention of nutrient absorption by the host. They also cause loss of
appetite (anorexia) which results in lowered food intake. A study in Kenya and
Indonesia showed a significant improvement after treatment with albendazole in the
appetite of school children infected with the hookworms T. trichiura, and A.
lumbricoides. The children gained more weight and improved in appetite
significantly when compared with placebo groups (Stephenson et al., 2000). Stunted
growth caused by helminthiasis in early childhood may remain significant even in
later childhood even after treatment of the worms (Moore et al., 2001). A study in
India reported significant improvement in absorption of vitamin A in patients with
Ascaris immediately after treatment of the worms (Albonico et al., 2008). Clinical
deficiency in vitamin A contributes to increased morbidity (such as blindness) and
mortality.
Cognitive function
Worm burdens are directly associated with poor school attendance and low cognitive
function in school children due to the fact that helminth infections cause
malnutrition, stunted growth and iron deficiency anaemia which in turn is associated
6with a deficit in cognitive functioning (Simeon and Grantham-McGregor, 1990).
However, it is not easy to provide correlation evidence between helminth infections
and educational achievement due to difficulties in separating the effects of infection
from other confounding variables (World-Bank, 1993). A trial conducted in Jamaica,
involving school children with moderate to heavy loads of T. trichiura reported a
significant improvement in auditory test of children after treatment of the worms
(Nokes et al., 1992). This suggests that T. trichiura infection affects certain cognitive
functions which are reversible after treatment.
Secondary infection
Helminth infections are endemic in developing countries where other infectious
diseases such as AIDS, malaria and tuberculosis are highly predominant (Hotez et
al., 2006). Thus helminth infections in humans impair the immune response to these
serious infections, which are controlled by a Th1 immune response (Maizels et al.,
1993). Helminth infections also induce the production of the T regulatory cytokines,
interleukin (IL)-10 and transforming growth factor (TGF-ȕ), which are
immunosuppressive and are believed to inhibit immune responses that protect against
TB (Bentwich et al., 1999). Studies in Zanzibar island in Tanzania indicated that
early exposure of infants to GI Nematodes induced Th2 dominant immune responses
(Wright et al., 2009). The existence of Th2 immune responses in infected individuals
may cause the individual to be unable to develop a protective Th1 response upon
vaccination against TB and other diseases caused intracellular parasites (virus,
bacteria and prozotoans). The presence of helminth infections increases the
susceptibility of individuals to secondary infections requiring a Th1 immune
7response for protection. Thus eradication of helminthic infections may have a major
impact on both AIDS and TB in developing countries (Clerici and Shearer, 1994).
1.3 GI nematodes of veterinary importance
The most important GI nematodes that parasitize domestic animals belong to the
family Trichostrongylidae. This family contains most of the economically important
parasitic nematodes of grazing livestock including Ostertagia, Teladorsagia,
Trichostrongylus, Cooperia, and Haemonchus species. The most pathogenic
nematode of small ruminants is Haemonchus contortus. This is a blood-sucking
parasite that attaches to the abomasal mucosa and causes anaemia and oedema,
which can lead to death of the animals. It is threatening the survival and productivity
of the sheep and goat farming industries throughout the world (Roberts, 2000,
Waller, 2005).
Almost all Trichostrongylidae family nematodes have similar life cycles
which start by adult female worms laying eggs which are passed out in the faeces.
The eggs contain embryos which will develop into first stage larvae (L1). L1 and
second stage larvae (L2) feed actively on bacteria, however the third stage larvae
(L3) are dormant and enclosed by a protective, impermeable sheath (the retained L2
cuticle) but remain infective. The hosts are exposed to infection by ingesting L3s, as
they graze on pasture. The next step in the host is exsheathment from the protective
sheath. Exsheathment is immediately followed by movement of parasitic L3 to sites
of preference where growth and development to the adult stage occurs (Johnstone,
2001).
8Helminths are the most economically devastating internal parasites of
livestock. They cause great losses to animal production mainly among ruminants
with important economic consequences for livestock owners (Waller, 2003). The
direct losses caused by these parasites are attributed to acute illness and death,
premature slaughter and rejection of some parts of meat at meat inspection such as
liver, heart, kidneys and some parts of muscles (Hansen and Perry, 1994 ). Indirect
losses include a reduction of productive potential due to stunted growth, weight loss
in young growing calves and late maturity of stock for slaughter (Swai et al, 2006).
Although ruminants can be infected with tapeworms, their effects on animal
performance is minimal compared to that of roundworms (Gadberry et al, 2009).
1.4 Control and treatment of GI nematodes
1.4.1 Use of Anthelmintics
Current methods for controlling nematodes both in human and livestock involve
repeated dosing with synthetic anthelmintic drugs. There are three broad-spectrum
anthelmintic classes available for treatment and control of GI nematodes and they
differ according to their chemical structure and mode of action (Kaplan, 2004).
The first group are the benzimidazoles which include albendazole (used for
treatment of threadworms, roundworms, whipworms, tapeworms and hookworms)
and mebendazole (more effective against pinworms, roundworms and hookworms)
for humans and thiabendazole for livestock. Benzimidazoles were initially
discovered as anthelmintics in 1961. They are heterocyclic aromatic organic
compounds synthesized by condensation of o-phenylenediamine with formic acid.
9Their anthelmintic efficacy is due to their ability to compromise the cytoskeleton
through a selective interaction with ȕ-tubulin, inhibiting its polymerization and so
interfering with microtubule-dependent glucose uptake by the parasite (Borgers,
1975).
The second group includes the imidazothiazoles (levamisole) and
tetrahydropyrimidines (pyrantel and morantel) which were introduced in 1970s.
These anthelmintics act as nicotinic receptor agonists by prolonging and over-
stimulating the excitatory nicotinic acetylcholine receptors on the body wall of
nematodes causing blockade of the neuromuscular junctions, and muscle paralysis of
the worms. The parasites are then unable to move in the intestinal tract and are
swept out by the peristaltic movement of the intestine. Studies have found that
levamisole, and related compounds, also cause spastic paralysis and egg-laying in
C.elegans (Holden-Dye and Walker, 2007).
The third group of anthelmintics are the macrocyclic lactones (avermectins
and milbemycins) which were introduced in the 1980s by Merck. The commercial
available avermectins include ivermectin, abamectin, doramectin, eprinomectin, and
selamectin. Avermectins are semi-synthetic derivatives of large macrocyclic lactone
fermentation products of the micro-organism Streptomyces avermitilis (Haber, 1991).
Their modes of action involve eliciting persistent paralysis of nematode pharyngeal
and body wall muscles. They act by opening glutamate-gated chloride channels,
increasing chloride ion conductance, leading to defects in neurotransmission and
flaccid paralysis. It is this high affinity for nematode glutamate-gated chloride
channels that correlates with its potent anthelmintic activity.
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There is a fourth group of anthelmintics which are narrow spectrum drugs
such as piperazine which was introduced in the 1950s and still used today in the
treatment of thread worm infections in children. Salicylanilides, closantel and
nitrophenols are used for treatment of blood feeding parasites (Haemonchus
contortus) in small ruminants. Also in some countries organophosphates are still
being used (Holden-Dye and Walker, 2007, Coles et al., 2006).
Other new classes of anthelmintics which have recently been launched
include emodepside introduced in 1990s for treatment of enteric worms in cats
(Buttle et al., 2011), monepantel labelled for use in sheep and introduced in the
market as Zolvix
®
in 2009 and derquantel (in combination with abamectin)
introduced in the market in 2010 as Startect
®
(Pfizer Animal Health) also labelled
only for use in sheep (Kaminsky et al., 2010, Hosking et al., 2010b).
These anthelmintics are relatively cheap, safe and have very few minor side-
effects. However, in treatment of humans very few are recommended for use by
pregnant women, who are most at risk from the severe effects of worm infections
such as iron deficiency anaemia, malnutrition, even death. It has been reported that
thiabendazole has high efficacy against Strongyloides stercoralis, however side-
effects with this drug are high including nausea, dizziness, weakness, anorexia,
vomiting and/or headache and may occur in up to 50% of cases (Cook, 1986, Stepek
et al., 2006a).
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1.4.2 Sanitation & hygiene
All human GI nematodes with the exception of E. vermicularis depend for
transmission on environmental contamination with egg-carrying faeces. As a result,
worm transmission is intimately associated with poverty, poor sanitation, and lack of
clean water (Hotez et al., 2007). Worm infections predominantly occur in rural areas,
where social and environmental conditions in unplanned slums and squatter
settlements of developing countries are ideal for their persistence. Hence the
provision of safe water, good personal hygiene and high levels of cleanliness are
essential for the control of helminth infection.
Treatment of all family members simultaneously is very important for the
prevention of infections with E. vermicularis because the female worms of this
species contaminate bed clothes with infective eggs while infected people sleep. Also
dogs can act as reservoirs of important zoonotic parasites, particularly in areas with
loose defecation. For example in India, viable eggs of T. trichiura and A.
lumbricoides, which are believed to be host-specific for humans, were found in the
faeces of dogs kept as pets and can be transmitted to humans (Traub et al., 2005).
Though treatment with anthelmintics can significantly reduce parasite burdens and
improve growth and development of millions of children, chemotherapy alone is
unlikely to prevent recurring infections with GI nematodes.
The best controlled approach for limiting infections with GI nematodes in
humans is believed to depend on integrated strategies, involving the provision of
clean water, better housing, good sanitation and hygiene, health education and
improvement in the general nutritional status, and the use of anthelmintics. Such
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integrated control strategies will prolong the efficacy of the current anthelmintic
drugs and delay the onset of resistance (Albonico et al., 1999). However, it is not
possible to integrate these strategies in developing countries where poverty is the
predominant limiting factor.
1.4.3 Rotational grazing (Livestock)
Rotational grazing involves periodically moving livestock to fresh pastures, to allow
the previous pasture to regrow and parasites stage to die out. Rotational grazing
practices may reduce the parasite burden in livestock; however, the method alone
will not guarantee parasite eradication. The process involves moving more
susceptible animals to a safe pasture. Always animals are dewormed prior to
placement on a safe pasture; otherwise, the pasture can become contaminated
immediately.
Sometimes rotational grazing can increase infection compared to continuous
stocking. This may be because rotational grazing allows higher stocking rates than
continuous grazing (Gadberry, 2009). Rotational grazing rather than conventional
grazing combined with strategic deworming programs can still reduce infection with
helminths. However rotational grazing depends on sufficient land to enable rotation,
with some pastures remaining ungrazed for long enough to allow transmission stages
to die which the majority of the farmers cannot afford (Behnke et al., 2008).
Therefore, the most applicable method for controlling helminths is the use of
chemotherapy; however, this strategy is limited by the development of resistance of
the parasites to the drugs.
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1.5 Anthelmintic resistances of GI nematodes
In many parts of the world, the control of intestinal helminth parasites has primarily
been based on the use of modern synthetic anthelmintic drugs. However, routine use
and misuse has resulted in development of parasite resistance to the drugs by the
nematodes and this has become a severe global problem for livestock farmers (Yue et
al., 2003, Coles et al., 2006, Sissay et al., 2006).
Resistance is the ability of parasites to survive the normal effective dose of an
anthelmintic and pass this genetic ability to their offspring (Prichard et al., 1980).
During anthelmintic treatments, a small number of worms survive due to the
presence of resistant genes that alter the site of attack of the drug in question and
hence endow the parasite with resistance (Anson, 2009). The gene can be transmitted
to subsequent generations, eventually creating a population of worms resistant to that
kind of anthelmintic (Papadopoulos, 2008, Kaplan, 2004). Unless new anthelmintic
drugs with different modes of action are introduced, worm resistance will continue
throughout successive generations.
The first report of resistance to broad-spectrum anthelmintics
(benzimidazoles) was in the 1960s. Subsequently, resistance was reported within a
few years of the introduction of each drug group (Waller, 2006) and it has been
reported in all major nematode species of goats and sheep, in particular Haemonchus
contortus, Teladorsagia (Ostertagia) circumcincta and Trichostrongylus spp
(Kaplan, 2004).
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Resistance to all 3 classes of anthelmintics has been reported to be
established in small ruminants throughout the world, especially in New Zealand,
Australia and South Africa (Besier, 2007, Waller, 2003). Resistance has been also
reported in developing countries such as Tanzania (Keyyu et al., 2002), Kenya
(Gatongi et al., 2003) and Ethiopia (Sissay et al., 2006) in Africa and in South
America (Gill and Lacey, 1998).
A greater concern is fast development of multiple-anthelmintic resistance
which has been reported also from various parts of the world, particularly from the
major sheep-producing countries; Australia, South Africa, New Zealand and several
South American countries (Kaplan, 2004). Multiple-drug resistance presents a
serious problem to livestock owners leaving them with no alternative effective drugs
for treatment of worm infections.
Despite the prevalence of parasitic worms and resistance, anthelmintic drug
discovery is very slow. The reason is that the nations which suffer most from these
tropical diseases have little money to invest in drug discovery or therapy (Geary,
2005). Although there are many anthelmintic products available in the market, all
belong to one of the 3 classes introduced more than 30 years ago, and we are still
constrained by our reliance on them. The lack of new drugs over the last 30 years
might be an indication that it is not an easy process to develop anthelmintic drugs
with different modes of action from those already in the market (Behnke et al.,
2008). However, new classes of anthelmintics have been introduced recently
including monepantel (2009) and derquantel (2010) but these are approved only for
use in sheep. Derquantel has already been shown to be less effective against
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macrocyclic lactone-resistant Haemonchus worm isolates with only 18.3% reduction
in faecal egg counts (Kaminsky et al., 2010).
There are few reports of anthelmintic resistance amongst nematodes of cattle.
This does not mean that there is no resistance but there is a general belief that
resistance is not yet an important issue (Kaplan, 2004). Recent reports have
indicated that resistance of worms like Cooperia spp in cattle has spread widely
throughout the world (Mejia et al., 2003, Loveridge et al., 2003, Coles et al., 2001).
In view of these findings, anthelmintic resistance in nematodes of cattle might be
more common than is generally considered to be the case.
It is believed that if the use of drugs is discontinued, a reversion to
susceptibility of worms to anthelmintics will occur. However, in practice, increased
susceptibility to anthelmintics does not seem to occur as readily as once thought,
meaning that once resistance has been generated it becomes a long term problem. A
study conducted in Tanzania (Keyyu et al., 2002, Kaplan, 2004) indicated that
nematodes of sheep were still resistant to albendazole even after ten years when the
drug had been withdrawn from use. This occurs because worms carrying resistance
alleles, although reduced in numbers, have a great selective advantage once the drug
is reintroduced.
Resistance is not yet a significant problem in the control of GI nematodes of
humans (Stepek et al., 2006a). However, there are indications of human nematodes
becoming resistant to benzimidazoles and to pyrantel. Studies in Pemba Island,
Tanzania have shown that the efficacy of mebendazole against hookworms in school
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children who were routinely given mebendazole has declined significantly within 5
years (egg reduction rate fell from 82.2% to 52.1%) (Albonico et al., 2003). Also, in
Mali mebendazole and pyrantel showed low efficacy against Necator americanus
infections (Sacko et al., 1999). Similarly, in North Western Australia, pyrantel
lacked efficacy against Ancylostoma duodenale (Reynoldson et al., 1997).
Currently, there are many programs introduced in developing countries based
on the mass treatment of people with ivermectin or praziquantel, each combined
either with mebendazole or albendazole. They have made a significant impact on the
prevalence of intestinal parasitic infections in the regions where such treatment has
been applied (Savioli et al., 2004, Hotez et al., 2007). In West Africa, control
programs for onchocerciasis have resulted in reduced susceptibility of microfilariae
of Ochocerca volvulus to ivermectin with high potential for drug resistance to occur
(Geerts and Gryseels, 2001). This provides a vital warning for the continued use of
anthelmintics as the sole method for controlling human GI nematode infections.
Moreover there is increasing consumer demand for organic food rather than relying
on chemically treated food, especial dairy products and meat (Behnke et al., 2008).
1.6 The search for new alternative anthelmintics
The problem of resistance has led to the search for alternative or complementary
methods of parasite control. There is potential for exploiting anthelmintics obtained
from natural plant extracts present in fruits, leaves and seeds of plants, and which
may have a different mode of action compared to the present classes of synthetic
anthelmintics.
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Medicinal plants have been used by indigenous people for centuries in the
treatment of diseases including parasites of livestock and humans (Hammond et al.,
1997, Waller et al., 2001). Some of the earliest known medicinal anthelmintics from
plants include use of the oil of the chenopodium plant (Chenopodium ambroisoides)
in the early 18
th
century by both the indigenous and European settlers in America,
for the treatment of Ascaris infections (Waller et al., 2001). The dried, unexpanded
flower heads obtained from Artemisia plants were used by Romans in the first
century, for the treatment of Ascaris, Enterobius and tapeworm infections (Sollmann,
1957). Ficus latex has been used in Central and South America as an anthelmintic
against Trichuris, Taenia, Ascaris and Enterobius (Hansson et al., 1986). In addition,
papaya (Carica papaya) and pineapple (Ananas comosus) have been used to treat
poultry, dogs, pigs and humans infected with intestinal parasites by the native people
of Panama and South America (Behnke et al., 2008). Their extracts have been shown
to be more effective than the current synthetic drugs (Keiser and Utzinger, 2008).
However with the development of synthetic anthelmintics, use of these natural plant
herbal remedies has declined (Waller et al., 2001). Since there is a rapid increase in
resistance to synthetic drugs among the GI nematodes, it is important to go back to
history and re-examine the efficacy of these traditional medicinal plants (Willcox et
al., 2001) and seek ways to improve their efficacies, exploiting modern technologies.
CPs are proteolytic enzymes secreted by most tropical plants including
papaya, fig, kiwi, pineapple and many other plants (O'Hara et al., 1995) as it is
summarized in Table 1.2 below. The enzymes are available in different parts of the
plants and they are involved in protein maturation, senescence, abscission,
programmed cell death, fruit ripening and protein rebuilding in response to internal
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and external stimuli (Grudkowska and Zagdanska, 2004). They are also involved in
removal of damaged or unnecessary proteins and defend mechanisms against
arthropod (Dussourd and Eisner, 1987) and parasite attacks (Konno et al., 2004).
These enzymes have been reported to possess strong anthelmintic effects against GI
nematodes (Satrija et al., 1994, Stepek et al., 2004, Robbins, 1930).
The CP enzymes belong to the papain family (Martínez et al., 2012) and
structurally they are made of a single polypeptide chain of 25 kDa, which is folded to
form a globular protein with two domains. There is a deep cleft in between the two
domains where the substrates can bind, and where the active-site cysteine and
histidine residues form a thiolate–imidazolium ion pair (Rawlings and Barrett, 1994)
which mediates the hydrolysis of the peptide chain.
Their enzyme activity can be quantified based on titration using commercial
available substrates, linked with the fact that they are irreversibly inhibited by L-
trans-epoxysuccinyl-leucylamido(4-guanidino)butane (E-64). E-64 is a class specific
inhibitor for cysteine proteinases isolated from Aspergillus japonicas. It inhibits the
CPs by blocking the active Sulphydryl residues (-SH), the thiol groups (Hanada et
al., 1978). Due to its fast reacting mechanism with CPs, it is regarded as an ideal
active-site titrant. Kinetic studies have indicated that E-64 is an irreversible inhibitor
of CP enzymes (Hashida et al., 1980). Titration with cathepsin B resulted in a 1:1
proportional decrease in titratable thiol groups. The activity of cathepsin in
increasing concentrations of E-64 indicates that E-64 reacts with an equimolar
amount of active thiol of cathepsin B (Hashida et al., 1980). The protocol for active
site titration with E-64 was first developed by Barrett et al. (1981). The solutions of
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papain and cathepsin enzymes were treated with a series of increasing concentrations
of E-64 and assayed for activity. They found that the activity declined linearly with
increasing amounts of E-64. It was possible for them to draw a straight line through
the points to the abscissa. The intercept was taken to give the molar concentration of
the enzyme and the slope of the line gave the specific activity of the enzyme in terms
of molar concentration. The protocol was later adapted by Zucker et al. (1985) for
papain, chymopapain and papaya proteinase III. Hence this protocol has been
adopted in this study as a standard assay for the determination of the concentration of
all the CPs used in this study.
However, factors such as pH, ionic strength and nature of the buffer can
contribute to variation in assay readings. CPs require addition of a small amount of
sulphydryl reducing agents such as cysteine, dithiothreitol (DTT) or 2-
mercaptoethanol to activate them before catalysis of the reaction (Wilk, 2001). These
reducing agents convert reversibly inactive forms of enzymes to the active forms and
protect their catalyzed essential thiol group from oxidation (Caygill, 1979). Thus the
assays in this study were performed in the presence of cysteine in activating buffer
(Barrett et al., 1981) and EDTA for removal of any heavy metal which might
inactivate the enzymes (Zucker et al., 1985).
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Table 1.2: Some plants containing CPs with potential anthelmintic activity
Plant species Enzymes contained
1. Papaya Papain, chymopapain, caricain, glycyl endopeptidase
(Balls and Jansen, 1952)
2. Fig Ficin, ficain (Robbins, 1930)
3. Pineapple Ananain, fruit bromelain, stem bromelain and
comosain (Rowan et al., 1988)
4. Kiwi fruit Actinidine (Brocklehurst et al., 1981b)
5. Egyptian milkweed Asclepain (Brockbank and Lynn, 1979)
These plants (papaya, pineapple and fig) have been used as medicinal plants by
indigenous communities for treatment of GI nematodes since antiquity (Behnke et
al., 2008). For example the crude latex extracted from papaya trees (Carica papaya)
was used successfully to treat ascarids, tapeworms, whipworms and hookworms in
the early 19
th
century (Berger and Asenjo, 1940). The recognition that the
anthelmintic activities in these plants are due to proteolytic cysteine proteinases has
offered the possibility of utilizing these plants as anthelmintics (Stepek et al., 2004).
Robbins (1930) was the first person to report that the active anthelmintic principle of
ficin to be an enzyme that damaged the cuticle of Ascaris suum, presumably by
proteolytic digestion. Fresh pineapple juice was found to possess an enzyme,
bromelain, which is similar to ficin, and which completely digested A. suum (Berger
and Asenjo, 1939). In 1940 the active ingredients which digested worm cuticle from
papaya latex (PL) preparations was described to be the enzyme papain (Berger and
Asenjo, 1940). These three separate studies suggested a similar mechanism of action
by rapid digestion of the Ascaris cuticle.
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In vivo assessment of these plant enzymes was neglected until the 1980s
when Hansson et al (1986) carried out a clinical trial involving 181 residents infected
with one or more GI nematodes in South America to examine the effectiveness of
latex from the Ficus glabrata. Upon oral administration a substantial reduction in the
number of worms was achieved, although not evaluated statistically. Later Satrija et
al (1994) reported a significant reduction in worm burden in pigs infected with A.
suum and in mice infected with H. bakeri (Satrija et al., 1995) when treated with
papaya latex.
Although encouraging results for the anthelmintic efficacy of natural plant
cysteine proteinases were provided by these studies, it is not until recently, that their
effect was confirmed and their mode of action was studied closely (Stepek et al.,
2007a, Stepek et al., 2007c, Stepek et al., 2005, Stepek et al., 2006b). It was reported
that the effects of these enzymes initially caused observable changes to the surface of
the cuticle, leading to lesions, fractures, and eventually complete destruction of the
cuticle and bursting of the worms. The mechanism was completely blocked by the
presence of the CPs specific inhibitor E-64, and is dependent on the presence of free
cysteine, in the incubation medium in vitro (Stepek et al., 2004).
The work was carried out in vitro using the latex of papaya, milkweed and
figs, and extracts of pineapple fruit and stems, and the purified enzymes papain
(papaya), chymopapain (papaya), and ficin (fig), and all caused detrimental effects
on adult H. bakeri worms (Stepek et al., 2005). The more convincing evidence was
the in vivo work with papaya latex (PL) using three rodent nematodes; H. bakeri
(Stepek et al., 2007b, Satrija et al., 1995), Protospirura muricola (Stepek et al.,
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2007a) and Trichuris muris (Stepek et al., 2006b) and sheep nematode; H. contortus
(Buttle et al., 2011) where the results showed a significant reduction in worm burden
and egg counts. However, kiwi fruit extract had no effect on H. bakeri in vitro
(Stepek et al., 2005) and young pineapple juice showed anthelmintic activity in vitro
but not in vivo against A. tetraptera worms (Satrija et al., 1995). Due to these
contradictory results there was a need to reassess cysteine proteinases from pineapple
and kiwi plant sources individually in vitro and if possible in vivo using H. bakeri, a
natural parasite of mice and PL as a positive control.
1.6.1 Animal model used in this study
The majority of intestinal nematodes are specific to their respective hosts. Human
GI nematodes or nematodes affecting domestic livestock cannot be investigated in
rodents other than in exceptional models such as Necator americanus in hamsters.
Experiments in domestic livestock are constrained with several difficulties,
including high cost to set up appropriate facilities for their husbandry. The
experiment may not be permitted unless the agents had been tested first in
laboratory animals. Also some basic principles may need to be established first in
laboratory rodents. Only then can the experiment be conducted in the animal species
most appropriate for both relevance and sentience. Similarly human trials would not
be permitted by ethics committees unless there was evidence of efficacy and safety
from animal trials. The University of Nottingham has suitable facilities for rodent
trials. For these reasons rodents and rodent nematodes were the best starting point
for this research. Moreover, rodents are the lowest vertebrate group in which well
characterised host-parasite relationships with minimal severity have been
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developed. Therefore Heligmosomoides bakeri (H. bakeri) worms were used and the
in vitro experiments were extended to horse nematodes.
1.6.2 Life cycle of model parasite – Heligmosomoides bakeri
H. bakeri is a natural parasite of Mus species (model of small intestinal nematodes
with a developmental stage in the intestinal wall) and related to hookworms of
humans (Ancylostoma duodenale) and trichostrongyloids of domestic animals such
as Haemonchus contortus and Teladorsagia circumcincta of sheep. It is an
elongated, cylindrical, unsegmented worm with tapering ends. Its body is covered
with a tough cuticle and it has an internal cavity with a high internal hydrostatic
pressure.
Its life cycle starts by an adult female worm laying eggs in the small intestine
(Fig.1.1). These are passed to the outside environment through host faeces. The eggs
hatch into first stage larvae 36-37 hours after being laid. The L1 larvae moult to the
L2 larval stage 28-29 hours after hatching. After 17-20 hours the L2 undergo partial
moulting giving rise to ensheathed L3 infective stage larvae. The L3 are active but
non-feeding. When the L3 infect a mouse orally, they migrate to the small intestine,
shed their sheath and penetrate into the intestinal mucosa and moult into L4. The
worms then migrate back to the lumen and develop into the adult worms (Bryant,
1973). In general the life cycle, from egg to egg, takes about 13.5 days.
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Figure 1.1: Life cycle of H. bakeri as maintained in the laboratory mice
The life cycle starts with collecting faeces from infected mice that are cultured for 7
days to allow the eggs to hatch and undergo a series of moults to infective L3 larvae.
The L3 larvae are collected and stored in refrigerators for future infection. The
infected mice develop the larvae into adult worms after 10 days when they start
laying eggs which are expelled out in the faeces for a new life cycle.
1.7 Formulation and delivery of cysteine proteinases (CPs)
PL has been demonstrated to have an anthelmintic effect against nematodes of mice
such as H. bakeri (Stepek et al., 2007b, Satrija et al., 1995), Trichuris muris (Stepek
et al., 2006b), Protospirura muricola (Stepek et al., 2007a) and that of sheep,
Haemochus contortus (Buttle et al., 2011).
Adult worms in mouse
small intestine Infected mouse
Infection of mouse
Eggs in mouse faeces
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The results of Buttle et al (2011), indicated that for the PL to be more effective it
requires an extended period of time for the active enzyme to damage the worms. This
was demonstrated by the failure of a single dose in comparison with a regimen of 4
daily doses. This suggested that enzymes could show more efficacy if the contact
time with worms was extended. Therefore for the enzyme to be safe and effective
delivered for human and livestock GI nematode treatment, various formulation and
delivery methods have to be reviewed before selecting the appropriate one.
1.7.1 Drug formulation
Drug formulation is the process in which different ingredients, active drug and
excipients, are combined to produce a final medicinal product. It is the initial stage in
the rational development of a dosage form (Undralla et al., 2011) which then
involves testing and modifying of the drug release profile, to provide optimum
absorption, distribution and elimination characteristics. The overall aim is to improve
efficacy and safety, as well as patient convenience and compliance. The formulated
drug can be administered through a variety of routes including orally, nasally,
buccally, rectally, topically or by inhalation. However, oral administration, in which
therapeutically active substances are taken by mouth, remains by far the most
popular route of drug delivery (Melia and Davis, 1989).
Different formulations and delivery systems have been employed to improve
the efficacy and safety of the drugs in both humans and livestock. This includes a
wide variety of liquid, semi-solid and solid based systems in formulations designed
to be appropriate for their route of administration.
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1.7.2 Liquid-based formulations
Liquid dosage forms commonly used for both human and livestock include oral
solutions, suspensions and gel or pastes. They are prepared by dissolving or
dispersing the active ingredients in aqueous or non-aqueous media. Liquid dosage
forms are easier to swallow and usually faster acting than solid dosage forms as the
active substances become available for absorption or contact with pathogens
immediately after swallowing (Blackburn, 2010). In ruminants, the reticular groove
closure allows oral solutions to flow directly into the absomasum by-passing the
reticulo-rumen. This provides an immediate release of the drug into the abomasums
and hence further down into the intestine (Grovum and Chapman, 1988). In cattle it
can also be induced by administering sodium bicarbonate solution, or in sheep, by
administering orally a copper sulphate solution or injecting intravenously a dose of
lysine–vasopressin (Baggot, 2007). Liquid dosage forms provide a suitable means of
drug administration not just to adults, but also to neo-nates and young animals
(Parasrampuria and Pitt, 2007).
Oral liquid drug formulations intended for livestock although convenient,
require frequent dosing. This is demanding on the farmer when treating their
animals, for example if they are on pasture they will need to frequently round up.
They also pose a hazardous risk of dosing the liquid to the lungs instead of the
stomach or may be spilled. They require careful measuring before administration, or
have special storage or handling requirements such as refrigeration or shaking before
use (Kockaya and Wertheimer, 2011). Drugs can have a bad taste which is difficult
to mask. In the case of CPs used in the current study, there is a possibility of losing
activity of the enzymes before being administered if they are in liquid form.
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1.7.3 Solid based formulations
Oral drugs are more conveniently administered in solid form, as tablets, capsules,
powder, premix or medicated blocks. Tablets are composed of one or more active
substances usually with various excipients. These include diluents, binders,
disintegrating agents, glidants and lubricants. They may also include substances
capable of modifying the behaviour of the preparation in the digestive tract (Melia
and Davis, 1989). Tablets have many advantages including easy self-administration
and convenient, packaging, handling, and shipping, storing and having longer shelf
life. The dosing is more accurate (single dose) and they are suitable for sustained
release preparations. However, their preparation needs expensive machinery and
some patients (e.g children and elderly people) may have difficulty swallowing them
(Blackburn, 2010). Tablets are not fast enough for immediate action (injection is
required) but they are highly convenient and therefore the most popular form of
human medicine. However tablets are less popular for animals due to difficulties in
administration as they require a special ‘bolus gun’ to make sure that they are placed
deep enough to be swallowed by the animal.
Capsules are solid dosage forms in which the drug is contained in a water
soluble outer shell they contain a mixture of the active and inactive ingredients. The
most common type of shell is gelatin shells (hard or soft) which can be filled with
powdered, pasty, or liquid medications. They are usually prompt release, but also can
be enteric coated or sustained release. One advantage of a hard gelatin capsule for
use in livestock is that it can be broken open and its contents spread over a food
substance or into water before administration. Also it can mask the taste and odour of
the active ingredient.
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Powders and granules are mixed with other powdered excipients to produce
final or aggregated products for oral administration. Powders and granules have
better chemical stability than liquids and dissolve faster than tablets or capsules,
because there is no need for disintegration. In livestock drugs which are in powder
form or prepared granules can be easily added to the feed. The disadvantages of this
method of administration are the unreliability in the amount of dose ingested by the
animal. It needs the drug to have a wide margin of safety and palatability in the feed
and that the animal must be feeding. Sick animals often eat less and are therefore less
amenable to treatment with in-feed powder formulations (Baggot, 2007). This
method can be improved by packaging of powders or granules in unit dose sachets.
This provides convenience of drug administration for owners when the number of
animals to be dosed is small. Drug powders are principally used prophylactically in
feed, or formulated as a soluble powder for addition to drinking water or as milk
replacer. Since PL is in powder form it would be possible for it to be added into feed,
but it might not provide the expected results as its efficacy is dose dependent (Stepek
et al., 2006b) and hence its effectiveness will depend on the amount consumed by
animals.
Premix and medicated blocks are specifically prepared for livestock. Premix
is a homogeneously mixed product of active ingredient with feed at rates that range
from few milligrams, to grams of drug per ton of feed. The common premix
formulations administered to poultry, pigs, and ruminants, include coccidiostats,
production enhancers, and nutritional supplements. Several factors need to be
considered in the design of premix formulations and to ensure their satisfactory
mixing in bulk feed. Premixes must always be diluted to the approved use level,
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usually parts per million (ppm) [g/tonne (feed) or mg/L (water)], as appropriate for
the animal species. For example IVOMEC® Premix
®
which is a free-flowing meal
mixture containing 0.6% ivermectin for incorporation into animal feeding stuffs, is
used for the treatment of pigs against mange mites, lice and worms.
Unlike the premix, medicated blocks are a compressed feed material that
contain an active ingredient, such as a drug, anthelmintic, surfactant (for bloat
prevention), or a nutritional supplement. It is commonly packaged in a cardboard box
(http://www.merckvetmanual.com). Medicated blocks need to be non-toxic, stable,
palatable, and of low solubility. Palatability can be improved by the addition of
excipients like molasses. Since blocks are palatable, they need to be offered in a
suspended position so that animals can lick, but not bite on the block, preventing the
animals from eating large amounts at a time.
1.7.4 Tablet classification
As reported earlier tablets are by far the most popular among all solid dosage forms
used for humans because of their convenience of self administration, compactness
and easy manufacturing. According to United States Pharmacopeia (USP) tablets are
classified based on the drug release rate either immediate release (Conventional)
tablet or modified release tablet which includes extended and delayed release (Fig.
1.2).
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Figure 1.2: Drug release rate from different types of tablets
The figure shows the change in drug release rate patterns for immediate, delayed and
extended release tablets.
1.7.4.1 Immediate release tablet dosage forms
In immediate release tablet, drug is intended to be released rapidly after
administration, or the tablet is dissolved and administered as solution (Hyder and
Sharma, 2011). The basic components of immediate release pharmaceutical tablets
are active drug substance, diluents or filler, binders, disintegrants and lubricants
(Fukami et al., 2006).
In general, immediate release formulations are applied both to conventional
tablets, which release the drug in the stomach and to those which are orally
disintegrating tablets (ODTs) that dissolve in the patient's mouth. Usually a polymer
or sugar coating is applied to increase patient compliance by creating a smooth,
glossy finish that enables easier swallowing compared with the uncoated cores.
Coating also provides mechanical protection and colour identification which helps
patients differentiate between tablets when taking multiple medications (Bebber,
Drug
release
Time
Immediate release
tablet
Delayed release
tablet
Extended
release tablet
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2011). In animals immediate release tablets are used to administer drugs to dogs and
cats
Immediate release tablets disintegrate soon after swallowing as a result of the
disintegrants within them. There are many disntegrants have been used but the most
common are starch and cellulose and their derivatives (Govedarica et al., 2011).
Their mechanisms of action involve swelling or wicking, and these create either a
disintegrating internal force or a wet network which dissolves soluble components of
the matrix. Modern derivatives are often termed super-disintegrants (see below).
These are effective at lower concentrations and impart greater disintegrating
efficiency or mechanical strength to the tablet. They are chemically modified
starches and cellulose, and are often obtained by crosslinking the
polysaccharide/polymer chains and introducing carboxymethyl substituents (Zhao
and Augsburger, 2005). Some common superdisintegrants used in this study are
described below:-
1. Sodium Starch Glycolate (Primojel
®
, Explotab
®
).
This is synthesized by cross-linking of the potato starch using an FDA approved
starch esterifying agent in alkaline suspension, along with carboxymethyl
substituents. The effect of crosslinking is to reduce both the water soluble fraction of
the polymer and the viscosity of dispersion in water (Edge et al., 2002). The carboxy
methyl substituents elicit rapid water uptake by the polymer causing swelling with
minimal gelling. The recommended concentration to be used is 2-8% with an
optimum of 4%.
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2. Low-substituted hydroxyl propyl cellulose (L-HPC
®
).
It is prepared from purified wood pulp cellulose and is insoluble in water. It rapidly
swells in water to a degree dependent on the level of substitution, with grades LH-11
and LH-21 exhibiting the greatest degree of swelling (Kiyose et al., 2007). Certain
grades can also provide tablet binding properties while retaining disintegration
capacity. The recommended concentration is 1-5%.
3. Croscarmellose sodium (Ac-Di-sol
®
)
Croscarmellose sodium is cross linked carboxymethylated cellulose. It has high
wicking and swelling with minimal gelling ability due to retaining its cellulose
fibrous structure. Each fibre can act as a hydrophilic channel to facilitate water
uptake into the tablet matrix and help increase the total water contact area with drug.
The effective concentration is 1-3% for direct compression tableting and 2-4% for
wet granulation (Zhao and Augsburger, 2005, Hyder and Sharma, 2011).
In selecting disintegrants there is no particular upper limit regarding the
amount to be used as long as the mechanical properties of the tablet are compatible
with its intended use (Mohanachandran et al., 2011). However, it is sometimes
necessary to evaluate different kinds of disintegrants in order to get a suitable
disintegrant which combines excellent compatibility with disintegrating properties.
1.7.4.2 Enteric coated (delayed release) tablets
Enteric coated tablets are intended to release a drug after the tablet has passed
through the stomach to other parts of the GI tract (Undralla et al., 2011). Other
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delayed-action tablets can be designed to release in the ileum or the colon. Enteric
coating is aimed to protect the drug from gastric fluid in the stomach or vice versa
and release the drug in the duodenum. Enteric coatings are used because some drugs
are unstable in the low pH of the stomach (e.g, erythromycin) whilst others if
released in the stomach may cause irritation, nausea or vomiting (e.g aspirin), Other
drugs need to be delivered and released at high concentration in the intestine for
absorption or local action.
The coatings used to produce enteric effects are natural modified polymers
which are insoluble in acidic media but dissolve at neutral pH. The most commonly
used are i) cellulosics such as cellulose acetate phthalate, hydroxypropylmethyl
cellulose acetate succinate and hydroxypropyl methylcellulose phthalate ii) polyvinyl
acetate phthalate (PVAP) and iii) polymethacrylates such as Eudragit® L and S. All
these types have the common feature of carboxylic or phthalic acids, sometimes in
partially esterified forms, which remain unionised and insoluble in gastric acid but
dissolve when the tablets leave the stomach as the pH increases and their substuitent
groups ionise (Chien, 1989). For this reason enteric coating is not suitable for drugs
intended to be delivered in the stomach like the CP enzymes which are being
developed to treat GI nematodes residing in the abomasums of sheep.
1.7.4.3 Extended release dosage forms
The United States Pharmacopoeia (USP) defines an extended release (ER) dosage
form as one that allows at least 2-fold reduction in dosing frequency or a significant
increase in patient compliance or therapeutic performance when compared with a
conventional dosage form. ER dosage forms are used when it is desirable to have
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drugs slowly and consistently released over an extended period of time, instead of all
at once (Blackburn, 2010). The terms sustained-release, long acting, controlled-
release, slow release or prolonged release have been used synonymously with
extended release (Tiwari and Rajabi-Siahboomi, 2008) and although the exact
meaning of these terms may differ in some respect, they all imply the gradual release
of drug over a longer period of time than standard dosage forms. Oral tablets and
capsules are the most common dosage forms that are formulated as extended-release
(Alderman, 1984).
ER dosage forms have demonstrated to improve by maintaining consistent
flow of drug throughout the given time period. The advantages of ER dosage forms
include better control of blood level profiles, minimization of side effects and
reduction in the number of dose administrations and (potentially) better patient
compliance. Cost of medication is reduced as patients require fewer doses but this is
often offset by a more prolonged period of formulation development and testing
(Brennan et al., 2007, Fernandes et al., 2003).
1.7.4.4 Technologies used for ER in livestock
The most common technologies used to achieve controlled drug release in ruminants
are intraruminal devices. According to the European pharmacopeia (2005)
intraruminal devices are solid preparations containing one or more active substances
intended for oral administration to ruminant animals and are designed to be retained
in the rumen to deliver the active substance(s) in a continuous or pulsatile manner.
Some intraruminal devices are intended to float on the surface of the ruminal fluid
while others are intended to remain on the floor of the rumen or reticulum. For
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continuous release, the intraruminal device is designed to release the active substance
at a defined rate over a defined period of time. This may be achieved by erosion,
corrosion, diffusion, osmotic pressure or any other suitable chemical, physical or
physico-chemical means. Different types of intraruminal devices have been
developed. These include erodible, reservoir, dispersed matrix and osmotic boluses.
i) Erodible boluses
These are boluses designed to dissolve or abrade under the mechanical action of the
rumen. The boluses can be made from drug, carnuba wax, barium sulphate,
polyethylene glycol and iron powder. Marston (1962) was the first person to develop
an erodible bolus containing cobalt oxide (a trace nutrient for ruminants) and other
diluents. The bolus was able to release cobalt throughout the grazing season. It was
found that a density of greater than 2.0 was sufficient to prevent bolus regurgitation
in cattle. Other examples include spanbolet
®
II which is available for controlled
release of sulphate drugs, and release of oxytetracycline and S-methoprene from
erodible boluses. Cardinal (1997) has recommended that erodible devices are best
utilized for delivery of nutrients than drugs, where therapeutic indices are usually
much broader.
ii) Reservoir systems
One of the earliest successful products for the treatment of parasitic infestations once
per season was the Paratect flex
®
bolus (Pfizer, USA). This product was designed to
provide continuous administration of the anthelmintic morantel tartrate. The system
is composed of a stainless steel cylinder which is about 4 inches in length and 1 inch
in diameter. It is capped at each end with porous polyethylene disks impregnated
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with cellulose triacetate. This creates a reservoir within the cylinder which is filled
with a mixture of drug plus polyethylene glycol. Drug release occurs over 90 days,
making it highly effective in season-long control of GI roundworms (Borgsteede,
1983).
iii) Dispersed matrix
A dispersed matrix device is defined as one in which the active ingredient is
dispersed within a non-biodegradable polymer matrix. It is designed to treat cattle
with prophylactic doses of an anthelmintic intended to prevent the establishment of
GI worms throughout the entire grazing season (Rothen-Weinhold et al., 2000). The
device is in the form of a large sheet consisting of a trilaminate design wherein a core
matrix containing a 50:50 mixture of morantel tartrate (anthelmintic) and ethylene
vinyl acetate (EVA) and is coated on both of its outer surfaces (but not the edges)
with a layer of pure EVA which is impermeable to the drug. The sheet is rolled up
and adhered by water soluble tape to form a cylinder for administration. Release of
drug occurs via diffusion within water filled channels of the porous core matrix to
the uncoated edges. In the rumen, the adhesive dissolves and the device unrolls and
its dimension increases preventing it from being regurgitated. This technology has
been commercialized and is sold in Europe under the trade name of the Paratect
Flex
®
bolus.
iv) Osmotic boluses
Osmotically controlled drug delivery systems utilize osmotic pressure as a driving
force for controlled delivery of the active agent. It consists of an outer semi-
permeable membrane enclosing a metal density element at one end, an osmotic
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energy source at the other end, and the core containing the drug in the centre. In
contact with the aqueous fluids, it absorbs water at a rate determined by the fluid
permeability of the membrane and osmotic pressure of core formulations.
Absorption of water through the semi-permeable membrane causes expansion of the
bolus, which drives the drug through the exit port (Verma et al., 2002).
The technology is appropriate for the delivery of parasiticides, insecticides,
nutritional supplements, antibiotics, growth promoters, repartitioning agents and
oestrus suppressants. It can provide controlled delivery of a drug for up to one year
in the rumen of cattle and sheep. The technology was originally developed by ALZA
for the OROS
®
for water soluble drugs and Push-Pull
®
systems for highly aqueous
insoluble drugs (Cardinal, 1997). This effort resulted in development of the
IVOMEC SR Bolus
®
which delivers the parasiticide ivermectin to cattle for 135 days
(Rothen-Weinhold et al., 2000).
v) Pulsatile boluses
In treatment of cattle or sheep with anthelmintics, the main concern is the
development of resistance. One of the methods used to minimize this problem is
through pulsed dosing, wherein therapeutic levels are administered on a regular
basis, followed by periods of no drug delivery. Holloway (1982) designed a device
which has a series of drug compartments separated by degradable cellulosic
partitions. Each partition degrades on exposure to ruminal content. As successive
partitions degrade, drug is released periodically.
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vi) Systems to by-pass the rumen
These oral delivery systems are intended to pass through the rumen without releasing
the drug and then the drug is released in the lower GI tract in areas such as the
abomasum. One application for this technology is the delivery of methionine, which
is degraded by exposure to the microbial flora of the rumen. To prevent drug release
in the rumen, polymers are sometimes used that prevent the dissolution of the coating
in the rumen fluids, similar to preparation of enteric coated dosage forms for human
applications. Such coatings lead to significantly higher blood levels of methionine,
which lead to great increase in wool production from treated animals (Cardinal,
1985).
vii) Hydrophilic matrices
Many current extended drug release systems are based on hydrophilic polymers
which swell forming a surface ‘gel’ barrier of hydrated polymer, which retards drug
release. The mechanism of drug release is complex but it is based on the diffusion
through and erosion of the gel (Tiwari and Rajabi-Siahboomi, 2008, Melia, 1991).
Water diffuses into the matrix, resulting in polymer chain relaxation with volume
expansion, wherein the incorporated drug dissolves and diffuses or is eroded out of
the system (Siepmann et al., 2002, Li et al., 2005).
The perceived advantages associated with hydrophilic matrices over other ER
technologies, include simple formulation, a wide range of drug release profiles, use
of existing tableting processes and the low cost of polymers, which are generally
regarded as safe (GRAS). Many swellable polysaccharides are available, allowing
flexibility for the needs of an individual formulation. Hydrophilic matrices are
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erodible and therefore, unlike inert matrices, they reduce in size and dissolve as they
pass through the GI tract. Swellable matrices are also suitable for other
administration routes, including buccal, vaginal and rectal delivery (Melia, 1991).
The hydrophilic matrices utilise three groups of retarding agents, a) Cellulose
derivatives which include methylcellulose, hydroxyethylcellulose,
hydroxypropylmethylcellulose (HPMC) and sodium carboxymethylcellulose, b)
Non-cellulosic gums and polysaccharides include guar gum, xanthan gum, sodium
alginates, pectin, chitosan and modified starches and c) other swellable materials
such as carbomers, copolymers of acrylic acid, and polyethylene oxide.
1.7.4.5 Factors to be considered in ER matrix formulation
Drug solubility, intrinsic dissolution rate and dose are the most important factors to
be considered in the design of ER matrices and they play a major role in the eventual
drug release profile. Tiwari and Rajabi-Siahboomi (2008) reported that to formulate
ER dosage form with high dose and extreme solubility is very challenging because
the drug dissolves within the gel layer and diffuses out into the matrix very easily
and this is common with HPMC hydrophilic matrices. In this case, use of high
viscosity grade HPMC (Methocel K4M CR, K15M CR OR K100MCR) tends to
generate consistency of diffusion-controlled systems. In addition hydrophilic matrix
formulation with high amounts (doses) of drugs is particularly challenging because
of the small quantity of polymer required to limit the size of the tablet to one that is
swallowable.
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Polymer levels are a key factor in controlling the drug release rate. Use of 20-
50% w/w is recommended for HPMC and 20% for xanthan gum, although 5% of
xanthan gum has been reported to provide sustained release of an insoluble drug such
as ibuprofen into gastric fluid (Melia, 1991). More prolonged extended drug release
profile is achieved with finer particle size polymers because hydration rate is faster
and this has lead to the marketing of specific ER grades of HPMC. The effect of
tablet compression force on drug release is minimal when tablets are made with
sufficient strength and optimum level of polymers are used (Velasco et al., 1999).
Tablets with smaller size require higher polymer content because of their higher
surface area to volume ratio and thus shorter diffusion pathway.
Coating of hydrophilic matrices with water-soluble polymers does not usually
alter the extended drug release profile, but water insoluble polmers (e.g
ethylcellulose) may modulate the drug release profile. The same also applies to fillers
and other excipients if used. However, the effect depends on the drug, the polymer
level and level of excipient (Levina and Rajabi-Siahboomi, 2004). Since the majority
of ER dosage forms are designed to remain in the GI tract over a prolonged period
(Williams et al., 2009), the formulation of CPs in this dosage form would be
appropriate as the enzymes will have enough time to damage the worm cuticle.
However various matrices need to be evaluated before selecting the suitable one.
1.8 Hypothesis, Aims and Objectives of the study
The work described in this thesis is based around the central hypothesis that plant
derived cysteine proteinases have anthelmintic activity and that this can be harnessed
to produce an effective medication for use in livestock and humans. As with all
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biological materials, the anthelmintic efficacy of plant derived CPs is likely to be
affected by a variety of host intrinsic and extrinsic factors, and the formulation in
which the drugs are made available to hosts will also affect their efficacy. This thesis
is concerned with evaluating the principal factors in each case in order to refine and
improve the delivery and prospects for effective removal of worms from infected
animals.
Objective 1
The first objective of this study was to determine the preparation method of
PLS and storage conditions for long term survival of the enzymes. Since it was
not clear which method of preparation would provide high yield of CPs in PLS and
under what storage conditions would maintain the stability of the active enzymes for
prolonged period of time.
Objective 2
The second objective of this study was to evaluate the anthelmintic efficacy of
CPs from sources other than papaya latex, such as pineapple fruit, stem and
kiwi fruit extracts. In earlier studies it has been shown that cysteine proteinases
have powerful anthelmintic effects on GI nematodes by removing more than 90% of
the parasites in mice (Stepek et al., 2005, Stepek et al., 2007b, Satrija et al., 1995)
and in sheep (Buttle et al., 2011). However throughout the studies the source of the
enzymes used was from papaya latex. The effectiveness of CPs from other sources of
related plants has been little studied. .
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Pineapple fruit and stem extracts have only been studied in vitro and been
shown to be effective against rodent nematodes (Stepek et al., 2005). This justifies
investigation of their effectiveness in vivo. On the other hand kiwi fruit extract was
shown to have no detrimental effect on worms; however it belongs to the same
papain C1 family CPs. There was a need therefore to verify why it behaves
differently from other CPs by repeating the in vitro trials under more refined
conditions.
Objective 3
The third objective was to assess the effect of fasting on the anthelmintic
efficacy of papaya latex supernatant (PLS). This is because in earlier studies with
CPs, a period of food deprivation was routinely employed before administration of
CPs, but there has been no systematic evaluation as to whether this does actually
benefit the anthelmintic efficacy of PLS or not. The information will be helpful in
formulating the optimal protocol for delivery of the drug to animals or humans, in
order to obtain maximum efficacy against the worms with the lowest possible dose.
Objective 4
The fourth objective was to examine whether the efficacy of PLS treatment is
host genotype dependent. In earlier work with CPs, only two strains of mice were
tested. These were the inbred male C3H strain (Stepek et al., 2007a, Stepek et al.,
2007b) and female BALB/c strain (Satrija et al., 1995). There has been no systematic
study comparing different mouse strains of known contrasting genotype. If the
efficacy of PLS is dependent on host genotype, differences in efficacy might be
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expected between animals within breeds on farms where the therapy has to be
applied. Thus the extent of variation arising from genetic differences between
animals is an important issue to be assessed.
Objective 5
The last objective was to formulate and design an appropriate delivery system
of the CPs from papaya latex to humans and livestock. As it has been stated early
CPs from PL have been demonstrated to have high efficacy against GI nematodes.
There is a need therefore to develop the enzyme preparations into an acceptable
medication that can be sold commercially to end users. However, for it to be
acceptable for commercial use, it has to be formulated into a safe, convenient and
compliant way of delivery to animals or humans. Thus there was a need to find out
the most suitable ways of delivering the drug to animals particularly sheep. In this
study two delivery methods were evaluated:
x Extended release hydrophilic matrix system. The enzyme mixed with polymer
was made into tablets and in vitro assessed for its slow release. The idea behind
this was that the tablet should settle in the rumen where it should act as a
reservoir dissolving the tablet in the rumen fluid and slowly releasing the enzyme
to the lower gut. The major advantage of this mechanism is that large amounts of
the drug can be given to animals at a time while extending the release time in this
way reducing the frequency of drug administration. Two hydrophilic matrix
polymers, xanthan gum (XG), and hydroxypropyl methylcellulose (HPMC) both
low and high viscosity were investigated based on their ability to induce slow
release while maintaining the enzyme activity.
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x Immediate drug release system. It was not clear whether the slow extended
release system would provide the optimum desired drug release rate, and so it
was necessary to have another formulation equivalent to liquid dosage form but
with minimum drug administration problems. In this case tablets with three types
of disintegrants primojel, L-HPC and Ac-Di-sol were evaluated to determine
their effectiveness in inducing fast release of CPs from these tablets.
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CHAPTER 2: MATERIALS AND METHODS
2.0 Summary
This chapter summarizes the general materials and methods used for enzyme
preparations, in vitro and in vivo assessment of the anthelmintic efficacy of the
cysteine proteinases (CPs) and the papaya latex supernatant (PLS) formulation and
delivery experiments. Details of the exact experimental design for each individual
experiment are explained in relevant sections of each experimental chapter.
2.1 Enzyme preparations
The enzymes used for both in vitro and in vivo experiments were PLS from Carica
papaya (containing a mixture of papain, chymopapain, glycyl endopeptidase and
caricain), stem and fruit bromelain from the stem and fruit (respectively) of the
pineapple plant (Ananas comosus) and actinidain from kiwifruit (Actinidia chinensis)
prepared as explained below. All these preparations were stored at -80
o
C until
required. Upon thawing the concentration of active cysteine proteinase was
determined by active-site titration with the cysteine proteinase specific inhibitor E-
64, and their concentrations were adjusted according to the exact requirements of the
experiments.
2.1.1 Papaya latex supernatant
PLS was prepared by dissolving 4 kg of Carica papaya spray-dried latex purchased
from Enzymase International S.A (Brussels, Belgium) in 12 litres of water. Since the
spray dried latex is hazardous to the respiratory system (Flindt, 1978), the process
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was carried out in a fume cupboard. The preparation was centrifuged at 17,700 x g at
4
O
C (Beckman model J2-21 centrifuge Rotor, UK) and the pellet was discarded. The
supernatant was concentrated to a third of its original volume by placing it in dialysis
tubing with MW cut-off 3,500 (SpectraPor 45 mm diam.) over polyethylene glycol
20,000. The concentrated PLS was aliquoted into individual vials and stored at -
80
o
C. Throughout this study the preparation is referred to as the papaya latex
supernatant (PLS).
At each step of the purification the molar concentration of the active cysteine
proteinase was measured by active site titration with L-trans-epoxysuccinyl-
leucyamido (4-guanidino) – butane (E-64) (Sigma-Aldrich and Apollo Scientific Ltd,
UK) with 4 mM L-cysteine as a reducing agent and Į-N-benzoyl-DL-arginine-p-
nitroanilide (BAPNA) was used as the synthetic substrate for PLS enzymes. The
initial activity in 4 kg was 70 mmol of active enzyme. However, this amount was
reduced by about half due to loss of activity during processing and freezing at -80
o
C.
The estimate of lost activity is based on the assessment of the activity remaining in
the individual thawed vials.
2.1.2 Pineapple fruit and Kiwi fruit extracts
Pineapple fruit extract (containing fruit bromelain) and kiwi fruit extract (containg
actinidain) were prepared from pineapple fruit and kiwifruit juices respectively. The
ripe fruits were purchased from Sainsbury supermarket, U.K and were peeled. Their
fruit portion was cut into small pieces and crushed in a laboratory juicer (Philips
juicer HR 1861) and filtered. The filtrate was then subjected to vacuum filtration to
remove the remaining fine debris (the process was conducted under ice whenever
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possible to avoid enzyme autolysis). The filtered juice was divided into two portions.
The first portion of the juice was directly concentrated by dialysis using MW cut-off
3,500 dialysis tubing (SpectraPor 45 mm diam.) over polyethylene glycol 20,000.
The concentrated juice was aliquoted into vials and stored at -80
o
C for future use.
The second portion of the juice was slowly mixed with 2/3 of its volume of
cold acetone for enzyme precipitation. The acetone mixture was filtered using fresh
filter paper and the waste filtrate was discarded. The collected precipitate was further
washed with 100 ml of acetone. Then the filter paper was gently removed and kept in
the fume cupboard to allow the acetone to evaporate and the filter paper to dry out.
The dried precipitates were scrubbed and dissolved into 100 ml of 1 mM EDTA,
dialysed and kept at -80
0
C.
2.1.3 Stem bromelain
Stem bromelain was obtained from Hong Mao Biochemical Co. Ltd, Thailand,
kindly given as a gift. This was a dried stem pineapple juice preparation. Two
hundred grams of stem bromelain were dissolved in 1 litre of distilled water and
centrifuged at 17,700 x g at 4
o
C and the pellets were discarded while the supernatant
was dialysed, aliquoted into vials and stored at -80
o
C. Individual vials were thawed
and assessed for enzyme activity before use.
2.1.4 Active site titration
The concentration of active cysteine proteinase (CPs) from different preparations
were determine by active-site titration adapted from Barrett et al. (1981) and Zucker
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et al. (1985). The samples were titrated with increasing concentrations of the
cysteine proteinase specific inhibitor, trans-epoxysuccinyl-L-leucylamido-(4-
guanidino) butane (E-64). The enzyme solution (10 µl) was added to 250 µl of
activating buffer (0.2 M Na2H/NaH2PO4 buffer/16mM L-cysteine, pH 6.85). From 0
to 100 µl of 20 µM E-64 were added to 11 tubes (at either 5 or 10 µl increments) and
1mM EDTA (Ethylenediaminetetraacetic acid) was added to prevent reaction of
enzyme with heavy metals and to make up a total of 1ml of final assay volume. The
mixture was vortexed and incubated at 40°C for 15 min to allow the E-64 to bind
with enzyme active sites. Depending on the source of the CPs 12.5 or 25 µl of 10mM
benzoyl-arginyl-p-nitroanilide (BAPNA) (Bachem Ltd, UK) substrate were added to
PLS, carbobenzyloxyarginylarginyl-para-nitroanilide (Z-Arg-Arg-pNA) (Bachem
Ltd, UK) to stem bromelain and Z-Phe-Arg-pNA (Bachem Ltd, UK) to pineapple
fruit bromelain and actinidain solutions. Each of these substrates can be easily
cleaved by its specific enzyme to release a yellow 4-nitroaniline compound, the
concentration of which can be determined by spectrophotometry. After 15 minutes of
incubation with the substrate the reaction was stopped by the addition of 1 ml of 0.1
M stopping buffer solution (sodium chloroacetate/ 0.2M sodium acetate buffer). The
concentration of 4-nitroaniline released was then determined at 410 nm (Mole and
Horton, 1973). Since E-64 inhibition results in a molar 1:1 stoichiometric
inactivation of CPs, a linear decrease in the concentration of 4-nitroaniline released
with increase in concentration of E-64 resulted. The intercept of the line with the
abscissa was the molar concentration of the enzyme.
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2.2 In vitro experiments
2.2.1 Parasites
The parasites used throughout this study were the rodent specific GI nematode,
Heligmosomoides bakeri. The parasites have been maintained at the University of
Nottingham in laboratory mice since 1976. For the in vitro studies BKW mice were
purchased from B & K Universal Ltd, UK at 5 weeks of age and were infected at 6
weeks of age by oral gavage with a suspension of 300 H. bakeri L3 larvae in 0.2 ml
of purified water. From day 14 post infection worms were already matured enough
for use. Faecal samples were collected from the mice for egg counts to establish
whether the mice were successfully infected with the parasites before the animals
were sacrificed. The mice were then killed by exposure to increasing concentrations
of CO2 and dissected. Their small intestines were removed in their entirety and
opened longitudinally with a pair of blunt-ended dissecting scissors. The intestines
were placed into a Petri dish containing pre-warmed Hanks’ Balanced Salt Solutions
(HBSS) and placed in bench incubator at 37
o
C for about 10 min to allow the worms
to detach from the intestine. Adult male and female worms were picked out with the
help of fine forceps under the microscope and washed in pre-warmed HBSS before
being used for motility assays.
2.2.2 Effect of CPs on the motility of adult worms
Adult male and female worms were transferred to 48-well plates (1 worm/well)
containing HBSS (without phenol red), pH7.2 and 16mM L-cysteine and one of the
following enzyme preparations: 0-3000 µM PLS, which was used as a positive
control, 0-4000 µM stem bromelain, 0-150 µM pineapple fruit extract and 0 - 50 µM
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kiwifruit extract. The control wells were incubated in parallel and contained no
enzyme, no inhibitor, no cysteine, or enzyme which had been pre-incubated with E-
64, in combinations as specified.
The worms were incubated at 37
0
C for 2 h and their motility was recorded
every 15 minutes using a standard motility scale from 0–5 adapted from Stepek et al.
(2005) where 0 was given to completely motionless worms not responding to manual
stimulation, 1- movement only when prodded, 2 – active only in the tip ends, 3 –
slowly spontaneously active, 4 - more active and 5 - highly active.
2.2.3 SEM for worms exposed to variety of plant CPs.
Adult H. bakeri worms were incubated in 48 well plates containing either 200 µM
PLS+L-cysteine, 200 µM stem bromelain+L-cysteine, 150 µM pineapple fruit and 50
µM kiwi fruit extract+L-cysteine or HBSS. At 0, 30, 60, and 90 min worms were
removed from each well plate and placed into bijous containing 2.5% glutaraldehyde.
After 1 h the glutaraaldehyde was carefully pipetted off and replaced with 0.1 M
phosphate buffer and left for 1 h. The worms were then prepared for scanning
electron microscope (SEM) by removing the phosphate buffer and fixing them in 1%
osmium tetrachloride for 1 h (this was done in the fume cupboard). The osmium was
removed and the worms were washed 3 times with distilled water and dehydrated in
increasing ethanol concentration from 30-100%. The specimen were transferred to a
metal basket boat (care was taken not to allow the specimen to dry) and placed into a
critical point drying (CPD) apparatus in which ethanol was replaced by CO2 and the
specimens were dried with their features intact. The dried specimens were then
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carefully mounted on disc stubs with quick-drying silver paint (Agar Scientific
Limited, Essex, UK) and sputter coated with gold before examination in SEM.
2.3 In vivo experiments
2.3.1 Parasites
The source of the parasites used for in vivo experiments came from BKW mice
previously infected with H. bakeri worms (between 14-30 days post infection). Mice
were placed on a grid in the cage suspended over moistened tissue paper placed in
the bottom of the cage in the evening and left overnight. The next day morning faecal
samples were collected and brought into the laboratory and mixed with about equal
amounts of activated carbon charcoal pellets. Distilled water was added and gently
mashed into a paste, care being taken not to make it too wet. Then the paste was
mounted at the centre of a damp 11 cm filter paper in a plastic Petri dish (Fig 1.2).
The Petri dishes were then placed in a plastic container lined with moistened tissue
papers and covered with a lid but not tightly leaving a space to allow exchange of air
and were then incubated at room temperature for 7 days. This period was sufficient
for eggs hatching and to enable the larvae to complete their free-living development
stages to the infective L3 stage. The L3 larvae descend from the faecal slurry onto
the filter paper and accumulate below it. These accumulated L3 larvae were washed
off with distilled water from the underside of the filter paper and were collected into
a clean bottle, which was covered and kept at 4
o
C in preparation for infection of
mice.
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2.3.2 Preparation of H. bakeri L3 larvae for infection
The number of fresh L3 larvae required for mice infections was estimated in 0.1 ml
aliquots pipetted from the larval suspension placed on magnet stirrer and being
gently stirred. Each 0.1 ml sample was emptied from the syringe, drop by drop onto a
clean Petri dish, and the larvae in each drop were counted with the help of a tally
counter under a dissecting microscope. The total number of larvae was doubled to
obtain the number of larvae in 0.2 ml required for mouse oral gavage. If the number
of suspended larvae in a 0.1 ml sample did not reach the required concentration for
infection, the larvae were left to settle down for some time and an appropriate
amount of supernatant was drawn off to concentrate the remaining larvae and then
more aliquots were counted to confirm that the required concentration had been
achieved. If the number of suspended larvae was more than the required number, a
suitable amount of water was added to dilute the larval suspension. Although mice
can tolerate quite heavy H. bakeri worm burdens it was necessary to be extremely
careful in choosing the appropriate dose of larvae to avoid distress to the animals. In
this study the doses of larvae used for infection did not exceed 300 L3, this level of
infection being associated with a minimal stress in accordance with the Animal
Procedure Acts (1986).
2.3.3 Animals
Eight strains of mice were employed including BKW (B&K Ltd, UK), C3H (Charles
River Ltd, UK and some from Harlan, UK), NIH (Harlan, UK), NIH swiss (Harlan,
UK), C57/BL (Charles River Ltd, UK), BALB/c (Charles River Ltd, UK), CBA/ca
(Charles River Ltd, UK) and CD1 (Harlan, UK). The animals were purchased at the
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age of 5 weeks and infected at 6 weeks of age. They were ear notched to enable
identification and kept in standard polypropylene cages (5 mice per cage). The
animals were provided with standard laboratory rodent food pellets and water ad
libitum with the exception of experiments that involved food restriction. All the
animal procedures were carried out under Home Office Project Licence 40/2942
under the regulations of the Animal Scientific Procedures Act 1986. The health of
the animals was assessed based on physical appearance and body weight, in
accordance with the terms of this licence that required avoidance of exceeding the
moderate banding (as defined by the Home Office ASPA, 1989), and animal care and
welfare was implemented throughout the experiment.
2.3.4 Faecal egg count (FEC)
On day 14, 16, 18, 21, 23 and 25 post infection faecal samples from the infected
mice were collected by placing individual mice in a plastic cage for about 1 h. The
mice were provided with water but not food. An amount of faeces approximating to 1
g was collected from each mouse into pre-weighed universal tubes. The faeces + the
universal tubes were weighed and 10 ml of saturated salt (NaCl) were added. The
pellets were allowed to soak and break up for 1 h using an Intelli-Mixer RM-2L
(EMLMI Ltd, Latvia). The mixture was agitated and poured quickly through a sieve
(5 diameters, 800X800 µm square apertures) and washed with a further 50 ml of
NaCl salt solution for egg floatation. The number of eggs present was counted using
a 2-chamber McMaster slide. The eggs that float within the designated grid lines of
each chamber (with a volume of 0.15 ml) of the McMaster slide were counted under
a microscope. The number of eggs per gram (EPG) was calculated using the
modified McMaster egg count technique (Behnke and Parish, 1979) as follows:
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ࡱࡼࡳ = ۼܝܕ܊܍ܚ ܗ܎ ۳܏܏ܛ ۱ܗܝܖܜ܍܌܅܍ܑ܏ܐܜ ܗ܎ ۴܉܍܋܍ܛ ܠ܂ܗܜ܉ܔ ܞܗܔܝܕ܍ ܗ܎ ۼ܉۱ܔ܄ܗܔܝܕ܍ ۱ܗܝܖܜ܍܌
2.3.5 Worm counts
On day 25 post infection mice were killed by exposure to increasing concentrations
of CO2 and the intestines were removed in their entirety. These were opened
longitudinally with a pair of blunt-ended dissecting scissors. Each intestine was
placed into a net made from gauze netting in a 50 ml beaker containing pre-warmed
(37
0
C) HBSS and kept in a water bath for about 4 h to allow the worms to dislodge
from the intestine. The female and male worms present in the net and those that had
collected at the bottom of the beaker were counted under a dissecting microscope to
provide a worm burden assessment.
2.4 PLS formulation and delivery experiments
2.4.1 Materials
Magnesium stearate was obtained from BDH Laboratory Supplies (Dorset, UK),
freeze dried PLS prepared from the stock purchased from Enzymase International
S.A (Brussels, Belgium), Ac-di-Sol (croscamellose sodium) was a kind gift of FMC
BioPolymer AS (Billingstad, Norway), Primojel (sodium starch glycolate) a kind
gift of DWV-Fonterra Excipients GmbH & Co.KG (Goch, Germany) and L-HPC 32
(Low- Substituted Hydroxypropyl Cellulose) was also a kind gift from Shin-Etsu
Chemicals Co., Ltd (Tokyo, Japan). Other chemicals were Xanthan gum from CP
Kelco, (Liverpool, UK) and Hydroxypropyl methylcellulose (HPMC) including
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Methocel-CR and Methocel-LVCR premium grades, were a kind of gift from
Colorcon Ltd (Dartford, UK). All other materials used for preparation of activating
and stopping buffers were routinely available laboratory analytical chemicals.
2.4.2 Tablet manufacture
Different proportions of freeze dried PLS with either a hydrophilic polymer (XG or
HPMC) or disintegrant powders were mixed and blended in a Y-cone blender (Neco,
London, UK) for 9 min. Then 0.5% w/w of magnesium stearate was added as a
lubricant to prevent the mixture from sticking to the machine and mixed for a further
1 min. These powder blends were compressed into 19 mm diameter, round, flat-
faced tablet using a Manesty F3 single punch machine (Manesty, Liverpool, UK)
operated manually.
2.4.3 Evaluation of tablet properties
Basic properties of the tablets including uniformity of mass, tablet hardness and
friability were measured. The uniformity of tablet weight was determined as the
relative standard deviation of 10 randomly selected tablets. The tablets were weighed
individually using an analytical balance Kern ALS 120-4N (Kern & Sohn GmbH,
Balingen, Germany). Then the individual weight was compared with an average
weight. According to the European Pharmacopoeia (2008), no tablet should deviate
from the average weight by more than 5 percent.
In each formulation 10 tablets were picked randomly for hardness testing.
The tablet crushing load, which is the force required to break a tablet by compression
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in the radial direction was determined using the tablet hardness tester C50
(Engineering systems (NOTTM) Ltd, Nottingham, England). Then the average value
was calculated.
Friability was determined by placing 10 tablets of each formulation in a TAR
10 friabilator (Erweka GmbH, Heusnstamm, Germany) and operating the drum for 4
min and 25 rpm. Friability was determined as the average loss in weight of the tablet
due to fracture or abrasion. Friability less than 1% was considered as normal.
Friability was calculated using the following formula:
ࡲ࢘࢏ࢇ࢈࢏࢒࢏࢚࢟ = [(ࡵ࢔࢏࢚࢏ࢇ࢒ ࢝ࢋ࢏ࢍࢎ࢚  ࡲ࢏࢔ࢇ࢒ ࢝ࢋ࢏ࢍࢎ࢚)/ࡵ࢔࢏࢚࢏ࢇ࢒ ࢝ࢋ࢏ࢍࢎ࢚)] ࢞ ૚૙૙
2.4.4 In vitro drug release studies
In vitro dissolution tests were used to simulate physiological conditions in the GI
tract. Drug release from the tablets was determined using an USP apparatus 2
(paddle) in 900 ml of 50 mM phosphate buffer medium pH 6.8 at 100 rev. min
-1
and
37±0.5
o
C. At specified time intervals 3 ml of sample were withdrawn from the
dissolution vessel using a plastic syringe attached to a filtered stainless steel cannula.
The volume of sample taken was replaced back by fresh medium in order to maintain
the volume of the medium. Then the content of protein (drug) release was quantified
by UV spectrometry using a WPA light wave II Spectrophotometer (biochrom Ltd,
Cambridge, England) at 280nm in a 10 mm path length quartz cuvette. The
absorbance values were converted into protein concentration using the linear portion
of the standard curve.
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In order to explore the whole dose, 8 normal tablets of 19 mm in diameter were
stacked together to form a bolus with weight about 15 g (Fig. 2.1). The tablets were
then assessed for drug released as usual using USP apparatus 2 but because the
tablets were too big to dissolve in a 900 ml vessel, then all the vessels from the
dissolution tester were removed. The water bath of the dissolution tester was then
used as the vessel for dissolution of the drug. In this case 16 litres of 50 mM
phosphate buffer were employed. Samples were withdrawn as explained above.
Figure 2.1: Preparation of ruminal bolus by sticking together individual tablets.
2.5 Statistical analysis
In vitro motility experimental data (raw data) and FEC transformed data
Log10(FEC+25) were analysed using repeated measures general linear model
(rmGLM) in SPSS (version 19.0). To assess whether there was a significant decrease
in worm mortality and faecal egg counts over time, time after introduction of
experimental treatments was fitted as the within-subject factor. To determine whether
the decrease in mortality or FEC was significant different among treatments then
treatments (concentrations of pineapple fruit extract, PLS, kiwi fruit extract and stem
bromelain) were fitted as between-subject factors. When the data did not meet the
Individual tablet
Stacking of tablets Bolus/horse pill
5.5cm
19mm
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requirements of Mauchley’s Test of Sphericity, Huynh-Feldt adjustment to the
degrees of freedom was used to interpret significance on the side of caution.
However, to assess the different treatment effects on in vivo intestinal worm
counts 1, 2 or 3-way ANOVA (depending on the experimental design) was used and
significance was checked at 0.05 and 0.01 levels of probability among the various
treatments. Statistical models were mostly fitted to raw data, rather than transformed
data (although in some cases these were also implemented), because in most cases
these conformed to their requirements of parametric tests. All parametric models
were assessed for goodness of fit by R
2
and their residuals were checked for normal
distribution. The IC50 for the motility assays was determined using curve fitting-
statistical software GraphPad Prism 6. The data were analyzed using a non-linear
regression model and sigmoid dose-inhibition curves were fitted using
Log10(inhibitor) vs. response – Variable slope (Four parameter dose-response curve)
equation.
Model: Y = Bottom + (Top-Bottom)/(1 + exp(S(LogIC50 - X)))
The bottom was constrained to a constant value of 0 (minimum motility) and the top
was constrained to upper limit of 5 (maximum motility).
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CHAPTER 3: PREPARATION AND PROFILING OF PLS
3.0 Summary
This chapter deals with the preparation and profiling of papaya latex supernatant
(PLS). The purification and profiling of PLS were conducted by centrifugation,
dialysis and concentration over PEG, freeze drying and storing at different
temperature conditions. Enzyme activity was assessed by active site titration. The
results indicate that concentration by dialysis remains the best way of preparing the
enzymes. There was a gradual decrease in enzyme activity for PLS stored at ambient
temperature as after 1 week of storage only 27.6% of the active enzyme remained
while the PLS stored at 4
o
C retained 27.9% of the active enzymes after 1 year.
However, PLS kept at -20
0
C and -80
0
C retained its activity at more than 80% of the
original level after 1 year. Freezing and thawing were found to have had no effect on
enzyme stability. Moreover it was shown that there was no decline in enzyme
activity over a period of up to 2 h during typical motility assays as described in
Chapter 4. The freeze dried PLS that was stored at 4
o
C for 1 year retained more that
80% of its active enzymes compared with that stored at ambient temperature which
retained only 40% of its original active enzymes.
3.1 Introduction
Like any other proteins, the extraction and purification of cysteine proteinases (CPs)
is highly dependent on their unique physical and chemical properties, such as
solubility, charge, hydrophobity and binding affinity (Grodzki and Berenstein, 2010).
Different methods have been employed for extraction of the CPs from plants,
whereby the initial steps involve extraction of the latex or juices from the plants of
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interest, followed by purification and concentration of the enzymes. Among the
common methods used in purification and concentration of the enzymes are salting
out (Grodzki and Berenstein, 2010), organic solvent fractionation (Merrill and
Fleisher, 1932) chromatography (Bertsch, 1985, Ehle and Horn, 1990),
concentration by ultra-filtration (Jiang et al., 2004), electrophoresis (Ros et al.,
2002), dialysis (Monti et al., 2000) and freeze drying (Roy and Gupta, 2004, Maa
and Prestrelski, 2000).
In most cases, the processes of extraction and subsequent treatment have been
shown to be detrimental to enzyme structure and/or its biological activity and these
changes have been attributed to many different factors including temperature, pH,
ionic strength, redox potential, autolysis, heavy metals, mechanical stress, damage of
thiol groups and dilution effects (Arakawa et al., 2001). The effect of temperature on
enzyme activity has been described by two thermal parameters: the Arrhenius
activation energy, which defines the effect of temperature on the catalytic rate
constant Kcat (Peterson et al., 2007) and the thermal stability which describes the
mechanism of inactivation of enzymes at higher temperatures (Erarslan and Kocer,
1992). Exposure of enzyme outside the active pH range, is known to affect the state
of ionization of either acidic or basic amino acids in that particular enzyme causing
the structure of the active binding site to change and thereby resulting in an inability
of the substrate to bind to the enzyme. These changes can lead to irreversible loss of
enzyme activity (Nicholas and Stevens, 2002).
Autolysis is another factor that affects enzyme stability by causing
degradation of enzymes through the activity of endogenous proteinases. The problem
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has been reported to be accelerated by exposure of the enzymes to oxygen (Balls and
Thompson, 1940) causing the active cysteine residue which is prone to oxidation, to
form either disulphide bonds or oxidized species (Wilk, 2001). However, autolysis
can be minimized by lowering the temperature to inhibit the action of proteinases or
addition of proteinase inhibitors during extraction (Yu et al., 1993). The oxidation
process can be catalysed also by the presence of heavy metal ions (e.g Cd
2+
, Pb
2+
and
Hg
2+
) which react with sulphydryl groups or transition metals (e.g Cu
2+
or Fe
2+
)
which promote formation of complexes with unreactive oxygen molecules. The
effect of heavy metals on proteolytic enzymes was first reported by Krebs in 1930
(Kozima, 1957) who found that Zinc, cadmium and mercury inhibited the hydrolysis
of papain. However, inclusion of a low concentration of EDTA in the assay can
remove any heavy metal through chelation (Zucker et al., 1985).
In extraction of plant CPs, papain is the most studied and its process of
extraction has been well established. Balls et al. (1940) were the first to develop a
process for isolating and purifying papain from fresh papaya latex. However, due to
the scarcity and high cost of fresh papaya latex the process was later modified by
Kimmel and Smith (1954) by using commercial dried papaya latex and this method
has become now the classic method for papain extraction.
The extracted enzymes need to be stored in such a way that the enzyme
activity is maintained for a long period of time. However storage of enzymes
depends on their stability and on when and how they will be used later on. For long
term storage enzymes are generally advised to be frozen at either -20
o
C or -80
o
C or
freeze dried. However during freezing and freeze drying the enzymes are exposed to
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low temperature and formation of ice and potential mechanical disruption by ice
crystals (Arakawa et al., 2001) which may lead to inactivation. Cold denaturation has
been documented clearly for several proteins and enzymes (Privalov, 1990) and the
effect can be demonstrated during freeze-thawing while at high temperatures,
enzymes are subjected to oxidation, resulting in loss of activity. Therefore, it was
important to ascertain the best storage conditions for PLS that would allow extracted
enzymes to be maintained for the experiments reported later in this thesis, over
prolonged periods of time without significant loss of enzyme activity.
Aims and objectives
The first objective of the experiments reported in this chapter was to determine
which method of concentration of papaya latex (e.g. centrifugation, dialysis or freeze
drying) would provide high yields of CPs in PLS.
CPs in PLS are in their natural conditions, unlike purified enzymes, but it was not
known if the latex has any particular role in protecting the enzyme during long term
storage. Therefore, the second objective of this chapter was to assess the stability of
CPs in PLS stored at different temperatures (ambient temperature, 4
0
C, -20
0
C and -
80
0
C).
Freezing in solution and freeze-drying are the most commonly used methods for
the long-term storage of enzymes but these processes have been reported to be
detrimental to many enzymes, although the exact consequences of these treatments
depend on the nature of the protein (Arakawa et al., 2001). This means that survival
of enzyme activity following this treatment depends to a large extent on the protein
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in question. Thus the third objective of this study was to determine the effect of
freeze-thaw cycles and freeze drying on the activity of the CP enzymes in PLS.
Determination of the anthelmintic efficacy of PLS against GI nematodes
involves in vitro assays in which the motility of the worms is monitored over a
period of 2-3 hours. However, it was not known whether the conditions used in these
assays would influence the enzyme activity, perhaps leading to rapid loss of enzyme
activity within the period of observation. So the fourth objective of this chapter was
to determine how active and for how long the enzymes retained activity after
introduction into the assay conditions, during a typical period of observation of worm
motility.
3.2 Experimental design and Results
3.2.1 Experiment 1: Preparation of PLS
This experiment was carried out to concentrate CPs in PLS using various methods of
purification including centrifugation, dialysis and freeze drying. The source of CPs
was the refined spray dried papaya latex powder (Enzymase, Belgium). The powder
is prepared by the Enzymase Company by mechanical filtration of freshly collected
latex from the Carica papaya tree. The process involves several filtration steps under
low temperatures with final spray drying. In this experiment 4 kg of powder was
mixed with 12 litres of water for 1 h and the product was centrifuged, the pellets
were discarded while the supernatant was collected. The supernatant was dialyzed
and concentrated by placing it into dialysis tubing with MW cut-off 3,500
(SpectraPor 45 mm diam.) over polyethylene glycol 20,000. The dialyzed PLS was
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frozen at -80
o
C. A portion of the frozen dialyzed PLS was taken for freeze drying, a
process of removing water from frozen samples by sublimation and desorption (Roy
and Gupta, 2004). The dried sample was reconstituted subsequently to its original
volume for determination of enzyme activity. The amount of active enzyme present
in each stage of purification was determined by active site titration with E-64 in the
presence of L-cysteine.
3.2.2 Experiment 1: Results
The results are shown in Fig. 3.1 and these indicated that the centrifuged PLS
prepared from refined spray-dried papaya latex showed comparable active enzymes
to the original un-centrifuged material (1.475 µM and 1.385 µM respectively). This
indicates that the spray dried papaya latex had a high level of active enzymes.
However, after dialysis there was a decrease in the amount of active enzymes by
30% remaining with 0.975 µM when compared to the original un-centrifuged
solution. The decrease in enzyme activity was continued further in the freeze dried
PLS to 44% (0.775 µM).
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Figure 3.1: Amount of active enzyme present in different preparation methods
The graph shows variation in enzyme activity of papaya latex extracts that have
undergone different treatments before active site titration. In this case the starting pre
centrifuge solution was a raw preparation of papaya latex. The supernatant was the
supernatant fluid after centrifugation of the raw preparation at 17,700 x g. The
dialysed PLS was the supernatant fluid which has been concentrated by dialysis to
remove extra water and small molecule impurities. The freeze dried PLS was the
powder of freeze dried supernatant (which had undergone dialysis) and reconstituted
to the original volume with water. The values are the mean of active enzymes (3
replicates) in nmol with standard errors.
3.2.3 Experiment 2: PLS profiling at different temperature storage conditions
This experiment was carried out to determine the most suitable storage condition for
PLS that would retain as much of the active enzymes for as long a period of time as
possible. Since CPs in PLS are still in their natural form, their stability and capacity
to retain enzyme activity at various temperatures was determined. To achieve this
objective PLS was aliquoted into individual containers and stored at a range of
temperatures and conditions including at ambient temperature (22
o
C), in refrigerator
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(4
0
C) and freezer (at -20
0
C or -80
0
C) for periods of 1, 4, 24 and 48 weeks, before
being assessed for the amount of active enzymes remaining.
3.2.4 Experiment 2: Results
The results showed that there was a progressive decline in amount of active enzymes
of the PLS kept at some temperatures but not at all (Fig.3.2). PLS kept at ambient
temperature there was an abrupt decrease in active enzymes, immediately after 1
week of storage, the amount of active enzyme went down to 27.6% and after 1 month
the activity was further reduced to 23.5% of the original active enzyme. After 1 year
almost all the active enzymes were gone (only 1.3% remained). PLS kept at 4
0
C
retained the active enzymes for a longer time; after 1 year it had remained with
27.9% of the active enzymes. For PLS stored at -20
0
C or -80
0
C more active enzymes
were retained after 1 year 82.4% and 79.4% respectively of the original level was
still active (Fig. 3.2, for numerical data see Appendix 3). Thus, as expected, the
activity of PLS is strongly influenced by the temperature at which it is being stored.
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Figure 3.2: PLS activity at different storage conditions over time
The figure presents the percentage in amount of active enzymes present in 10 µl of
the original sample of PLS stored at different temperature conditions (ambient, 4
o
C, -
20
o
C and -80
o
C) assessed at different time intervals.
3.2.5 Experiment 3: Effect of freezing and thawing on PLS enzyme activity
This experiment was made to follow up the results of Experiment 2 which indicated
that when PLS was stored at -20
o
C or -80
o
C it had retained more enzyme activity
compared with PLS stored at higher temperatures. However, it is recognized that a
critical phase for the survival of protein integrity and enzyme activity is the process
of freezing and thawing from very low temperatures i.e. freeze-thaw cycles. This was
an important consideration in the case of CPs because the enzymes were to be stored
for the experiments conducted in the following chapters of this thesis and there was
no published data on the stability of CPs during cycles of freezing and thawing.
Therefore, this experiment was carried out to determine whether repeatedly freezing
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and thawing of PLS would have an influence on enzyme activity. The dialyzed PLS
was first frozen at -80
o
C and after 1 month the sample was thawed to ambient
temperature (22
o
C). One ml of sample was taken from the thawed PLS (freeze-thaw
1) and tested for enzyme activity. The sample was re-frozen at -80
o
C for another 1
month and was thawed again to room temperature and a second 1 ml was taken from
sample (freeze-thaw 2). This cycle was repeated 5 times yielding 5 freeze-thaw
cycles. Each time the sample was thawed, and tested for enzyme activity.
3.2.6 Experiment 3: Results
The stability of enzyme activity due to repeated freeze-thaw cycles was assessed
based on percentage reduction in amount of active enzymes in 1 ml assay (Fig.3.3).
The first, second, third, fourth, and fifth freeze-thaw cycles reduced enzyme activity
by 19.7%, 27.6%, 26.4%, 20.5% and 25.3% respectively when compared with the
activity of the original sample. From these results it appears that there was little
further reduction in enzyme activity after the first freeze-thaw cycle. This means that
after the first freeze-thawed cycle the enzyme activity remains relatively stable and
the number of freeze-thaw cycles have little impact on enzyme activity.
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Figure 3.3: Effect of freeze-thawing cycles on PLS active enzymes
The figure shows the percentage change in amount of active enzymes for dialyzed
PLS frozen at -80
o
C for 1 month and then thawed. The process was repeated 5 times
and each time the amount of active enzymes remaining was determined. There was a
reduction in enzyme activity at the first cycle and then the activity remained
relatively constant in the succeeding cycles.
3.2.7 Experiment 4: Freeze dried PLS profiling at ambient temperature and
4
o
C
Enzymes and other proteins are said to be more stable in the solid state compared
with solution (Roy and Gupta, 2004) and the freeze-drying process is perceived to be
a gentle process for drying biologically active substances. Therefore, Experiment 4
was carried out to determine the post storage stability of the freeze-dried PLS at two
storage conditions (ambient temperature and 4
o
C). These conditions were chosen
based on the fact that the product being developed here is intended for use by farmers
whose storage facilities are likely to be limited. Thus dialysed PLS was aliquoted
into portions of 25 ml and sealed with perforated cling film. The samples were frozen
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at -80
o
C before being placed into an SB4 freeze-dryer (Chemlab, England) and left
overnight to freeze dry. The next day the freeze-dried PLS was taken out and tested
for enzyme activity. Some portions of the freeze dried PLS sample were stored at
ambient temperature (22
o
C) and the other portions were kept in a refrigerator at 4
o
C
and then at different time intervals the samples were tested for enzyme activity.
3.2.8 Experiment 4: Results
The results are shown in Fig. 3.4 and these indicate that there was a decline in active
enzymes immediately after freeze drying storage in both samples. However the
decrease was higher in the sample stored at ambient temperature after 1 month (4
weeks), the active enzymes of PLS falling by 14.3% while that PLS kept at 4
o
C
decreased only by 10% of the original total active enzymes. After 1 year (48 weeks)
the freeze dried PLS stored at ambient temperature had retained only 57.1% of its
original active enzymes whilst the PLS store at 4
o
C retained its active enzymes by
more than 86.4%.
71
Figure 3.4: Freeze dried stored at different temperature conditions.
Freeze-dried PLS was stored at ambient temperature (O) and 4
o
C (¨ 7KH UHVXOWV
showed that there was a gradual percentage loss in amount of active enzymes in PLS
stored at ambient temperature than that stored at 4
o
C.
3.2.9 Experiment 5: Enzyme stability in motility assay
This experiment was aimed at determining the stability of CP enzymes during a
typical motility assay. Since motility assays are carried out at 37
o
C, the mammalian
body temperature that the worms require, it was important to determine the stability
of CPs under these experimental conditions. In addition to the effect of temperature,
the inclusion of Hanks’ buffered saline solution (HBSS) and other ingredients in the
incubation assay may have affected the stability of CPs and these had to be
evaluated. To achieve these objectives PLS was incubated at 37
o
C in the HBSS and
activating buffer. Then at 0, 15, 60 and 120 min a sample was drawn from the assay
for the assessment of enzyme activity.
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3.2.10 Experiment 5: Results
The results in Fig.3.5 indicate that the motility assay conditions have little/no
influence on the enzyme activity. Initially there appeared to be a slight increase in the
amount of active enzymes, particularly at first hour (113%), but then it remained
stable until the end of the experiment, 2 hours later.
Figure 3.5: Enzyme stability in motility assay conditions
PLS was incubated under typical motility assay conditions and at 0, 15, 60 and 120
min a sample was taken for assessment of the amount of active enzyme. The amount
of active enzymes remained stable throughout the incubation time over a period of 2
hours.
3.3 Discussion
PLS was concentrated in this study for the purpose of profiling, storage and to
facilitate formulation into different sets of doses to be used for subsequent in vitro
and in vivo experiments. The results have indicated that the amount of active enzyme
in spray dried papaya latex solution and the supernatant was almost identical,
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indicating that the original source, the sprayed dried PL, had less debris. This is in
line with what Kimmel and Smith (1954) had reported in their study on the use of
commercially available dried PL, that it contains sufficient amounts of the active
enzyme for the crystallization of papain. There was a decrease in amount of active
enzymes by 30% during dialysis process and further reduction was observed during
freeze drying process (44%). This is due to the factor that most proteins become less
stable against these stresses (Arakawa et al., 2001).
It was also observed that there was a negative relationship between storage
temperatures and enzyme activity. For example PLS stored at ambient temperature
(about 22
0
C) rapidly lost its enzyme activity remaining with only 27.9% of the
original active enzymes within 1 week of storage while that stored at -80
o
C had
retained more than 94% of its active enzymes. The effect of temperature on enzyme
activity has been widely documented and it is said to be associated with the oxidation
of the functional Sulphydryl group in CPs (Balls and Thompson, 1940). This group
in the protein can occur as a free Sulphydryl group or in disulphide linkages with
other cysteinyl residues. During long term storage, these free Sulphydryl groups may
be oxidized to the disulphide form. Then several different disulpide molecules can
link together to form higher molecular mass aggregates which are less active or
oxidation occurs to form cystine or even sulphinic, sulphonic or sulphenic acid, all of
which represent essentially irreversible oxidation states (Arakawa et al., 2001).
Proteolytic enzymes like papain can also degrade themselves when in solution
resulting in loss of activity. However, in this study the enzymes were still in the latex
which is very similar to their natural conditions and it was assumed that the latex
would prevent CPs from being exposed to oxidizing agents, thus preventing it from
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being oxidized although the latex in this case seems to have had less protective effect
at high temperatures. Devakate et al. (2009) also reported the same trend with a
significant decrease in the enzyme activity of the CPs from pineapple plants stored at
4
o
C, 30
o
C and 60
o
C for 4 days to be 4%, 50% and 90% respectively.
Although the PLS kept in the refrigerator continued to lose enzyme activity,
the extent of loss was slow, achieving 72% reduction after 1 year, in contrast to
ambient temperature at which a similar loss had occurred within 1 week. However
PLS stored at -20
o
C and -80
o
C decreased by only 20% after the entire period of 1
year. The decrease in activity of proteinase enzymes has also been reported by
Hansson et al. (1986) who found that the fresh latex extracted from the ficus (Ficus
glabrata) tree in Amazonia, fermented very rapidly at the ambient environmental
temperature. However, when the latex was stored in a refrigerator it remained active
for more than 4 months of storage, and when the latex was mixed with local brandy,
uguardiente, sugared water (sugar cane juice or honey), orange juice or banana drink
and kept in the refrigerator the enzyme activity was improved and remaining active
for up to 9 months. This was probably due to alteration in protein-solvent
interactions by the added substances (uguardiente and honey). Hale et al. (2005) also
reported similar findings with diluted bromelain solutions which were found to lose
enzyme activity by 50% within 24 h at ambient temperature but remained relatively
stable for at least 1 week when in concentrated solution. It has been reported that
many additives, such as sugars, certain amino acids, some amines, and glycerol,
stabilize proteins against temperature and pH stresses (Wang et al., 2009, Arakawa
and Timasheff, 1983, Gerlsma and Stuur, 1974).
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Balls et al. (1940) found that fresh latex was extremely powerful
proteolytically, but it was easily inactivated by oxidation. It was predicted that air
and other ingredients of the crude proteinases caused the rapid deterioration of the
enzymes. They observed that the inactivation of enzymes was at first reversed by
addition of reducing agents (hydrogen sulphide, hydrogen cyanide, and cysteine) but
with continued exposure to oxidizing influences, the protein was no longer capable
of reactivation after irreversible oxidation has occurred. This might be one of the
reasons why the people of Amazonia kept the fresh Ficus latex preparation for 4-7
days before use (Hansson et al., 1986), probably to provide time for the enzyme
activity to fall to a desirable/acceptable level. It was observed that if the latex was
taken still fresh it was associated with side effects but when taken after being stored
for some days the side effects were reduced and it was more acceptable to the
subjects that were treated.
Devakate et al. (2009) described the effect of temperature on inactivation rate
of enzymes to be similar to the kinetics of the chemical reactions by the Arrhenius
type of equation: K = k0 exp(íE/RT), where k0 is the numerical index representing
the nature of the substance and characterizing the state of an object i.e. the presence
of labile sites and bonds as well as their heat tolerance; E is the inactivation energy
(kcal mol
í1
), namely, the minimum energy that causes an irreversible change in the
substance exposed to the temperature, R is a universal gas constant (kcal mol
í1
K
í1
)
and T is temperature and (K) is the calculated inactivation energy.
Freezing is the most commonly used method for long term storage of
enzymes and other proteins, however during this process enzymes are exposed to
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critical stresses of low temperature and the formation of ice which can be damaging
to protein structure. These cold temperatures have been reported to cause
inactivation of many proteins which can be exaggerated further by repeated freezing
and thawing (Privalov, 1990). Although it is recommended that samples for frozen
storage should be dispensed and prepared in single-use aliquots so that once thawed
the unused enzyme solution is discarded and not refrozen, this is not always
practical. For example, for commercial purposes this process may not be practically
feasible as single-usage is associated with additional costs of packing, room for
storage and other inconveniences. However, the results of Experiment 3 show that
freeze-thaw cycles have little influence on CPs enzyme activity after the first cycle.
This implies that CPs do not need to be in single-use aliquots. Since PLS is a mixture
of 4 proteinases (papain, chymopain, caricain and gycyl endopeptidase) which may
have different stabilities, this suggests that a rapid loss of part of the enzyme activity
in the first cycle may be due to instability of one of these components. For instance
papain tends to be less stable than the other proteinases. The stability of the enzymes
in the subsequent cycles may have been enhanced by the concentration of the PLS,
the preparation having been dialysed and concentrated before being frozen. It has
been reported previously that in many proteins, increasing protein concentration
helps to increase the stability of proteins during freeze-thawing (Carpenter and
Crowe, 1988). Another possibility may stem from the latex acting as cryoprotectant.
This result is in accordance with several other studies which have investigated the
effect of freeze-thaw cycles, including Hsing et al. (1989) who looked at the
changes in the serum concentration of several hormones during 3 freeze-thaw cycles
and only follicle stimulating hormone was found to have fallen in concentration by
3%. Comstock et al. (2008) studied the effect of repeated 10 freeze-thaw cycles on
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concentrations of hormones in human plasma and serum. They found that repeated
freezing to -70
o
C and thawing had no meaningful effects on plasma and serum
concentration of hormones.
Another aspect which was investigated in this chapter was the effect of post
freeze-drying storage stability of PLS. The results of Experiment 4 indicated that
immediately after freeze drying there was a gradual fall in enzyme activity of the
PLS stored at ambient temperature. Several factors have been reported to contribute
to loss of enzyme activity of freeze dried powders (Roy and Gupta, 2004). The first
factor is the way the freeze-drying process is carried out. It has been reported that the
stability of freeze-dried powders depends critically on how the freeze-drying is
carried out (Mazzobre et al., 2001). The second factor is moisture content in the
freeze-dried powder. Costantino et al. (1998) provided an example of how freeze
dried proteins can become denatured in the presence of moisture during storage
periods. A freeze dried protein at pH 7.3 with a moisture content of 40 g/100 g of
protein stored at 37
o
C underwent aggregation resulting in diminished solubility. The
aggregation was via thiol-disulphide interchange. However, when the same protein
was freeze-dried from acidic solutions which inhibited the thiol groups from being
ionized, the protein did not aggregate and the resultant solubility problem was
solved. Arakawa et al. (2001) generalized that the inactivation mechanisms
responsible for deactivation of freeze-dried powders at the storage stage are identical
with those which have been known to operate in solutions (including mechanical
stress, pH, ionic strength etc). This might be the reason why the PLS stored at 4
o
C
retained more active enzymes than that stored at ambient temperature.
78
There was some concern that the motility assay conditions that were to be
used in subsequent experiments might have an effect on the active enzymes present
in PLS, with resultant deterioration of enzyme activity well short of the full
experimental period. This is due to the fact that the assay contains different
ingredients and is carried out at high temperature (37
o
C) which may have influenced
the stability of enzyme activity. However, the results of Experiment 5 are reassuring,
confirming that the enzymes remained stable under typical motility assay conditions
throughout the entire period of 2 h used for motility assay experiments. The stability
of CPs under the motility assay conditions may also be due to the short period of
time used for assessment. Normally under these temperature conditions, enzymes
lose their activity after a few days and not within a few hours, as reported here. Thus
the typical assay duration is too short for any noticeable loss of enzyme activity.
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CHAPTER 4: ANTHELMINTIC EFFICACY OF SOME PLANT CYSTEINE
PROTEINASES
4.0 Summary
This chapter extends the in vitro and in vivo experiments examining the efficacy of
plant cysteine proteinases (CPs), here focusing on pineapple and kiwifruit derived
enzymes against the rodent nematode, Heligmosomoides bakeri. Additionally, PLS
was tested against the equine nematode, Strongylus vulgaris. It was found that
pineapple fruit extract and stem bromelain derived enzymes had significant in vitro
detrimental effects on H. bakeri but in comparison there was little effect of kiwi fruit
extract. Moreover, PLS had a marked detrimental effect on S. vulgaris which caused
rapid loss of motility and digestion of the cuticle leading to death of the worms, thus
demonstrating the anthelmintic efficacy of CPs from PLS against equine GI
nematodes, in vitro. However, In vivo trials revealed far less efficacy of stem
bromelain and pineapple fruit extract than expected from the in vitro experiments
(24.5% and 22.4% reduction in worm burdens respectively) against H. bakeri.
Scanning electron microscopy pictures indicated signs of cuticular damage for
worms incubated in pineapple extract, stem bromelain and kiwi fruit extract but far
less extensive when compared with those incubated in PLS.
4.1 Introduction
Cysteine proteinases from papaya latex have been thoroughly studied and confirmed
to be efficacious against rodent, poultry, pig and sheep nematodes (Stepek et al.,
2006b, Stepek et al., 2007a, Stepek et al., 2007b, Mursof and He, 1991, Buttle et al.,
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2011). However, little has been reported on the efficacy of CPs from other plant
sources including pineapple and kiwi fruits.
Pineapple plants contain 2 main CP enzymes collectively called bromelain.
The enzymes can be distinguished as either stem bromelain (EC.3.4.22.32) or fruit
bromelain (EC 3.4.22.33) depending on its source in the plant. Other CPs found in
pineapple stem are comosain and ananain (EC 3.4.22.31) (Rowan et al., 1988). In
most cases the term bromelain is used to mean crude pineapple CP enzymes.
Bromelain has been used traditionally as an anti-parasitic agent in the Philippines
and as a medicinal plant to reduce swelling, bruising, healing time and pain
following surgery and physical injuries by different native societies of the world
including South America, China and Southeast Asia (Gregory and Kelly, 1996,
Chobotova et al., 2010) and as a wound-debriding agent (Rowan et al., 1990).
Bromelain is also sold in health food stores as a digestive aid and used as a
non-prescription anti-inflammatory agent, particularly in large animals such as
horses and cattle (Hale et al., 2002, Gregory and Kelly, 1996). It has been reported to
have both direct and indirect actions involving other enzymes like trypsin in exerting
its anti-inflammatory effects. Moreover, bromelain has been proven to be capable of
reducing oedema induced by cotton tissue, carrageenin and croton oil in various
animal models (Smyth et al., 1962). As a result of its anti-inflammatory effect
bromelain has been found to reduce dramatically post operative swelling and pain by
lowering the level of both plasma kinin and prostaglandins which play important
roles as mediators of pain and inflammation (Leipner et al., 2001). However, its
mechanism of absorption from intestine into the body is not yet clearly known.
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Lorkowski (2012) suggested to be through the mucosal barrier of the GI tract after
oral dosing but how the enzymes survive in the blood in the presence of proteinase
inhibitors is still not yet clear.
Bromelain has been demonstrated to have a variety of clinical benefits in
therapeutic applications and it has been shown to be safe at high doses (LD50 
10g/kg) for prolonged periods of time (Hale et al., 2002). Clearly then, as was done
with other CP family members from papaya and fig plants, and since bromelain has
shown to digest worm cuticle in vitro (Berger and Asenjo, 1939; Stepek et al., 2005),
it was of interest to re-evaluate its anti-parasitic efficacy using the methodologies
employed in the current project. In this chapter the anthelmintic efficacy of pineapple
fruit extract and stem bromelain were investigated using in vitro and in vivo
approaches and rodent GI nematodes to determine whether bromelain has potential
as a novel anthelmintic, comparable to that now associated with PLS.
Another relatively unstudied CP is actinidain (EC 34.22.14) from the
kiwifruit or Chinese gooseberry (Actinidia chinensis)(McDowall, 1970). Although
the enzyme is used widely as a meat tenderizer (Christensen et al., 2009), stabilizer
of beer (Préstamo, 1995), for milk clotting (Katsaros et al., 2010) and protein
digestion (Kaur et al., 2010) there is little published research on its medical
applications. Stepek et al. (2005) reported this CP to have no detrimental effect on
worms even though the enzyme contains the free Sulphydryl group essential for its
activity (Kaur et al., 2010) as do other members of the papain family such as ficin,
papain and bromelain (Kamphuis et al., 1985). It is not clear why the enzyme has
been reported to behave so differently. Therefore, it was important to repeat the in
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vitro experiments originally conducted by Stepek et al. (2005) under more
standardized conditions to establish firmly whether this enzyme, actinidain, actually
has any potential whatsoever as a novel anthelmintic.
To date studies have reported significant reductions in nematode parasite egg
output and significant reductions in worm burdens of GI nematodes in monogastric
animals such as rodents (Stepek et al., 2006b, Stepek et al., 2007a, Stepek et al.,
2007b), pigs (Satrija et al., 1994), humans (Hansson et al., 1986) and even in poultry
(Mursof and He, 1991), as well multi-gastric animals, ruminants e.g. sheep (Buttle et
al., 2011) after treatment with papaya latex. However, no work has yet been
conducted on parasites of horses, in which nematode infections are an economically
important problem, especially with regard to the increase in anthelmintic resistance,
which continues to grow as a problem in horse husbandry, especially in the racing
and leisure industries (Little et al., 2003).
GI horse nematodes, particularly the large strongyles, are the most important
parasites of horse and are the most pathogenic, exerting a significant economic
impact wherever horses are raised (McCraw and Slocombe, 1976). Of the three
species of strongyles (Strongylus vulgaris, Strongylus edentatus, and Strongylus
equines) S. vulgaris is the most pathogenic, often affecting 85-90% of horses
particularly the yearlings (Slocombe and McCraw, 1973). For this reason, it is
considered to be the most important of all equine endoparasites (Osterman Lind et
al., 1999). Horses become infected with these parasites through ingestion of L3
larvae which shed their protective sheath in the small intestine and penetrate into the
mucosa and submucosa of the ileum caecum or ventral colon and moult to L4s. The
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L4 larvae migrate to the anterior mesenteric artery and moult to immature adults
which then return to the caecum and colon to complete maturation and begin
producing eggs (Duncan, 1973). The migrating larvae cause great damage and
inflammation to the mesenteric artery and its branches. Severe infection with
strongyles causes colic, gangrenous enteritis, rupture of the intestines and even death
(Duncan and Pirie, 1972, McCraw and Slocombe, 1976).
The main control and treatment of equine parasites relies on the use of
chemotherapy including the benzimidazole family, pyrantel pamoate, ivermectin and
oxibendazole. However, there is rapid development of resistance against these
anthelmintics (Kaplan, 2004). Thus, PLS was tested to assess whether this source of
plant-derived CPs could also be developed as an alternative anthelmintic against
equine GI nematodes.
The aims of this chapter were: -
i) To investigate in vitro and in vivo anthelmintic potential of pineapple fruit
extract and stem bromelain against H. bakeri, a natural parasite of mice.
ii) To assess the anthelmintic effect of actinidain from kiwi fruit extracts against
H. bakeri.
iii) To determine the in vitro anthelmintic efficacy of PLS against horse
nematodes.
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4.2 Experimental design and Results:
4.2.1 Experiment 1: The effect of pineapple fruit extract on worm motility
The molar concentrations or quantities of CPs used throughout this chapter are those
derived from active-site titration with E64 (See Chapter 2 Section 2.1.4). Thus the
various enzyme preparations are standardised in terms of the actual concentration of
functional active sites, making experiments investigating enzyme activity absolutely
comparable. The aim of this experiment was to determine the effect of pineapple
fruit extract (fruit bromelain) on worm motility. Male and female H. bakeri worms
were extracted from infected BKW mice and incubated individually in 48 well plates
(1 worm/well) with 3 replicates per treatment in the following concentrations: 150
ȝM, 100 ȝM, 60 ȝM and 30 ȝM pineapple fruit extract + 16 mM L-cysteine
dissolved in Hanks’ buffered saline solution (HBSS). The control worms were
incubated in HBSS+cysteine and 100 ȝM pineapple fruit extract without cysteine.
The plates were incubated at 37
0
C and the motility of the worms was assessed by
visual observation every 15 minutes for 2 h using a standard 0–5 motility scale
adapted from Stepek et al. (2005) as explained in Chapter Two section 2.2.2.
4.2.2 Experiment 1: Results
Worms in pineapple extract with cysteine showed some reduction in motility after
just 15 minutes of incubation. A rapid decline in motility was observed in worms
incubated in higher concentrations of the enzyme. Although motility declined in all
preparations, the extent of the decrease in motility was very low at low
concentrations of pineapple fruit extract+cysteine. However, importantly, there was
no decline in motility for worms incubated in pineapple extract without cysteine,
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indicating that the effect of the pineapple extract depended on the presence of
cysteine (Fig. 4.1), and there was very little loss of motility among worms
maintained in Hanks’ with cysteine.
To assess the changes in motility over time, the data were analysed using
rmGLM, time being fitted as the within subject factor and the concentration of
pineapple fruit extract as the between subject factor. Since the data did not meet the
requirement of Mauchley’s test of sphericity (p< 0.001), the Huynh-Feldt adjustment
was used to aid interpretation of the data. There was a significant time-dependent
reduction in motility which varied with different concentrations of the enzyme (2-
way interaction between time and concentration of pineapple extract; F12.6,67.1 =
3.855, p<0.001). The main effect of the concentration of pineapple extract was
highly significant (between subject factor analysis; F5,18= 7.528, p<0.001).
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Figure 4.1: Motility change of the worm incubated in pineapple fruit extract
over time
Adult H. bakeri were incubated individually in 48 well plates (mean± SEM, n=3) at
37
0
C for 2h in the following concentrations of active enzyme in pineapple fruit
extract + 16mM L-cysteine: 150 ȝM, 100 ȝM, 60 ȝM and 30 ȝM with the control
being HBSS + L-cysteine and 100 ȝM active pineapple derived enzyme without
cysteine. The results indicated that there was a significant decline in the motility of
worms incubated in pineapple fruit extract + cysteine over time.
4.2.3 Experiment 2: Effect of stem bromelain on the motility of H. bakeri
This experiment aimed at testing the in vitro effect of stem bromelain on worm
motility. Stem bromelain was a kind of gift from Hong Mao Biochemical co. Ltd
(Thailand) to Prof. Behnke. The enzyme was concentrated as described in Chapter 2
section 2.1.3. Adult H. bakeri worms were incubated in 48 well plates containing the
following concentrations of stem bromelain + 16 mM L-cysteine 4000 µM, 2000
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µM, 400 µM and 200 µM, while the control worms were incubated in 400 µM stem
bromelain without L-cysteine and HBSS with L-cysteine.
4.2.4 Experiment 2: Results
The motility of the worms declined in all preparations, including the controls over
the observational period of time. However, the loss in motility was significantly
greater among worms exposed to stem bromelain+cysteine (Fig.4.2). The data were
statistical analysed by rmGLM where time was fitted as within subject factor and
different concentrations of stem bromelain as between subject factors. The results
indicated a significant effect of time as the within subject factor (F2.6,73.3 = 170.47,
p<0.001) and the 2-way interaction between time and concentration of stem
bromelain (F25.9,73.3 = 6.713, p<0.001) indicated that the reduction in worm motility
over time depended on the concentration of stem bromelain. The between subject
factor analysis showed a significant main effect of stem bromelain concentration
(F6,17 = 17.049, p<0.001). As in the case of the enzyme in the pineapple fruit extract,
worms incubated in stem bromelain without cysteine and those in Hanks’ with
cysteine showed only minor loss of motility over the 2h long incubation, compared
with those incubated in stem bromelain with cysteine, indicating that the inhibitory
effect is dependent on active enzyme and on the presence of cysteine (Fig.4.2).
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Figure 4.2: Effect of stem bromelain on worm motility
Changes in motility of adult H. bakeri worms incubated in stem bromelain
(mean±SEM, n = 3) in the following concentrations with cysteine, 4000 µM, 2000
µM, 400 µM, 200 µM and 400 µM stem bromelain without cysteine and HBSS + 16
mM cysteine. The worms were incubated at 37
0
C for 2 h and a rapid decline in
motility was observed in worms incubated in the stem bromelain + cysteine but the
motility of worms in the control groups declined considerably more slowly.
4.2.5 Experiment 3: Effect of kiwi fruit extract on H.bakeri worm motility
The aim of this experiment was to assess the effect actinidain from Kiwifruit
(Actinidia chinensis) which has been reported previously to have no detrimental
effect on worm motility (Stepek et al., 2005). The experiment was repeated to verify
the original conclusion about the lack of anthelminctic activity with this CP. The
enzyme was concentrated from fresh kiwifruit juice by dialysis as described in
chapter 2 of materials and methods. However, the fruits seemed to contain less active
enzymes with only 50 ȝM as the maximum possible concentration available for the
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motility assay. Thus H. bakeri worms were incubated at 37
0
C for 2 h in 50 ȝM, 33
ȝM and 10 ȝM kiwifruit extract + 16 mM L-cysteine, and HBSS with and without
cysteine.
4.2.6 Experiment 3: Results
Worms incubated in the highest concentration of kiwifruit extract+cysteine (50 ȝM)
showed some loss of motility while worms in the lower concentrations and in control
groups had little change in motility (Fig. 4.3). Analysis of changes in motility by
rmGLM with time as the within subject factor gave a significant 2-way interaction
(time and dose of enzyme, F33.2,99.6 = 2.054, p<0.001) indicating that the changes in
motility over time were dependent on the concentration of the enzyme. When
concentration of kiwi extract was fitted as the between subject factor the results gave
a significant main effect of concentration (the between subject factor analysis; F5,15 =
7.238, p<0.001). There was no loss of motility among worms incubated in Hanks’
with enzyme and in 50 ȝM enzyme without cysteine.
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Figure 4.3: Effect of kiwi fruit extract on worm motility
Adult H. bakeri worms were incubated in different concentration of kiwi fruit extract
(mean±SEM, n=3) i.e. 50 ȝM, 33 ȝM and 10 ȝM kiwi fruit extract with cysteine, and
in 50 ȝM kiwi fruit extract without cysteine and in HBSS + cysteine at 370C for 2 h.
Their motility was recorded every 15 minutes. Worms in higher concentrations of
kiwifruit extract+cysteine showed a more marked reduction in motility than worms
incubated in low concentration of kiwifruit extract and in control groups.
4.2.7 Determination of IC50 values for CPs derived from a variety of plants
Pineapple extract and stem bromelain were compared with PLS in their ability to
inhibit the motility of worms by estimating their half maximal inhibitory
concentration (IC50) using dose-response relationships after 30 min of incubation
with adult H. bakeri worms in vitro. Since the concentration of active enzyme
(actinidain) in kiwi fruit extract was so low, the IC50 for this enzyme was estimated
after 2 h of incubation of worms in the extract. The IC50 values were estimated by
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GraphPad Prism 6.0 software using sigmoidal dose response regression. For PLS,
pineapple extract and stem bromelain the IC50 values estimated at 30 min. The values
of the IC50 for PLS and pineapple fruit extract were 39.65 ȝM and 81.95 ȝM
respectively However that of stem bromelain did not reach to the half of motility.
While that of the kiwi fruit extract was estimated at 2 h and its value was 47.53 ȝM.
According to these IC50 values, PLS had the most potent effect in the motility
inhibition assays followed by pineapple fruit extract and then stem bromelain (Fig.
4.4). However, it was difficult to compare the effect of kiwi fruit extract with that of
other sources of CPs as its value was determined after 2 h of incubation when at this
time worm motility in other CPs was reduced to almost zero motility.
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Figure 4.4: IC50 values for CPs from different plant sources
The in vitro comparison of anthelmintic efficacy of plant derived cytseine
proteinases (PLS, pineapple fruit extract, fruit bromelain and kiwi fruit extract) as
determined by their ability to inhibit the motility of the worms. Sigmoidal dose-
inhibition curves were fitted with an upper limit of 5 (maximum motility) and lower
limit of zero (minimum motility) in GraphPad Prism (version 5). PLS was found to
be more potent followed by pineapple fruit extract and then stem bromelain
(excluding the kiwi fruit extract).
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4.2.8 Experiment 4: SEM of worms incubated in CPs of pineapple and kiwi
plants
In order to consolidate the results and to obtain visual information on the extent of
the damage caused by CPs to the cuticle; adult worms were incubated in pineapple
extract, stem bromelain, kiwi fruit extract and PLS. PLS was used as a positive
control. At different time intervals (i.e. 0, 30, 60 and 90 min) the worms were fixed
for scanning electron microscopy (SEM) to enable examination of the cuticular
damage arising from exposure to CPs.
4.2.9 Experiment 4: Results
The results in Fig. 4.5 show the cuticular changes over the course of time for H.
bakeri worms incubated in different CPs as seen under SEM at equivalent points
along the body of the adult worms. Progressive cuticle damage was seen within 30
min for worms incubated in PLS, starting with the appearance of transverse wrinkles
followed by blistering (at 60 min), finally digestion of the cuticle with expulsion of
the worms’ internal structures and contents (at 90 min). The same effect was seen in
the worms incubated in pineapple extract and stem bromelain but not at the same
intensity as that of PLS. However, the worms incubated in kiwi fruit extract
(actinidain) only showed some initial signs of cuticular damage i.e. formation of
transverse wrinkles along some parts of the cuticle after 60 min. This was probably
due to the low concentration of active actinidain in the extracts used; 50 µM
compared with 200 µM of PLS, 200 µM stem bromelain and 150 µM of fruit
bromelain. In contrast, in the worms incubated in HBSS the cuticles remained intact
throughout the experimental period with no sign of cuticular damage.
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Figure 4.5: SEM of H. bakeri adult worms exposed to different sources of plant
CPs
SEM of H. bakeri adult worms exposed to different sources of plant CPs in vitro.
Clear evidence of damage to the cuticle was seen at 30 min for worms incubated in
200 µM PLS (A) and at 60 min in 150 µM fruit bromelain (B), 200 µM stem
bromelain (C) and only slightly changes in 50 µM kiwi fruit extract (D) as indicated
by the arrows. Note the transverse wrinkling leading to expulsion of the internal
structures and contents. In contrast the worms incubated in HBSS (E) showed no
detectable signs of cuticular damage with the longitudinal ridges remaining intact
even after 90 min of incubation.
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4.2.10 Experiment 5: In vivo efficacy of stem bromelain against H. bakeri
The aim of this experiment was to determine the efficacy of stem bromelain against
H. bakeri, in vivo. Since stem bromelain has been used widely as a medicinal plant
product and its concentration was higher than that of pineapple fruit extract or even
that of PLS, the enzyme was tested in vivo to assess whether this source of CPs
would be equally efficacious with PLS in expelling worms. To achieve this
objective, 3 groups of 5 male C3H mice were infected orally with 150 H. bakeri L3
larvae on day 0. Mice were orally treated daily for 5 days from day 20 to day 24 post
infection. Each group of mice received different treatments. The first group was
treated with 240 nmol PLS in 0.2 ml of pure water, the second group was treated
with 240 nmol stem bromelain in 0.2 ml water and the last group was given ultra
filtered distilled water. Faecal egg counts (FEC) were conducted on days 14, 16 and
18 before treatment and on days 21, 23 and 25 during treatment. Autopsies of mice
were carried out on day 25 post infection and the number of worms in the small
intestine was counted.
4.2.11 Experiment 5: Results
The results (Fig. 4.6) show that FEC in the stem bromelain and the water groups
remained steady whereas those in the PLS treated animals fell sharply soon after
treatment began. The divergence in FEC between treatments over time was
significant (2-way interaction between time and treatment in rmGLM with time as
the within subject factor, F3.99,23.97 = 7.65, p<0.001). There was also a highly
significant overall difference between treatment groups (main effect of treatment
F2,12 = 25.754, p<0.001). Arithmetically, the anthelmintic efficacy of PLS was higher
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than that of stem bromelain (92.93% and -13.85% reduction in FEC respectively).
This reduction in egg output was due to reduction in the number of worms present
and was consistent with the reduction in worm number 95.8% for mice treated with
PLS and -1.9% for stem bromelain (worms in this group were completely unaffected
and the mean worm burden was slightly higher than that of the control group). As
with the FEC, the reduction in worm burdens was significant (main effect of
treatment F2,14 = 97.68, p<0.001).
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Figure 4.6: In vivo efficacy of stem bromelain against H.bakeri worms
Fifteen C3H mice were orally gavaged with 150 L3 larvae on day 0. Then the mice
were divided into 3 groups, and the first group was treated with a standard dose of
240nmols PLS, the second group with 240nmol of stem bromelain in 0.2 ml water
and the third groups received 0.2 ml pure water. There was a significant reduction in
FEC and intestinal worm counts in the group treated with PLS. However, there was
no reduction in FEC or worm counts for the groups treated with either stem
bromelain or receiving water. *indicates day of treatment.
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4.2.12 Experiment 6: In vivo efficacy of pineapple fruit extract and stem
bromelain against H. bakeri
Since the results in Experiment 5 above showed no efficacy of stem bromelain in
vivo, it was considered nevertheless worthwhile to repeat this experiment. However,
this time pineapple fruit extract was included in order to complete the picture. Their
efficacies were also compared with that attributable to PLS, in the extent of the
reduction in FEC and worm burdens. To achieve this objective, 20 male C3H mice
were infected orally with 150 H. bakeri L3 larvae on day 0. Then the mice were
divided into 4 groups and on day 20 each group was given a different treatment daily
for 5 days. The first group was treated with 240 nmol PLS in 0.2 ml of water, the
second group was treated with 240 nmol stem bromelain, third group was treated
with 60 nmol pineapple fruit extract and the last group was given water. Faecal egg
counts (FEC) were conducted on days 14, 16 and 18 before treatment and on days
21, 23 and 25 during treatment. Autopsies of mice were carried out on day 25 post
infection and the number of worms in the small intestine was counted.
4.2.13 Experiment 6: Results
It can be seen clearly in Fig. 4.7 that FECs in both pineapple extract and stem
bromelain and in the control groups remained steady, as in Experiment 5, whereas
those in the PLS treated animals fell sharply soon after treatment began. Statistically,
analysis of FECs using log+25 transformed data indicated significant divergence
between treatment over time (rmGLM with time as the within subject factor, 2-way
interaction between time and treatment F6.3,39.6 = 9.699, p<0.001). There was also a
highly significant overall difference between treatment groups (main effect of
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treatment F3,19 = 19.023, p<0.001). Arithmetically, the anthelmintic efficacy of PLS
was higher (94.5%) than that of pineapple extract and stem bromelain (14.0% and
21.9% reduction in FEC respectively). This reduction in egg output was attributable
to the reduction in the number of worms present and was consistent with the
reduction in worm numbers, 93.5% for mice treated with PLS, 24.5% for stem
bromelain and 22.4% for pineapple extract. As with the FECs, the reduction in worm
burdens was also significant (main effect of treatment F3,20 = 50.932, p<0.001). Post
hoc analysis by the Dunett indicated that worm burdens in the treatment groups of
mice (PLS, stem bromelain and pineapple fruit extract) were significantly different to
those in the control group (p < 0.001, p = 0.017 and p = 0.029 respectively)
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Figure 4.7: In vivo efficacy of fruit and stem bromelain against H.bakeri
The figure shows the response of mice to treatment with 240 nmol PLS, 60 nmol
fruit and 240 nmol stem bromelain. Effect on FECs (A) and intestinal worm counts
(B). Mice treated with PLS exhibited a sharp fall in both FEC and worm burdens
whereas those treated with either pineapple extract or stem bromelain showed a
considerably weaker effect.
Ĺ
indicates day of treatment, **indicates significant at
p<0.001 and *significant at p<0.05 level.
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4.2.14 Experiment 7: In vitro assessment of PLS against horse nematodes
The aim of this experiment was to examine the in vitro efficacy of PLS against the
horse nematode (Strongylus vulgaris). The worms were collected from naturally
infected British horses culled at Turner’s abattoirs - Nantwich, Cheshire. The worms
were then kept in a flask containing horse caecal fluid and stored in a polyethylene
box. The flask was kept in between bottles containing warm water to maintain
temperature throughout the return journey to Nottingham. They were immediately
transported back to the University of Nottingham (School of Biology) for in vitro
assessment.
On arrival to School of Biology adult S.vulgaris worms were isolated from
the caecal fluid and incubated in 48 well plates containing the following
concentrations of PLS+16 mM L-cysteine: 3000 µM, 1000 µM, 300 µM, 100 µM,
and 30 µM while the control worms were incubated in 300 µM PLS without L-
cysteine and HBSS with 16 mM L-cysteine and 300µM PLS+cysteine+500µM E64.
4.2.15 Experiment 7: Results
The results showed that the motility of the worms incubated in PLS+cysteine
declined rapidly compared with worms incubated in PLS without cysteine,
HBSS+cysteine and PLS+cysteine+E64 (Fig. 4.8). The line graphs for worm
incubated in 3000 µM and 1000 µM are not shown because the worms died within
15 minutes of incubation in PLS. However, the decline was most evident in worms
incubated in higher doses of PLS+cysteine. The data were analysed by rmGLM
where time was fitted as within subject factor and concentration of PLS as between
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subject factor. Since, the data did not meet the requirement of the Machley’s test of
sphericity (p<0.001), the Huynh Feldt adjustment to the degree of freedom was used.
A time dependent reduction in motility was found in the presence of different
concentation of PLS (rmGLM with time as the within-subject factor, interaction of
time and PLS concentration F38.3,108.4 = 15.937, p<0.001). The between subject factor
analysis indicated significant main effect of concentration of PLS (F6,17 = 57.139,
p<0.001). Incubation of worms in Hanks’ with cysteine but without enzyme, or in
enzyme without cysteine did not result in loss of motility over the period of
observation. The presence of E-64, the specific inhibitor of CPs, with enzyme and
cysteine, blocked loss of motility completely.
The time at which, the PLS caused damage to the worm cuticle was also
assessed under the light microscope. Clearly observable signs of cuticular damage
were detected from 5-15 min of incubation impairing movement of the worms and
eventually becoming so severe that the cuticle was ruptured releasing the internal
structures (Fig. 4.9).
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Figure 4.8: In vitro assessment of PLS against equine nematodes
S.vulgaris worms were incubated in 48 well plates (mean±SEM, n=3) at 37
0
C for 90
min in different concentrations of PLS (300ȝM, 100ȝM and 30ȝM) with cysteine,
300ȝM PLS + cysteine + E65, 300ȝM PLS +cysteine and HBSS + cysteine and their
motility was recorded every 15 minutes. Worms in the PLS+cysteine showed a
significant rapid reduction in motility compared with worms incubated in PLS
without cysteine, HBSS+cysteine and PL+cysteine+E64 which remained active
throughout.
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Figure 4.9: cuticular damage of horse nematodes incubated in PLS
Observable signs of cuticular damage to S. vulgaris worms after 15 min of
incubation in different concentrations of PLS (10-1000 µM) as viewed by light
microscopy. The signs of damage intensified as the concentration of PLS increased.
However, there were no detectable signs of cuticle damage for the worms incubated
in Hanks’ solution. Scale bar = 2.65mm.
4.3 Discussion
In this chapter the in vitro anthelmintic efficacies of pineapple fruit extract, stem
bromelain and kiwi fruit extract (actinidin) were assessed. As found in Experiment
4.1, pineapple fruit extract which is said to contain fruit bromelain, had detrimental
effects on worm motility in vitro. The mechanism of reduced motility was identical
to that reported by Stepek et al. (2005) which involved digestion of the cuticle as
shown by the SEM pictures in Experiment 4. The decrease in worm motility was
noted from 30 min of incubation in the 150 µM pineapple fruit extract. Similarly
Berger and Asenjo (1939) reported complete digestion within 24h of Ascaris
10µM PLS 30µM PLS 100 µMPLS
300µM PLS 1000µM PLS Hanks solution
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lumbricoides from a hog’s intestine, when incubated in freshly squeezed pineapple
juice, which contrasted with worms incubated in heat-inactivated pineapple juice that
remained active throughout the period of the experiment. The same trend on worm
motility was also observed in stem bromelain preparations although not to the same
extent as that of the pineapple fruit extract (Experiment 2). Even at high
concentrations the inhibitory effect on motility of stem bromelain was still low when
compared with that of pineapple extract. This can be supported by the IC50 value
which was did not reached 50% reduction in mortality for stem bromelain compared
with 96.12 µM for the pineapple fruit extract. Moreover, the intensity of the cuticular
damage was shown to be higher in pineapple extract than in stem bromelain (Fig.
4.5). On the basis of these results it can be argued that at identical active enzyme
concentrations pineapple fruit extract is more efficacious than stem bromelain in
vitro, although both enzymes are from the same plants but located in different parts
of the plant. This may reflect the natural functions of the two enzymes in the plant
and the nature of the target proteins in the organisms the plants have evolved to
defend against. It is known that fruit and stem bromelains have very different
substrate specificities (Rowan et al., 1990) and are therefore unlikely to be targeting
the same peptide bond(s) in cuticle proteins.
Kiwi fruit extract caused some detrimental effect on worm motility
(Experiment 3) in contrast to reports in previous work. Stepek et al. (2005) reported
no effect of actinidain from kiwifruit against parasitic nematodes in vitro. Although
the motility reduction was not as high as in other CPs this might be due to the low
concentration of the enzyme used, which was 50 µM and at this particular
concentration even PLS shows little effect. Like any other cysteine proteinase,
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actinidain from kiwi fruit contains a free Sulphydryl group essential for its activity
and logically a similar effect on target proteins might be expected. However, the
enzyme extracted from kiwifruit in this study was of low concentration making it
difficult to concentrate to the desirable amount of the active enzyme. Other studies
have also reported low yields of actinidain from kiwi fruits. For example
Brocklehurst et al. (1981a) reported a yield of actinidain of less than 450mg/kg from
fruit pulp compared with a yield of papain from papaya latex of about 40g/kg of the
latex. Moreover, actinidain is more susceptible to oxidation than any other plant thiol
protease (Kaur et al., 2010). The enzyme has been reported also to vary remarkably
in its activity depending on the growth stage of the fruit, postharvest storage and part
of the fruit being tested (Lewis and Luh, 1988). There is also wide variation in the
levels of actinidain within the genus, where fruits with low actinidain activity have
been reported to lack actinidain precursors (Boyes et al., 1997).
To confirm that kiwifruit extract had a detrimental effect against H. bakeri
worms, the worms were incubated in the enzymes and examined by scanning
electron microscope (SEM), and initial observable signs of damage on the surface of
the worm cuticle started to appear after 1h of incubation which involved formation of
transverse wrinkling unlike their counterpart worms incubated in Hanks’ solution
(Experiment 4). Since the kiwi fruit extract had been found to contain low active
enzyme concentration, it is suggested that in the future work the worms are incubated
for longer periods of time so that clear signs of cuticular damage could be detected.
In order to determine which of the of CP source had the best potential for
inhibiting worm motility, the results of the motility assays were compared using
107
dose-inhibition curves and their IC50 values were estimated. Again, since the
concentration of active enzyme in kiwifruit extract was low, its IC50 was estimated
after 2 h of incubation rather after just 30 min of incubation as in other CPs. Based
on the IC50 values, PLS was found to be more effective in motility inhibition
followed by pineapple fruit extract and then stem bromelain. For this reason the
pineapple extracts and stem bromelain were assessed also in vivo (Experiments 5 and
6). The results of the in vivo experiment indicated less efficacy of these pineapple
enzymes compared to that routinely obtained with PLS in comparable trials. In the
case of the pineapple fruit extract, the lower efficacy may have been due to the lower
concentration of the active enzymes administered to animals but the lack of a marked
reduction in worm burdens is difficult to explain in the case of stem bromelain which
was used at the same concentration as that of PLS. In this case it may be due possibly
to host environmental effects, as for example with PLS which works well only in
some strains of mice. Therefore, it is suggested that before concluding that pineapple
CPs have less anthelminitc effect in vivo it is worth repeating these in vivo trials in
different strains of mice or with different model parasites, particularly those residing
completely in the lumen such as Ascaris. To some extent this result was
disappointing given that bromelain is widely used as a natural plant derived medicine
for other ailments and is conveniently available commercially.
It is not clear why some sources of plant CPs have anthelmintic effects
against H. bakeri while others do not. Stepek et al. (2005) screened CPs from a
variety of plant species in vitro and found that all were efficacious against H. bakeri
but at different concentrations with the exception of actinidain which had no effect at
all in her experimental systems. Brocklehurst et al. (1981a) compared the structure of
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papain and actinidain and found that they differ in the interactions of the catalytic
groups of their active centres. However, they have identical enzyme catalytic sites.
This suggests that further biochemical studies of these enzymes are required to
achieve a clearer understanding of their modes of action. If each of these enzymes
has a higher affinity for a particular amino acid sequence in the target proteins, the
differences in their efficacy as anthelmintics could be ascribed to the degree to which
each is capable of attaching to the complementary site on the target proteins in the
nematode cuticle.
This chapter also examined the in vitro effects of PLS against the blood
feeding equine nematodes, Strongylus vulgaris. As expected, there was a significant
rapid decline in motility of worms incubated in PLS. The mechanism of action was
as reported in previous studies with the papaya and Ficus lattices causing observable
changes on the surface of the cuticle, leading to lesions, fractures, and eventually
complete destruction of the cuticle and bursting of the worms with release of the
internal contents (Stepek et al., 2005, Robbins, 1930). This experiment confirmed
that CPs from PLS are able to digest equine nematodes and have potential as equine
anthelmintics if their efficacy in vivo can be confirmed. The signs of cuticular
damage were observed within less than 15 min., unlike with the rodent nematodes
where signs of cuticular damage were reported between 15-30 min (Stepek et al.,
2005) at similar concentrations of active enzyme. This suggests that horse nematodes
may be more susceptible to PLS, thus justifying the need for carrying out in vivo
experiments in the future. If PLS is to be developed as an equine anthelmintic, as an
alternative treatment for equine GI nematodes to the synthetic drugs currently used
for treatment of horses, in vivo trials are the obvious next step.
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CHAPTER 5: EFFECT OF FASTING ON THE EFFICACY OF PAPAYA
LATEX AGAINST H. BAKERI, IN VIVO.
5.0 Summary
This chapter is based on the paper published in the Journal of Helminthology (2012)
86 (3):311- 316, first available online on 28 July 2011. In earlier studies of the
anthelmintic activity of plant CPs, a period of food deprivation was routinely
employed before administration of CPs, but there has been no systematic evaluation
as to whether this does actually benefit the anthelmintic efficacy. Therefore we
assessed the effect of fasting on the efficacy of CPs from papaya latex (PL) against
Heligmosomoides bakeri in C3H mice. The source of CPs was from a refined,
supernatant extract of PL with known active enzyme content. The animals were
divided into three groups (fasted prior to treatment with PLS, not fasted but treated
with PLS and fasted but given only water). The study demonstrated clearly that
although food deprivation had been routinely employed in much of the earlier work
on CPs in mice infected with nematodes, fasting has no beneficial effect on the
efficacy of PLS against H. bakeri infections. Administration to fed animals will also
reduce the stress associated with fasting.
5.1 Introduction
It is routine for some therapeutic drugs to be taken after a specified period of food
deprivation. The rationale for this is based on the presence of food in the stomach
influencing drug absorption and bioavailability by either physiological changes in the
intestinal tract or physical or chemical interactions between food components, acid in
the stomach, intestinal enzymes and drug molecules. Depending on the class of drug
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and the resulting interaction, food has been reported to have reducing, delaying,
increasing, or in some cases no effect on the absorption and bioavailability of
different drugs when taken together with food (Toothaker and Welling, 1980,
Welling, 1977).
In the case of orally administered antibiotics such as penicillin and
amoxycillin, a 2h period without food is recommended because food reduces their
bioavailability due to delayed stomach emptying (Welling, 1977). It is recommended
that milk and other dairy products are avoided when taking tetracycline where
absorption is inhibited because of chelation by calcium or magnesium present in milk
(Dearborn et al., 1957, Winstanley and Orme, 1989) or complexation with protein.
Additionally, milk has the effect of the decreasing dissolution rate of the drug (Kohn,
1961). It is reported that demethyl chlortetracycline absorption was reduced by about
70% in the presence of skimmed milk whereas tetracycline bioavailability was
reduced by 50 to 60% in the presence of whole milk (Welling et al., 1977).
However, bioavailability of some drugs increases with food intake. One study
found that serum concentrations of erythromycin in non-fasted individuals were 30-
80% higher than in fasted individuals following a single dose oral administration of
erythromycin (Toothaker and Welling, 1980). It was concluded that food caused
delayed stomach emptying, thereby enabling greater amounts of the drug to dissolve
in the stomach before passing into the small intestine for absorption. It has been
found also that eating fatty food before treatment with some anthelmintics increases
absorption, e.g. albendazole (Horton, 1997) mebendazole (Winstanley and Orme,
1989) and flubendazole (Munst et al., 1980).
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Therefore, whether to fast animals and humans before oral dosing with drugs
has been an issue of some concern for a long time. In some cases fasting is
recommended before oral chemotherapy, in others it appears to be unnecessary. In
earlier studies with plant cysteine proteinases (CPs), a period of food deprivation was
routinely employed before administration, but there has been no systematic
evaluation as to whether or not this does actually benefit the anthelmintic efficacy. It
is relevant that CPs do not need to be absorbed and anyway, are too large to be
absorbed as such. They need to be available in the gut lumen to make direct contact
with the parasite’s cuticle. It could be argued that in the presence of food there would
be an increase in substrate for the enzyme together with an increase in the volume of
the GI contents, both of which could reduce efficacy of the enzyme on the nematode.
However, fasting prior to administration appears to have been adopted through
tradition rather than because of any convincing evidence that it actually enhances the
efficacy of the CPs. The first example of food deprivation combined with oral
treatment with CPs can be found among native people of South America where CPs
in fresh latex of fig was taken early in the morning after fasting (Caldwell, 1929).
This protocol was adopted by Caldwell & Caldwell (1929) in their clinical trial with
higuerolatex (latex from Ficus laurifolia) in treatment of trichuriasis in Alabama.
Participants were given a light supper in the evening preceding the day of treatment
and no breakfast was taken in the morning before the treatment. Hansson et al.
(1986) applied the same protocol in their trial with the latex of Ficus glabrata, a
traditional anthelminthic used in the Amazonian area. The same protocol was used
by Satrija et al (1994) in assessment of the anthelmintic efficacy of papaya latex
against Ascaris suum in pigs (using a single dose) where food was withdrawn the day
of treatment and animals received only water. Then in the series of experiments by
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Stepek et al. (2006, 2007a, b) food deprivation for a standard period of 6h was
employed throughout the programme of research.
Because of the complexities involved, it is not easy to predict a priori, the
exact nature of the interaction between food and drug efficacy in any particular case
based solely on theory. In some cases, fasting may simply be based on tradition
rather than on hard scientific evidence. Winstanley and Orme (1989) recommended
that any development of new drugs should include assessment of food effects,
including the benefits and disadvantages of fasting before treatment. Since there has
been no systematic evaluation of the benefits of fasting prior to treatment of animals
or people with intestinal worm infections with CPs, we undertook such a study. Here,
we evaluate the effect of fasting on the efficacy of CPs from PL in mice infected
with H. bakeri. The results should help to formulate optimal protocols for delivery of
the drug to animals or humans, aiming to obtain maximum efficacy against the
worms with the lowest possible dose and to minimise side-effects of treatment.
5.2 Experimental design and results
5.2.1 Experiment 1: Pilot study to determine effect of fasting
This experiment was a pilot run conducted to determine whether fasting enhanced
the anthelmintic effect of papaya latex. Fifteen C3H mice were divided into three
groups, each with five animals. The first and second groups of mice received orally
0.2 ml containing 240 nmoles of PLS for five consecutive days in total, beginning on
day 20, while the last group (group 3) was given distilled water. Mice in groups 1
and 3 were fasted for 5 h before treatment (food was deprived at 07.00 hours and
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restored at 12.00 hours on relevant days) while those in group 2 had access to food
and water ad libitum. The fasting time interval was chosen because research has
shown that this is an adequate time period to assure that the rodent stomach will be
empty (Mittelstadt et al., 2005). The mice were infected with 150 H. bakeri L3
larvae on day 0, faecal egg counts (FEC) were carried out on days 14, 16, 18, 21, 23
and 25, and mice were all killed on day 25 after infection for worm counts, one day
after the last treatment.
5.2.2 Experiment 1: Results
The faecal egg counts from Experiment 1 are illustrated in Fig. 5.1. These show that
egg counts declined in both PLS-treated groups of mice soon after the onset of
treatment on Day 20, whereas those in the control group stayed steady, and even
drifted upwards with days of experiment. Analysis by rmGLM was confined to the
two PLS-treated groups to determine whether fasting resulted in better anthelmintic
efficacy on log10(EPG + 25) transformed data, fitting TIME (day on which faecal egg
counts were carried out) as the within subject factor and TREATMENT (two levels,
fasted or not-fasted excluding the not-treated, fasted control group) as the between-
subject factor. There was no significant main effect of treatment (fasted versus not-
fasted mice, F1,8=0.015, p=NS).
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Figure 5.1: Faecal egg counts during the course of Experiment 1.
The result of control group is illustrated by open circles, fasted group by open
squares and the not-fasted group by open triangles. Treatment with papaya latex
commenced on day 20 after infection and was given then each day for 5 days.
*indicates day of treatment
At autopsy on day 25, the control mice had a mean worm burden of 126.8 ±
24.88, while the fasted, PLS-treated mice had 16.4 ±6.41 worms and the non-fasted,
PLS-treated mice had 14.0 ±5.43 worms (Fig 5.2). Worm counts were analysed by
one-way GLM, fitting treatment group (either two or three levels as above). There
was a highly significant overall effect of treatment (F2,12= 18.1, p<0.001), reflecting
the difference between the control group and the two PLS-treated groups, but no
difference between the latter two (fasted versus not-fasted).
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Figure 5.2: Worm counts at the end of Experiment 1.
The figure illustrates the intestinal worm recovery after 5 days of treatment with PLS
prior to mice being either fasted or not-fasted. The worm count was assessed on day
25 post infection.
5.2.3 Experiment 2: Effect of fasting on the anthelmintic efficacy of PLS
Since in Experiment 1 worm burdens were only assessed after 5 daily treatments
with PLS, a further experiment was carried out, in two blocks, to establish whether
fasting had any additive effect with PLS earlier, after 1, 3 or 5 daily treatments. In
block 1, 45 mice were divided into three groups, each group having 15 animals. The
first group of mice was fasted for 5 h prior to treatment with 0.2 ml containing 240
nmoles of PLS on day 20 after infection, while the second group of animals was
treated with the same dose of PLS but not fasted. The third group was the control
group, with the animals being orally gavaged with 0.2 ml of ultra-filtered distilled
water and, as for group 1, fasted for 5 h before oral dosing. Treatment was repeated
daily for 5 days. After the first, third and fifth treatments five mice from each group
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were killed for worm counts, so depending on the day on which the animals were
killed for autopsy; they received 1, 3 or 5 treatments. Faecal egg counts were
conducted on days 14, 16 and 18 (pre-treatment) and on days 21, 23 and 25 (during
treatment) of the experiment on the groups destined for culling at the end of the
experiment. The number of worms remaining in the intestines of treated and
untreated mice was counted on days 21, 23 and 25 post-infection. Block 2 of this
experiment was designed similarly, except that a total of 72 mice were used in three
groups of 24, with eight mice culled at each time point. Another difference is that the
2 blocks were carried out at different times.
5.2.4 Experiment 2: Results
The data were analyzed first with both blocks included in the statistical model. The
key hypothesis being tested was whether fasting was essential for treatment to be
efficacious, and hence the analysis was confined first to the two PLS-treated groups
(fasted and not-fasted) excluding the non-treated, fasted control group. Best-fit
models were adopted after first exploring models with raw worm counts, and
log10(worm count + 10) transformed data, checking R
2
values, and the residuals for
approximately normal distribution. Three-way GLM (fitting TREATMENT group
(either two or three levels as above and Block two levels, block 1 or block 2 and
DURATION three levels, 1, 3 or 5 days of treatments with PLS). However, the
results indicated that there was a significant difference between the two blocks (3-
way GLM, main effect of block F1,66=12.7, p=0.001) and therefore the results have
been illustrated separately for each block in Fig. 5.3A and B (which also shows
worm burdens in the control untreated group for reference).
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Figure 5.3: Effect of fasting or not-fasting on worm recovery of Experiment 2.
Effect of fasting or not-fasting on worm recovery after 1, 3 or 5 days of treatment
with PLS. The results of block 1 are illustrated in A, and those of block 2 in B. The
mice were treated either for 1 day, 3 days or 5 days and killed for worm counts on
days 21, 23 and 25 post infection respectively.
As can be seen, and with the difference between blocks taken into account,
overall there was no consistent difference in worm counts between the fasted or not-
fasted treated groups (main effect of TREATMENT (fasting versus non-fasting,
excluding the non-treated control group), F1,66 = 0.009, P = NS). There was a huge
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effect on worm burdens with increasing duration of treatment (main effect of
DURATION, F2,66 = 76.0, P < 0.001), and this differed to some degree between the
two blocks of the experiment and between whether mice were fasted or not fasted
(three-way interaction, BLOCK x DURATION x TREATMENT(fasted versus non-
fasted), F2,66 = 5.7, P = 0.005), but there was no consistent effect in favour of either
fasted or non-fasted animals.
As a final step, and to establish firmly that treatment with PLS was effective,
albeit a posteriori, we fitted a three-way GLM but included the control water-treated,
fasted group of mice this time. Not surprisingly there was a huge overall effect of
TREATMENT (main effect of treatment (control, fasted plus PLS and non-fasted
plus PLS), F2,99 = 404.1, P < 0.001), which is clearly apparent in Fig. 5.3 in both
blocks of the experiment by the difference in worm burdens between the control
water-treated, fasted group versus the two PLS-treated groups irrespective of whether
the mice were fasted or not. With the data from both experiments combined, and
relative to the control group, the reduction in worm burdens of the fasted mice was
54.4%, 87.3% and 92.8% after 1, 3 and 5 rounds of treatment, and for the not-fasted
group the corresponding values were 55.2%, 82.9% and 96.2%, respectively.
Faecal egg counts were also carried out in each of these two blocks (Fig. 5.4)
and these were broadly similar to those in Fig. 5.1 of Experiment 1, indicating that
prior to treatment all mice had similar faecal egg counts, and that towards the end of
the experiment they reflected the differences in worm burden between groups.
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Figure 5.4: Faecal egg counts during the course of Experiment 2.
FEC results of block 1 Fig 5.4A and those of block 2 in B. The control group is
illustrated by open circles, fasted group by open squares and the not-fasted group by
open triangles. FEC was carried out on day 14, 16 and18 (pre-treatment) and on day
21, 23 and 25 (during treatment). Treatment with PLS commenced on day 20 after
infection and was given each day for 5 days. *indicates day of treatment.
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5.3 Discussion
This chapter has demonstrated conclusively that the efficacy of PLS did not depend
on fasting the animals prior to oral dosing (at least for the period of 5h that was
explored here). Our results on the efficacy of PLS are in agreement with those of
Satrija et al. (1995) who demonstrated anthelmintic activity of PL against H. bakeri
worms in mice treated without food deprivation, but who did not evaluate the
benefits or disadvantages of fasting per se.
In previous studies (Stepek et al., 2007b) assessing the anthelmintic efficacy
of PL against H. bakeri, mice were treated daily over 7 days with 313 nmoles of
crude PL, preceded each time by food deprivation for 5–6 h. These experiments gave
a 79% reduction of worm burdens. However, the present experiment has
demonstrated that just three treatments, over three consecutive days with 240 nmoles
of PLS without food deprivation was sufficient to eliminate 82.9% of the worms.
Therefore, the current protocol, based on a refined extract of the active enzyme
compartment of PL and less intervention (in that only three doses with less active
enzyme content/dose were given), achieved comparable efficacy to that observed
previously with seven doses (Stepek et al., 2007b). This is likely to be beneficial for
the wellbeing of the treated animals, reducing stress and the likelihood of side-
effects.
Although food deprivation prior to oral dosing with CPs has been employed
routinely in much of the earlier work on CPs in mice infected with nematodes, the
present study has demonstrated clearly that fasting has no beneficial effect on the
efficacy of PLS against H. bakeri. The presence of food typically affects a drug
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through effects on absorption, but in this case the active ingredients work within the
gut rather than relying on absorption. The results from this work are still surprising,
as it would be expected that the presence of food could reduce the activity of the
enzyme by dilution in gastrointestinal chyme and competition with other potential
substrates for the enzyme. The maintenance of activity in the presence of food
suggests that there must be other compensating factors influencing activity, which
may include an increased residence time of the enzyme within the gut due to the
increased volume of the gastrointestinal contents.
It can be concluded that there is no need in the future to fast the animals prior
to treatment and this will also help to avoid any adverse side-effects of treatment,
since food deprivation, even for limited periods of time, can cause stress and
discomfort. Treatment for just 3 days at the active enzyme doses employed here is
sufficient to eliminate a substantial worm burden from mice. These findings will be
helpful for the research currently being undertaken to improve the formulation and
delivery of these naturally occurring plant-derived enzymes for use as
environmentally sound, organic therapies for the treatment of intestinal worm
infections in humans and livestock, while achieving maximum efficacy and minimal
side-effects.
122
CHAPTER 6: INTRINSIC FACTORS CAUSING VARIATION IN THE
ANTHELMINTIC EFFICACY OF PLANT DERIVED
CYSTEINE PROTEINASES: HOST GENETICS, HOST SEX,
BODY SIZE AND INFECTION DOSE
6.0 Summary
Eight strains of mice (BALB/c, CBA/ca, BKW, C3H, C57/BLK, CD1, NIH and NIH
Swiss) were used to assess whether the anthelmintic efficacy of PL varied between
mouse strains and therefore whether there is an underlying genetic basis influencing
the degree to which PL is effective in removing H. bakeri worms from treated
animals. The mice were first treated with 330nmol crude papaya latex (PLX) in
0.2ml pure water and then in the consecutive experiments were treated with 240nmol
papaya latex supernatant (PLS) in 0.2 ml water. The results indicated wide variation
of response in different strains of mice to PL medication. At the dose used, the
treatment was most effective in C3H mice ranging from 90.5% to 99.3% reduction in
worm counts and least effective in NIHS, CD1 and BALB/c strains (7.9%, 36.0%
and 40.5% respectively). However, host sex and cimetidine treatment were shown
not to have any influence on the anthelmintic efficacy of PLS. There was also no
significant difference in efficacy between mice treated with the standard dose of
240nmol and those treated with adjusted doses based on mouse body weight
(8µmol/kg body weight) in two strains, BKW and NIH. Physiologically there was no
significant difference in pH changes along the GI tract, trypsin concentration and
PLS activity of the poor (BALB/c) and high responder mice (C3H) to PLS treatment.
It was also shown that the enzyme activity of PLS is not irreversibly inactivated even
at low pH of 1.2. Finally, in responder mouse strains the efficacy of treatment was
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not affected by the intensity of the worm burden, all worm burdens being removed
with equal success.
6.1 Introduction
Epidemiological/pharmacological observational studies have shown that there is
wide between-patient variability in the response to standard doses of drug therapy
(Bosch, 2008). Such variation may range from failure to respond to a drug to life-
threatening adverse reactions. These between-individual differences in response to
standard doses may be attributable to the nature and severity of the disease being
treated, nutritional status, individual age and race, organ function, concomitant
therapy and illness. Although these factors are important, genetic differences
between individuals within otherwise uniform subsets of the population (i.e. same
racial background, age, sex etc.) are thought to be perhaps the most important factor
in influencing the efficacy and toxicity of medications (Evans and Johnson, 2001).
For many medications, these inter-individual differences are due in part to
polymorphisms in genes encoding drug metabolizing enzymes, drug transporter
and/or drug targets. This genetically determined variability among individuals in
drug response defines the research area known as pharmacogenetics, where
historically clinical observations on inherited differences in drug effects were first
documented in the 1950s (Alving et al., 1956).
The role of pharmacogenetics is to identify the network of genes that govern
an individual’s response to drug therapy with the ultimate goal of providing a
stronger scientific basis for selecting the optimal drug therapy and dosages for each
patient. It is also suggested that these genetic insights should be used as guidelines
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for the discovery and development of new medications (McLeod and Evans, 2001).
However, most of the literatures available for pharmacogenetics are based on the
drugs absorbed in the blood and very few for drugs which act directly in the lumen of
the intestine. Evans and Relling (2004) tried to summarize different genes controlling
drug metabolizing enzymes and their influence on drug effects in humans. Only two
drugs were found to have direct effects in the lumen. These drugs include
omeprazole (an antacid treatment) which is used for treatment of peptic ulcers and
heartburn and Irinotecan for treatment of colon and rectal cancer. These medications,
however, have different modes of action when compared with PLS which directly
attacks the parasitic cuticle.
In earlier chapters it has been shown that PLS has powerful anthelmintic
effects on H. bakeri removing >90% of the parasites after 5 doses, and even 68%
after just a single dose. Throughout the study, the mice used were males from the
inbred C3H strain, which had been used by Stepek et al. in earlier work (Stepek et
al., 2007a, Stepek et al., 2007b), whereas Satrija et al. (1995) used female mice of
the BALB/c strain to assess the anthelmintic activity of papaya latex against H.
polygyrus (currently known as H. bakeri). However, there has been no systematic
study comparing mouse strains of known contrasting genotype.
Unlike drugs that are absorbed by the host, orally administered cysteine
proteinases mostly stay in the lumen of the intestine where they act on worms
directly. In this case therefore, between-host variation in drug efficacy could arise
from polymorphic genes that influence the exact physiological conditions within the
intestine, such as pH, host digestive enzyme concentrations, time of passage of food
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through the gut, etc. The concentration of drug in the intestinal site where it is
required to target worms may also vary due to differences in body size and weight,
and hence proportionally differences between strains in the size and volume of the
intestine.
Genetic differences between individuals that affect their susceptibility to a
drug or affect the way the drug works on a targeted infectious organism can be
considered as an intrinsic factor since genetic differences originate from within the
host. Another prominent intrinsic factor is host sex. Male and female mammals differ
markedly in the hormones that control their sex and reproductive cycles and these in
turn have marked effects on their physiology. The differences in response to
medication between males and females seem to be caused by steroid sex hormones
(oestrogen, testosterone and progesterone) which can induce or inhibit the expression
of Cytochrome P450 genes responsible for secretion of Cytochrome P450 enzymes
in the liver (Cristofol et al., 1998). Cytochrome P450 enzymes are involved in
metabolism of exogenous toxic substances as well as endogenous substances
(Kubota et al., 2011, Finnstrom et al., 2002). Variations in cytochrome P450 enzyme
metabolism are seen prominently in the breakdown of medications. Depending on
gene expression, drugs can be metabolized quickly or slowly. If a cytochrome P450
enzyme metabolizes a drug slowly, the drug stays active for longer and less is needed
to get the desired effect. A drug that is quickly metabolized is broken down sooner
and a higher dose might be needed to be effective. It is reported that Cytochrome
P450 enzymes account for 70 – 80% of the enzymes involved in drug metabolism
(http:// ghr.nlm.nih.gov/gene Family/cyp). Finnstrom et al. (2002) found a higher
expression of CYP1B1 (a major P450 gene) in females than in males, a finding that
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is consistent with its known role in the metabolism of oestrogens. Other factors
which differentiate between males and females in drug responses include body
weight (males weigh more than females), yet few drugs are dosed based on body
weight. Additionally gastric acid secretion and its movement are lower in females
than in males (Meibohm et al., 2002, Henriksson et al., 1986). Another relevant
difference between the sexes is the higher percent body fat in females compared with
males, which can increase the distribution of lipophilic drugs in females (Jochmann
et al., 2005). Also excretion of drugs through the kidneys is slower in females than in
males because of the lower glomerular filtration rate (Anderson, 2008) and slower
creatinine clearance rate due to testosterone which induces increased muscle
metabolism in males (Meibohm et al., 2002).
There are many examples of differences between the sexes in their
susceptibilities to particular infections (Kiyota et al., 1984, Alexander and Stimson,
1988, Bundy, 1988, Poulin, 1996) as also in the metabolism of and efficacy of
administered drugs (Gokbulut et al., 2009, Wolf et al., 2000). Although sex
difference in pharmacotherapy has been identified, only a few drugs exhibit
differences, e.g. verapamil, beta-blockers and selective serotonin reuptake inhibitors
(Meibohm et al., 2002). It was important therefore to determine whether worm
infections in mice of both sexes were equally susceptible to treatment.
Apart from the genetic host related factors, intensity of worm infection has
been also reported to influence the efficacy of anthelmintics. Van Lieshout et al.
(1999) reported a significant decrease in cure rate of praziquantel with increasing egg
counts in individuals infected with Schistosoma mansoni before treatment in Senegal.
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The same level of treatment failure was also observed in individuals treated with
oxamniquine (Reis et al., 2006). Recently a significant reduction in efficacy of
albendazole against Trichuris trichiura with increase in intensity of infections has
been reported (Levecke et al., 2012). Due to these variations in efficacy of different
types of anthelmintics there is also a need to determine whether the efficacy of PLS
is affected by the intensity of worm burden.
Therefore the objective of this chapter was first to determine whether the
efficacy of PLS treatment is host genotype dependent, by comparing inbred strains of
mice which have defined genetic differences. Inbred mouse strains are expected to be
>99% homozygous at all genetic loci, as a result of brother-sister mating for at least
20 generations and each strain has had a different selection history
(http://jaxmice.jax.org). Thus within strains no significant genetic variation is
expected, but between strains major differences in alleles are known to exist
throughout the genome. Livestock on farms usually comprise well known and
productive breeds but although breeds differ genetically between each other, within
breeds there is still considerable genetic variation, allowing farmers to further select
breeding stock and to improve breed quality with respect to productive traits such as
meat, milk, wool etc. If the efficacy of PLS is dependent on host genotype,
differences in efficacy might be expected between animals within breeds on farms
where the therapy will be applied in the future. Thus the extent of variation arising
from genetic differences between animals is clearly an important issue to assess.
A second objective of the chapter was to determine whether worm infections
in male and female mice were equally susceptible to treatment with PLS.
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The third objective was to examine the effect of cimetidine, an antacid which
blocks acid in the stomach that might be inhibiting the activity of the PLS which is
susceptible to pepsin degradation at low pH.
The fourth objective was to assess the degree to which genetic differences
between strains might be attributable to differences in host body weight.
And finally, since recent data has shown that efficacy of anthelmintics can be
dependent on the intensity of infection (Levecke et al., 2012) the efficacy of
treatment with CPs was assessed in two strains of mice that differ widely in their
sensitivity to CPs, carrying three different levels of infection.
6.2 Experimental design and results
6.2.1 Experiment 1: Treatment of different strains of mice with crude papaya
latex
This experiment was conducted by Stepek et al in 2004 and analyzed by WL. It
comprised five strains of mice, three being inbred (BALB/c, C3H and CBA/ca) and
two outbred (BKW and CD1). For each strain 10 mice were used with the exception
of CD1 where 16 mice were used. All mice were infected with 200 H. bakeri L3
larvae on day 0. Then the mice in each strain were divided into two groups each with
5 mice, except CD1 which comprised groups of 8 mice. The first group of mice in
each strain was treated with 330nmol crude papaya latex (PLX) in 0.2ml water daily
for 7 days and the second group was given 0.2ml of ultra filtered pure water, both
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treatments starting on day 19. All mice were fasted for about 6 hours prior to
treatment but had ad libitum access to water. Faecal samples were collected on day
14, 16, 18 (pre treatment) and on day 19, 21, 23 and 25 (during treatment) post
infection for quantification of parasite eggs and the mice were autopsied on day 25.
6.2.2 Experiment 1: Results
The results indicated that different strains of mice responded differently to treatment
(Fig 6.1 and 6.2). In terms of faecal egg counts (FEC) BALB/c strain showed 75.3%
reduction, CBA/ca mice had 82.1% reduction and BKW strain had 69.4% while CD1
strain had 56.6% reduction. On the other hand the C3H strain showed the greatest
change in FEC amounting to 97.8% reduction, considerably greater than in any other
strain (Table 6.1).
Statistically FEC were analysed by repeated measure GLM on log10
(FEC+25) transformed data with time after infection as the within – subject factor,
treatment (PLX or distilled water) and strains of mice as the between subject factors.
The results indicated that there was a significant 2-way interaction of time* treatment
(within subject measure; F6,264 = 45.31, P<0.001) and a main effect of treatment
(between subject measure; F1,44 = 52.13, P<0.001). There was also a significant 2-
way interaction between treatment*strains (F4,44 = 5.14, P < 0.05). The 3-way
interaction between time*treatment*strain was also significant (F24,264 = 5.55, P <
0.001) and again as expected there was a significant overall effect of time (main
effect of time, F3.3,264= 22.88, p < 0.001).
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Figure 6.1: Faecal egg counts in different strains of mice treated with PLX
The figure shows the response of different strains of mice to PLX against H.bakeri
measured in terms of average eggs/gram of faeces/mouse. Five strains of mice
(BALB/c, CBA/ca, BKW, CD1 and C3H) each were divided into two groups. The
first group was treated with 0.2ml of PL and the second group given distilled water,
each group having 5 animals. First mice were orally gavaged with 150 L3 larvae and
then treated for 7 days from day 19 post infection. Faecal egg counts were conducted
on day 14, 16 and 18 (pre treatment) and on day 19, 21, 23 and 25 (post infections).
The graphs show a progressive decline in egg counts with increased days of
treatment. The decline is high in C3H and CBA strains for the groups treated with
PLX (93.8% and 82.1% respectively) compared to those receiving water. Other
strains experienced less reduction in worm burden (75.3%, 69.4% and 56.6% for
BALB/c, BKW and CD1 respectively). *indicates day of treatment.
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As in FEC the worm count data also indicated great variation in the extent of
the reduction in worm burdens due to treatment between different strains of mice.
The strain with the highest response to treatment was C3H (92.1%) and lowest
response was observed in BALB/c and CD1 (40.3% and 36.0% respectively).
Analysis by 2-way GLM using raw data gave a significant effect of treatment, F1,46 =
189.34, p < 0.001 and a significant interaction between strain and treatment F4,46
=7.13, p < 0.001 indicating that the reduction in worm counts varied significantly
between different strains of mice (Fig 6.2). Post hoc analysis by the Tukey indicated
that post treatment worm burdens in C3H mice were significantly different to those
in BALB/c and CD1 strains (p < 0.05 and p < 0.001 respectively).
Figure 6.2: Intestinal worm count in different strains of mice treated with PLX
Intestinal worm burdens were assessed on day 25 post infection. Worm burdens from
the treated and untreated group (n=5) of each strain are indicated by the different
bars with standard errors of the means. The figure shows that C3H and CBA strains
had a greater degree of reduction in worm burdens following treatment with PLS
than other strains.
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Table 6.1: Percentage reduction in FEC and worm counts in various strains of mice
Experiment
1
Experiment 2 Experiment 3 Experiment 4 Experiment 6
Mice
strain
FEC worm FEC worm FEC Worm Combined
sex
FEC Worm FEC Worm
M F M F FEC worm
BALB/c 75.3 40.3 5.0 47.2 - - - - - - - - - -
BKW 69.4 53.6 - - - - - - - - - - 69.9 60.1
CBA/c 82.1 85.4 - - - - - - - - - - - -
CD1 56.6 36.0 - - - - - - - - - - - -
C3H 97.8 92.1 97.1 95.9 96.1 90.6 93.1 88.5 92.5 90.6 99.3 98 97.0 91.9
C57/BLK - - 64.1 84.9 - - - - - - - - - -
NIH - - 33.2 59.0 73.9 77.6 63.3 46.2 75.6 55.7 50.7 88 - -
NIHS - - - - - - - - - - - - 38.2 7.9
Experiment 1: treatment of different strains of mice with PLX, Experiment 2: Treatment of additional strains of mice with papaya latex
supernatant, Experiment 3: Response of male and female mice to PLS treatment, Experiment 4: Treatment of NIH mice with PLS based on body
weight and Experiment 6: Response of BKW mice to PLS treatment based on body weight. FEC mean faecal egg counts
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6.2.3 Experiment 2: Treatment of additional strains of mice with PLS
The second experiment extended the first by the addition of further strains of mice,
and it differed in that in this case PLS was used rather than PLX. In this case two
additional strains of mice were used C57/BLK and NIH, both inbred. BALB/c and
C3H strains were used as negative and positive controls respectively (as they had
shown contrasting results in Experiment 1, C3H showing a marked reduction in both
FEC and worm counts while BALB/c a relatively poor change in both parameters).
The experimental design was the same as that of the first experiment with the
exception that mice were infected with 150 H.bakeri larvae instead of 200. Also they
were treated with 240nmol PLS in 0.2 ml water daily for 5 days unlike in the first
experiment when mice were treated with PLX for 7 days.
6.2.4 Experiment 2: Results
The results showed different responses to treatment in different strains of mice, as
observed in Experiment 1. The effect of strain on the anthelmintic activity of PLS as
assessed by FEC was analysed statistically by repeated measures GLM on
log10(FEC+25) transformed data, with time after infection as the within-subject
factors, and treatments and strains as the between subject-factor in the full factorial
model. The analysis was carried out only for four days of treatment as BALB/c were
killed after 4 days of treatment, because of their deteriorating condition. The results
indicated that the main effect of treatment was significant (F1,36 = 9.274, p<0.005).
The 3-way interaction time*treatment*strains was also significant (within subject
analysis F12,128 = 4.257, p < 0.005). Based on arithmetic means there was great
variation in the extent of FEC reduction, with reduction being weakest in BALB/c
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(5%), intermediate in NIH and C57/BLK (33.2 & 64.2% respectively) and most
intense in C3H (97.1%) mice (Fig 6.3). A Post hoc Tukey HSD analysis indicated a
significant decline in FEC in C3H and C57/BLK mice (p<0.001 and p<0.005
respectively) when compared with BALB/c.
Figure 6.3: Mean FEC in different strains of mice treated with PLS.
The figure shows the mean FEC over time in 4 strains of mice (NIH, C3H, BALB/c
and C57BLK). All 4 strains of mice were first orally gavaged with 150 L3 larvae and
then each strain was divided into 2 groups, treated with PLS and those given distilled
water for 5 days from day 20 post infection. FECs were conducted on day 14, 16, 18,
21, 23 and 25 post infections. The faecal egg counts decreased with increased days of
treatment and the decline was more marked in C3H (97.1%) compared to the other
strains (64.1 for C57/BLK, 33.2% for NIH and 5% BALB/c. *indicates day of
treatment.
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In terms of changes in worm burden due to treatment, marked variation
between strains of mice was also observed, with reduction following treatment with
PLS being greatest in C3H (95.9%) followed by C57/BLK (84.9%) then NIH
(59.0%) and least in BALB/c mice (47.2%) (Fig 6.4). Analysis by 2-way GLM
indicated a significant effect of treatment, F1,32 = 481, p<0.001 and significant
interaction between treatment and strain of mice F3,32 =6.16, p<0.002 indicating that
the outcome of treatment depended significantly on strain of mice being treated.
Figure 6.4: Intestinal worm count in different strains of mice treated with PLS
Mice were infected with 150 L3 larvae on day 0 and then treated with 8ȝmol/kg
(240nmol/mouse) PLS once per day for 5 days from day 20 post infection. The worm
burdens were assessed on day 25 post infection. The intestinal worm burdens of each
strain, both groups treated with PLS and those receiving distilled water, are shown.
Mice receiving PLS in each strain showed a significant reduction in intestinal worm
burdens (F1, 9 = 10.364, p<0.012) compared with those given water.
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6.2.5 Experiment 3: Response of male and female mice to PLS treatment
The objective of this experiment was to compare the response to treatment of male
and female mice from a high and a lower responder strain. In this case two strains of
mice were employed: C3H as the high responder and NIH as an intermediate
responder, both inbred mice. The intermediate NIH strain was used rather than as
originally intended the BALB/c because BALB/c mice showed intolerance to PLS in
Experiment 2 and therefore in accordance with the 3Rs principle, NIH mice were
selected as the contrasting strain to minimise suffering. In each strain 20 mice were
used (10 male and 10 female). All mice were infected with 150 H.bakeri larvae on
day 0. Then the mice in each strain were divided into two groups each with 10 mice
(5 males and 5 females). The first group of mice in each strain was treated with
240nmol PLS in 0.2 ml water daily for 5 days and the second group was given 0.2ml
of ultra filtered distilled water. Faecal samples were collected on day 14, 16, 18 (pre
treatment) and on day 21, 23 and 25 (during treatment) post infection and mice were
autopsied on day 25 for intestinal worm counts.
6.2.6 Experiment 3: Results
The results (Fig 6.5 & 6.6) indicate a different response to treatment between the
strains as found in the previous experiments. For combined data of both male and
female mice, C3H mice showed a better response in terms of reduction of both FEC
and worm burden (92.5% and 90.6% respectively) due to treatment than NIH strain
with 75.6% reduction in FEC and 55.7% reduction in worm burden (Table 1).
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The Data for FEC were analysed by 4-way rm GLM with strain, sex and
treatment as between subject factors and time as the within subject factor.
Statistically, the results showed a significant main effect of treatment (F1,32 = 37.54,
p<0.001). The 3-way interaction time*treatment*strain was also significant (F2.9,93.4 =
3.186, p < 0.005). However, the main effect of sex was not significant and no
interactions involving sex were significant.
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Figure 6.5: Mean FEC in male and female mice treated with PLS
Both strains (C3H & NIH) of mice were first orally gavaged with 150 L3 larvae on
day 0 and then each strain was divided into 2 groups. The first group was treated
with PLS and the second group was given distilled water for 5 days from day 20 post
infection. FECs were conducted on day 14, 16, 18, 21, 23 and 25 post infections. The
faecal egg counts decreased with increase in days of treatment and the decline was
more marked in C3H mice irrespective of sex compared with NIH strain. A) FEC in
male mice and B) in female mice. *indicates day of treatment.
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Analysis of worm burdens by 3-way GLM indicated a significant effect of
treatment, F1,32 = 155.726, p<0.001 and a significant interaction between
treatment*strain of mice F1,32 =25.044, p<0.001 but no significant interactions
between treatment*sex (p = NS) and no main effect of sex, indicating that the
efficacy of PLS does not depend on the sex of mice being treated in either strain,
whether good responder to PLS therapy or intermediate.
Figure 6.6: Intestinal worm count in male and female mice treated with PLS
Treatment details are as for Fig 6.5. The worm burden was assessed on day 25 post
infection. The intestinal worm burden of each group treated with PLS and those
receiving distilled water are shown, with the sexes of each strain illustrated
separately. Mice receiving PLS in each strain showed a significant reduction in
intestinal worm burdens (F1 32 = 155.726, p<0.001) when compared with those
receiving water. However the decline was significantly higher in C3H than in NIH
mice indicated by the treatment*strain interaction (F1 32 = 25.044, p<0.001).
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6.2.7 Experiment 4: Treatment of NIH mice with PLS based on body weight
The aim of this experiment was to assess the efficacy of PLS based on mouse body
weight. In this case NIH mice were used as they have been shown to have great
variation in body weight and to vary in their response to treatment between
individuals of the same age when compared with C3H mice. Thus 25 mice were
used, 15 being NIH and 10 C3H mice. The 15 NIH mice were then divided into three
groups of 5 mice each. One group of mice was treated with 0.2ml of the standard
dose of 240nmol PLS regardless of their difference in body weight and the second
set of mice was treated with an adjusted dose based on body weight of mouse (i.e.
8µmol/kg body weight). In this case the amount of PLS used was adjusted each day
according to the weight of the mouse. It was assumed that the amount of PLS
required depends on the body weight of the mouse and hence differences in amount
of drug administered arise if body weight is not taken into account. The last group
was gavaged orally with ultra-filtered distilled water. While the C3H mice were used
as positive controls and divided into 2 treatments, the first group was treated with a
standard dose of 240nmols of PLS and the second group was given distilled water.
This experiment was conducted simultaneously with Experiment 7.
6.2.8 Experiment 4: Results
The results (Fig 6.7) showed indistinguishable responses of mice to treatment with
PLS whether given as a standard dose of 240nmol/mouse or adjusted daily for host
body weight to comprise 8µmol/kg body weight. There was a 50.7% FEC reduction
for mice treated with the standard dose and 63.2% for those treated based on body
weight. In terms of worm burden there was a reduction of 88% for mice treated with
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the standard dose and 85.1% for those treated based on their body weight. Although
the mice treated according to daily body weight showed a slightly higher figure for
the reduction of FEC, when statistically tested by repeated measure GLM on
log10(FEC+25) transformed data, there was no significant difference between the 2
groups (F2,10= 0.042, p = 0.958).
In terms of worm burden one-way ANOVA was used to analyse the data and
this indicated a significant difference between groups of mice treated with PLS and
those given water F2,14 = 65.75, p<0.001). Post hoc analysis indicated no significant
difference between mice treated with the standard dose and those treated with an
adjusted dose based on their body weight (Tukey test; p=0.944). The C3H mice
which were used as positive controls showed the expected superior response to
treatment with a 99.3% reduction in FEC and 98% for worm burdens. The NIH had
body weight variation of 25 g to 35 g.
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Figure 6.7: FEC and worm count in NIH mice treated based on body weight
NIH mice were first orally infected with 150 L3 larvae on day 0 and then divided
into 3 groups. The first group of mice was treated with the standard dose of PLS for
5 days, the second group was treated based on adjusted body weight dose and the
third group was given distilled water. Two groups of C3H mice were also included,
the first group being treated with the standard dose of PLS and the second group was
given water. FECs were conducted on day 14, 16, 18, 21, 23 and 25 post infections
and worm counts on day 25. Both FECs (A) and worm counts (B) decreased
significantly in the PLS treatment groups and there was no significant variation
between the treated groups. *indicates day of treatment.
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6.2.9 Experiment 5: Response of NIH Swiss mice to PLS treatment
In this experiment NIH Swiss (NIHS) mice were tested for their response to
treatment with PLS. This strain is an outbred strain from which the inbred NIH strain
was developed. The latter was selected as intermediate responder to compare with
the C3H mouse response to PLS treatment. The aim of the experiment was to
examine how this outbred strain responds to treatment with the standard dose of PLS
when compared with C3H. It was expected that they would show a similar response
to treatment if there was not any underlying genetic effect. This experiment was
carried out simultaneously with Experiment 6 so that the same positive control C3H
mice could be used in both experiments in order to minimize the number of animals
used. In this case 10 NIHS mice were divided into 2 groups, the first group was
treated with the standard dose of PLS and the second group was given distilled water.
6.2.10 Experiment 5: Results
The results indicate that NIHS mice experienced only a 37.3% reduction in FEC and
7.9% reduction in worm burdens, while C3H showed 97.0% reduction in FEC and
91.9% worm burden (Fig 6.8). Statistical analysis based on repeated measure GLM
on log10(FEC+25) transformed data showed a significant main effect of strain (F1,15 =
22.742, p<0.001) and the 2-way interaction between treatment*strains was also
significant (F1,15 = 8.601, p < 0.01). However there was no significant main effect of
treatment (F1,15 = 0.006, p=0.938) nor a significant interaction between
time*treatment*strain (F3.8,57.26 = 0.924, p < 0.453).
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Analysis of worm burdens by 2-way GLM indicated a significant main effect
of treatment, F1,15 = 45.594, p<0.001 and interaction between treatment*strain of
mice F1,15 =35.983, p<0.001 but no significant main effect of strain F1,15 =3.715,
p=0.073.
Figure 6.8: FEC and intestinal worm count in NIHS mice treatment with PLS
NIH swiss and C3H strains infected with 150 L3 on day 0 were divided into 2 groups
for each strain (those treated with standard dose of 240nmol of PLS and those given
0.2ml distilled water). FEC were conducted on day 14, 16, 18, 21, 23 and 25 and
worm burden on day 25 post infections. The results indicated significantly higher
reduction in both FEC and worm burden in C3H strain compared with the NIHS.
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6.2.11 Experiment 6: Response of BKW mice to PLS treatment based on body
weight
This experiment was a repetition of Experiment 4 which aimed at assessing the
efficacy of PLS based on mouse body weight. In this experiment BKW mice were
used, instead of the NIH mice which had been used in the previous experiment but
showed low variation in body weight and hence less deviation in response to
treatment. BKW mice were chosen because they are heavier than NIH mice and are
outbred with expected greater variation in body weight. Thus they were expected to
show more deviation in response to treatment within the same group than the inbred
strains. As usual C3H mice were used as the positive control.
Therefore 25 mice were used, 15 BKW and 10 C3H mice. All mice were first
infected with 150 L3 H. bakeri then the 15 BKW mice were divided into 3 groups of
5 mice each. The first group was treated with the adjusted dose based on body weight
of the mouse as explained in Experiment 4, the second group was treated with the
standard dose of 240nmol PLS in 0.2 ml pure water and the third group was gavaged
orally with ultra-filtered distilled water. The C3H mice were divided into 2 treatment
groups, the first group was treated with a standard dose of 240nmols of PLS and the
second group was given distilled water.
6.2.12 Experiment 6: Results
In this experiment, treatment was only continued for 4 days instead of the normal 5
days treatments. This is because some mice in the treatment groups showed some
signs of distress with one of them having a distended abdomen. Although all the
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animals were still within the moderate band of our Home Office project licence, it
was suspected that the distressed animals might develop the same problem of
distended abdomen, causing distress and suffering to the animals. For this reason the
animals were culled one day before the planned end of the experiment while 3 of
them were terminated 2 days before as they showed earlier signs of distress. One of
the mice was from the group treated with a standard dose and 2 from the group
treated based on body weight. The data from these mice were excluded in the final
analysis as they had received fewer doses. Only the C3H mice were left until the end
of the experiment as they did not appear to develop similar symptoms in this or any
of the previous experiments in which they had been used.
The results (Fig 6.9) showed that the mice treated with a standard dose had a
high reduction in the FEC (62.5%), in fact greater than those treated based on body
weight (38.2%). However, when statistically tested by repeated measures GLM on
log10 (FEC+25) transformed data between the 2 groups (analysis confined to the two
treatments in BKW mice), there was no significant difference between treatments
(F1,5 = 3.32, p = 0.128). However, when BKW and C3H mice treated with the
standard dose were analyzed by repeated measure GLM on log10 (FEC+25)
transformed data, the results showed a significant main effect of treatment (F1,15 =
22.464, p<0.001) and the main effect of strain (F1,15 = 23.58, p < 0.001). The 3-way
interaction time*treatment*strain was also significant (F4,60 = 4.207, p < 0.005) but
there was no significant interaction between strain and treatment (F1,15 = 0.221, p <
0.645).
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In terms of effects on the worm burdens there was a reduction of 60.1% for
mice treated with the standard dose and 56.7% for those treated based on their body
weight. One-way ANOVA was used and indicated no significant difference between
the 2 groups of mice treated with PLS based on body size and those treated with the
standard dose (F1,8 = 0.081, p=0.7841). But when the two strains, BKW (treated with
standard dose) and C3H were analysed by 2-way GLM. There was a significant
main effect of treatment (F1,16 = 186.76, p<0.001) and an interaction between
treatment*strain (F1,16 = 15.905, p<0.001). The C3H mice which had been used as
positive controls showed the expected greater response to treatment with a 97.0%
reduction in FEC and 91.9% in worm burden. BKW mice had body weight variation
was between 28 g to 40 g.
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Figure 6.9: FEC and worm counts in BKW mice treatment based on body
weight
BKW and C3H mice were orally gavaged with 150 L3 on day 0. Then BKW mice
were divided into 3 groups (those treated based on body size, treated with standard
dose of 240nmol of PLS and those given 0.2ml distilled water), while C3H mice
were divided into two groups (those given standard dose and those given distilled
water). FECs were conducted on day 14, 16, 18, 21, 23 and 25 and worm burdens on
day 25 post infections. There was a significant reduction in FEC (A) and intestinal
worm counts (B) in the treatment groups when compared with control group.
However, the reduction was not significantly different between the group treated
based on mouse body size and that given the standard dose. *indicates day of
treatment.
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6.2.13 Experiment 7: Effect of cimetidine on the efficacy of PLS
The objective of this experiment was to assess the effect of cimetidine on the
efficacy of PLS and whether cimetidine had any effect on worm burden. In this
experiment 10 NIH mice were divided into two groups, the first group was given
cimetidine 15 minutes prior to being treated with 0.2ml of the standard dose of
240nmol of PLS while the second group was only given cimetidine. This treatment
was intended to block the acid secreted in the stomach which is assumed to inhibit
the activity of the PLS. Based on 3Rs principle this experiment was carried out at the
same time as Experiment 4 so as to use the same control groups (NIH & C3H treated
with standard dose of 240nmol and those given water).
6.2.14 Experiment 7: Results
The results of this experiment showed no difference between mice treated with PLS
alone and those given cimetidine prior to being treated with PLS (Fig 6.10). There
was a 50.7% FEC reduction for mice treated with only PLS and 56.3% for those
given cimetidine prior to being treated with PLS. In terms of worm burdens there
was a reduction of 88% for NIH mice treated with PLS alone and 80.5% for those
administered with cimetidine before being treated with PLS. In C3H mice the
reduction was 99.3% in FEC and 98% for worm burdens.
FEC data were analysed by rm GLM with treatment as the between subject
factor and time as the within subject factor. The results showed a significant main
effect of treatment (F3, 14 = 7.141, p<0.04). However, there was no significant main
effect of cimetidine (F1, 27 = 2.769, p=0.108) or 3-way interaction, time*PLS
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treatment*cimetidine (F3.04, 81.97 = 0.808, p = 0.494). Analysis of worm burdens by 2-
way ANOVA indicated a significant main effect of PLS treatments (F1,16 = 143.814,
p<0.001) but no significant main effect of cimetidine (F1,16 = 0.021, p<0.886) or
interaction of PLS*cimetidine (F1,16 = 1.107, p<0.308). This implies that the efficacy
of PLS is not influenced by cimetidine administration.
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Figure 6.10: FECs and worm burdens in mice given cimetidine before treatment
NIH mice were orally gavage with L3 larvae on day 0. Then mice were divided into
4 groups, 2 treatment groups (those treated with standard dose of 240nmols and those
given cimetidine 15 minutes prior to being treated with 240nmol of PLS) and 2
control groups that received cimetidine alone and another group given distilled
water. C3H mice comprised 2 groups, those treated with standard dose of PLS and
those given water. There was significant reduction in FEC (A) and intestinal worm
counts (B) in the treatment groups when compared with those receiving either
cimetidine alone or water. However, there was no significant reduction between the 2
treatment groups (PLS and cimetidine + PLS).
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6.2.15 Experiment 8: Enzyme survivability at low pH.
This experiment was carried out to determine whether the CPs at low pH are
permanently damaged by either the the low pH itself or by pepsin secreted in the
stomach. To achieve this objective PLS was diluted in a ratio of 1:10 either in i) a
saline solution made with 0.85% NaCl at pH 7, ii) saline solution + HCl at pH 1.2,
iii) saline solution + HCl + 1% pepsin at pH 1.2 or iv) saline solution + HCl + 1%
pepsin at pH 3.2 (mimicking the mouse stomach environment). All the solutions
were made in duplicate and incubated at 37
o
C for 2 hours and then tested for enzyme
activity. The absorbance values were then converted into concentrations by
multipying with molar extinction coefficient of 8800M
-1
cm
-1
for papain (Mole and
Horton, 1973). Under these assay conditions 1 unit of enzyme activity was defined as
that which produced 1 nmol min
-1
of product.
6.2.16 Experiment 8: Results
The results shown here are the percentage enzyme recovery when compared to that
incubated in saline without pepsin at pH 7 and were 93.3% for enzyme incubated at
pH 1.2 with pepsin, 92.0% for that incubated at pH 1.2 but without pepsin and 89.1%
for the enzyme incubated at pH 3.2 with pepsin. Examining these results it is evident
that the amount of enzyme activity recovered under the different conditions tested
was almost similar to that when PLS was incubated at pH 7 which is the optimum pH
for CPs activity. This means that if the enzyme was inactivated at pH1.2 then it was
reactivated subsequently in the activity assay after being incubated with L-cysteine.
153
6.2.17 Experiment 9: Measurements of pH of the GI tract of mice.
This experiment was conducted to test whether the reduced efficacy of PLS in some
strains of mice could be due to lower intestinal pH, with resultant inhibition of the
enzyme activity against the nematodes. Thus there was a need to determine whether
there was any difference in pH levels along the GI tracts of the poor and high
responder strains of mice.
A group of 10 mice (5 BALB/c and 5 C3H) was used but unfortunately, 1
mouse in C3H group died before the start of the experiment thus leaving 4 mice for
the actual experiment. All mice had free access to food and water. One mouse at a
time was killed and immediately dissected, after which the intestinal tract was
removed and divided into sections: stomach, upper small intestine (duodenum),
lower small intestine (Ileum), caecum and colon. A small cut was made in the middle
of the gut wall in each section in which a 6 mm electrode of a pH meter was inserted
and the pH was read when stability was achieved. Measurements were made in
sequence from the stomach to the colon. The electrode was rinsed with distilled
water between each reading. The same procedure was repeated on all mice and it
took about 3-5 minutes for the whole procedure on each animal to be completed.
6.2.18 Experiment 9: Results
The pH values of the different GI sections of both BALB/c and C3H are shown in
Figure 6.11. As expected the lowest pH value was seen in the stomach of both strains
BALB/c (3.53) and C3H (3.54) and then pH increased steadily in the duodenum to
colon. The lower part of small intestine had slightly higher pH values than any other
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parts of the GI tract (6.83 for BALB/c and 6.61 for C3H). Statistically the pH varied
significantly along the GI tract sections (F4,28 = 93.232, p<0.001), however there was
no significant difference in the variation observed in pH between the two strains of
mice (F1,7 = 2.159, p<0.185), even the interactions between pH change in different
sections of the GI tract and the strains being not significant (F4,28 = 0.32, p<0.862).
Therefore, it is clearly evident that the pH in particular regions of the intestine and
how this changes along the length of the mouse GI tract does not differ between
these two strains of mouse.
Figure 6.11: Measurements of pH along the mouse GI tract
The figure shows the change in pH along the GI tract (stomach, duodenum, ileum,
caecum and colon) of the 2 strains of mice (BALB/c and C3H).
6.2.19 Experiment 10: Enzyme activity along the mouse GI tract
This experiment aimed at assessing the activity of CPs along the GI tract in poor
(BALB/c) and higher responder (C3H) strains of mice. To achieve this objective 12
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uninfected mice (6 from each strain) which had free access to both water and food
were administered orally with 240 nmol PLS in 0.2 ml pure water and then one
mouse from each strain was killed, by cervical dislocation, after the following time
intervals: 10, 20, 60, 90, 120 and 180 minutes. At each time interval, entire GI tract
from the stomach to the large intestine was removed from each mouse, briefly
washed in a Petri dish of PBS and then divided into 5 sections: the stomach, the
upper half of small intestine (duodenum), lower half of small intestine (ileum),
caecum and the large intestine (colon). These sections were opened longitudinally
and washed individually with 1 ml of PBS before the contents were filtered using
muslin cloth.
The enzyme activity in each section over a 3h period was determined by
activity assays using BAPNA as the substrate with and without E-64. The E-64 was
used in order to distinguish the activity of the CPs and that of trypsin and other GIT
enzymes, which can also cleave BAPNA. To ensure complete inactivation of CPs 2.0
nmol E64 in 100 µl water was incubated with 1.6 nmol PLS enzyme solution in 10 µl
water. The following equation was used to calculated the hydrolysis units (U) of
BAPNA: U= A(410nm)/minx1000x1/8800, where 8800M
-1
cm
-1
is the p-nitroaniline
molar extinction coefficient and 1 unit of enzyme activity was defined as that which
produced 1 nmol min
-1
of the product.
6.2.20 Experiment 10: Results
The results indicated that there was a similar pattern of enzyme activity variation
along the GIT of both strains (BALB/c and C3H) of mice. In both strains the activity
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was initially higher in the stomach but rapidly declined after 90 min with only
negligible levels of enzyme activity remaining thereafter. Whereas the activity of the
enzyme in the small intestine rose steadily in the first 60 min and then started to
decline rapidly by 90 min, a relatively low level of activity was observed particularly
in the upper small intestine. At the same time the activity appeared to increase
steadily in the caecum and colon, although in BALB/c the levels of activity in the
lower intestine remained higher until 120 min. In short, the enzyme activity in both
strains of mice decreased gradually in the stomach and small intestine over the first
90 min and then increased steadily in caecum and colon, so that by 180 min the
majority of the enzyme activity was only in the large intestine particularly in the
caecum (Fig 6.12).
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Figure 6.12: Enzyme activity along the mouse GI tract
The figure shows the variation in enzyme activity along the GI tract (stomach,
duodenum, ileum, caecum and colon) of the 2 strains of mice (BALB/c and C3H)
after different time intervals. Enzyme activity in both strains of mice declined rapidly
in stomach and intestine over time but increased steadily in the caecum and colon.
6.2.21 Experiment 11: Determination of trypsin concentration in mouse
intestine
The aim of this experiment was to determine the activity of trypsin in the GIT of the
poor and higher responder strains of mice. It was possible that in poor responder
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mice trypsin is secreted at higher levels than in responder strains, thus causing
greater digestion of PLS and degradation of the enzyme with resultant reduction of
the activity of PLS. To achieve this objective eight untreated mice were killed (4
BALB/c & 4 C3H) and the entire GI tract from the stomach to the large intestine was
removed from each mouse, briefly washed in a Petri dish of 20mM tris buffer and
then divided into 5 sections: the stomach, the upper half of the small intestine
(duodenum), lower half of the small intestine (ileum), caecum and colon. As usual
the sections were opened longitudinally and washed individually with 1 ml of tris
buffer before the contents were filtered using muslin cloth.
The activity of trypsin was determined by activity assay using BAPNA as
substrate. Briefly 10 µl of enzyme solution was added to 12.5 µl of 100 mM BAPNA
solution and then 977.5 µl of 20 mM tris.HCl pH 7.5, 5 mM CaCl2 buffer were added
to make 1 ml of the assay. The production of p-nitroaniline was measured by
spectrophotometry at 410nm. BAPNA hydrolysis units, which are equivalent to
enzyme activity, were calculated using the same producer as in Experiment 10.
Stomach readings were used as negative control.
6.2.22 Experiment 11: Results
As expected, high activity was found in the small intestine of both strains of mice
particularly in the lower part of the small intestine (Fig. 6.13). Statistical analysis by
one-way GLM showed that there was no significant difference between the two
strains (F1,6 = 0.462, P= 0.522). These results indicate that the patterns of trypsin
activity are similar along the length of the intestines of both strains of mice, and
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hence variation in secretion of trypsin is not likely to be an explanation for the
difference in the efficacy of PLS between these two strains of mice.
Figure 6.13: Trypsin activity along the GI tract of the 2 strains of mice
The variation in the amount of trypsin along the intestine of BALB/c and C3H strains
of mice.
6.2.23 Experiment 12: Effect of worm burden intensity on the efficacy of PLS
This experiment was aimed at assessing the effect of worm intensity on the efficacy
of PLS. In this experiment, 2 strains of mice were used, BALB/c, which had been
excluded previously from experiments because the mice had shown less tolerance to
PLS and C3H which has been used all the time as positive control. Since they had
been used only once (Experiment 2) and then showed such marked side effects of
treatment, it was necessary to conduct at least one more experiment with this strain to
provide confirmatory evidence of their susceptibility to side effects. Also this strain
was used here because it had earlier been shown to be a very poor responder to PLS
even though the mice in this strain have lower body weight than C3H mice, and
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hence one might anticipate a proportionally higher concentration of the active drug in
the intestine. However, in this experiment much care was taken to ensure that the
mice experienced minimal signs of intolerance to PLS and hence side effects. This
involved more thorough cleaning of the oral gavage needle before and after each
treatment to avoid the remaining PLS in the needle irritating the oesophagus, and
thereby causing reflux of the PLS from the stomach.
The experiment employed 60 mice, 30 from BALB/c strain and another 30
from the C3H strain. The mice were divided into 3 groups of 20 animals (10 mice
from each strain). Each group of 20 was infected with a different dose of L3 larvae of
H. bakeri (50, 150 or 300 L3). Then the ten mice of each strain within each intensity
category were divided into 2 groups of 5, one of which was treated with a standard
dose of PLS and the other was given distilled water. Because of logistic limitations,
faecal egg counts were only carried out for referencing in the groups of mice infected
with 150 L3 larvae.
6.2.24 Experiment 12: Results
As earlier the BALB/c mice were less tolerant to PLS treatment, although this time
not as seriously as before but nevertheless one mouse had to be culled as it lost
substantial amount of weight exceeding the 20% moderate band limit allowed by the
Home Office on our project licence. Another mouse was accidentally trapped by the
bedding materials and dislocated the neck thus it also had to be terminated
prematurely. One mouse from the control group was excluded from the analysis as it
had a very low worm infection of only 8 worms out of the 300 L3 infected. All these
3 mice were from the BALB/c strain. Therefore the results reported herein are based
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on 57 mice instead of 60 mice which were initially infected with different levels of
worm intensity.
The results showed that in the reference group (mice infected with 150 L3)
there was a 99.1% reduction in FEC for C3H and -16.0% for BALB/c mice. In terms
of worm burdens, mice infected with 50 L3 larvae had 89.9% and 23.6% reduction in
worm burden for C3H and BALB/c respectively. Those infected with 150 L3 larvae
had 89.4% and 2.8% for C3H and BALB/c respectively. While those infected with
300 L3 larvae had a reduction of 91.7% and 14% for C3H and BALB/c respectively
(Fig 6.14).
Statistically FEC were analysed by repeated GLM on Log10(FEC+25)
transformed data with strain and treatment as between subject factors and time as the
within subject factor. The results showed a significant main effect of treatment (F1,15
= 7.086, p<0.05). However, the main effect of strain was just outside the threshold
for significance (F1,15 = 4.457, p = 0.052). The 3-way interaction
time*treatment*strains was significant (F2.5,36.85 = 7.413, p < 0.001).
Analysis of worm burdens by 3-way GLM showed a significant main effect
of treatment (F1,45 = 89.521, p = 0.001), strain (F1,45 = 89.521, p = 0.001), worm
burden intensity (F2,45= 117.428, p = 0.001) and interaction of
treatment*strain*worm intensity (F2,45 = 6.181, p = 0.004). Mice were also monitored
for the pathological effects of treatment by observing hair coat and taking daily body
weight. All the animals were active and healthy throughout the period of treatment,
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except the mouse which lost more than 20% body weight and was terminated
immediately before the end of the experiment.
Figure 6.14: FEC and worm counts for mice infected with different intensity of
L3 larvae
BALB/c and C3H mice were gavaged orally with different intensities of L3 larvae,
50L3, 150L3 and 300L3 on day 0. Then the mice were divided into 2 groups, those
treated with standard dose of 240nmol and those given distilled water. FECs (A)
were conducted on groups of mice infected with 150L3 on day 14, 16, 18, 21, 23 and
25 and worm burdens were assessed in all groups on day 25 post infection. There
was significant variation in reduction of FECs and intestinal worm counts (B)
between the 2 strains of mice. *indicates day of treatment.
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6.3 Discussion
The results of the experiments presented in this chapter indicate clearly that mouse
strains differ in the extent to which a standard dose of PLX or PLS removes worms
from the intestines of mice and that the efficacy of PLS does not vary between the
sexes of the animals being treated. Moreover, the difference between strains is not
dependent on their body weights and efficacy in the poor responder strains does not
improve when stomach acidity is blocked by cimetidine, and is not dependent on the
intensity of the worm burden or on the levels of secreted trypsin.
In the first experiment C3H and CBA/ca strains were shown to have more
marked responses to treatment with PLX than the other strains and the same
observation was seen in Experiment 2 with regard to the C3H strain of mice. The
reason for C3H and CBA/ca having similar responses to PLX and PLS treatment
might be due to the fact that these 2 strains are closely related, originating from the
same stock. They were developed from crossing Bagg albino female and a DBA
male by Strong in 1920 followed by selection for high incidence of mammary
tumours in the case of C3H and low incidence of mammary tumours for CBA/ca
(http://jaxmice.jax.org).
BALB/c mice which are also an inbred strain had a relatively poor response
to drug treatment in Experiment 1 with only a 40.3% reduction in worm counts. This
led the strain to be used as a negative control in Experiments 2 and 11, where the
results, this time using PLS rather than PLX were of a similar magnitude. Although
in Experiment 2 the strain was found to be less tolerant to PLS as evidenced by some
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toxicity and this became especially apparent towards the end of the period of
treatment. The PLS treated mice showed loss of coat integrity and some loss of body
weight although still within the recommended 20% moderate band by the Home
office restrictions on our Animals Act licence. However, due to concerns about their
wellbeing the mice in this group were terminated one day before the end of the
experiment. For this reason the strain was excluded from the next experiment.
However, the strain was used again in Experiment 11 where improvement in
administration of treatment resulted in better tolerance of the mice to PLS.
The response of BALB/c mice to PLS on the other hand concurs with the
prediction that individuals with likelihood of low drug efficacy are also likely to
express high drug toxicity, whereas individuals with a high probability of drug
therapeutic efficacy are likely to have low probability of drug toxicity (Evans and
Johnson, 2001). Thus BALB/c mice responded poorly but showed some level of drug
toxicity, in contrast to C3H mice which had a high response to treatment with
minimum drug side effects. Inter-patient variations in response to medication have
been reported also by other researchers (Wood, 2001) who found that individual
patients responded differently to standard doses where a drug had toxic effects in
some patients but failed to produce the expected therapeutic effect in others.
To some extent this result conflicts with that of Satrija et al. (1995) who
reported a reduction in worm burden in female BALB/c mice of 84.5% after 3 days
of treatment with papaya latex. Perhaps the sex of the mice had contributed to a
better response to treatment than in the male mice which had been used earlier in the
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experiments reported herein. Satrija et al. (1995) had used female mice, a factor
which needed to be further investigated.
In this case a third experiment was conducted, where both male and female
mice of a high and an intermediate responder strain (C3H & NIH respectively) were
used. The results clearly indicated that the sex of the mice played no role in
explaining variance in data and hence the efficacy of PLS is not dependent on host
sex. Host sex has also been found to have no influence even in conventional
synthetic anthelmintics (Hosking et al., 2010a). In their paper, Hosking et al. (2010)
reported no statistical differences between male and female sheep treated with half
doses of monepantel but a significant difference between breeds. This strongly
argues that host sex is not a factor affecting the efficacy of intestinal anthelmintics
including PLS.
Another possible reason for varying efficacy between strains of mice might
be host weight. The standard treatments in Experiments 1, 2 and 3 involved giving a
dose of PLX or PLS delivered in a volume of 0.2 ml. The amount of PLS was not
adjusted in accordance to the exact weight of individual mice and since some strains
are heavier than others, it could have been that the heavier strains actually received a
lower dose of drug on a per kg basis, especially in the site in the intestine where
contact with worms was required. Although most drugs are recommended to be
administered on a dose per kilogram body weight basis, there are few data showing
that weight is an important factor in dosing to achieve a desired drug effect. Thus in
Experiments 4 and 6, the efficacy of PLS was compared between mice treated with
the standard dose (240 nmol per mouse in a volume of 0.2 ml) regardless of their
166
body weight variations and those treated based on body weight-adjusted dose (8µmol
per kg body weight). However, the results showed no significant difference in the
response of mice to PLS treatment between the 2 groups. Even when an outbred
strain with greater variation in body size of the individuals within the same group
was used, the result was the same (Experiment 6).
Since the mice used in this experiment were of the same age, it was expected
that their body weight should be more or less similar within strains. The presence of
variation could be due to a different degree of fat deposition between individuals and
strains (obesity). Therefore, another approach may be to use lean body weight (total
body weight minus excess weight due to obesity/fat or, in the case of a lean
individual, actual body weight) instead of using total body weight as the content of
the GI does not change with fat deposition (Kirking et al., 1985). However, it is not
easy to get lean body weight from live animals. Although lack of variation in body
weight to have influence on PLS efficacy was contrary to our expectation,
nevertheless it was a useful finding because the dosing of mice with PLS can now be
simplified to a standard dose regimen of 240 nmol PLS/mouse in 0.2ml water and the
exact dose a mouse received does not have to be adjusted for its exact body weight
on the day of treatment.
In these experiments it was expected that the actual doses delivered, as
reflected in weight of drug/kg body weight, would vary between strains when their
weights were taken into consideration. Larger mice with larger intestines should
experience a greater dilution of the standard volume of drug. In the first three
experiments a standard dose was delivered to each mouse irrespective of their
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weight. However, Experiment 4 and 6 showed that this is an unlikely explanation for
variation in efficacy of PLS between strains, because NIH and BKW mice, the
intermediate and variable responders, did not differ in their response when the dose
given was adjusted for daily changes in body weight and a consistent daily dose (not
varying in terms of weight of drug/kg body weight) was delivered over the entire
period of treatment.
The genetic explanation may hinge on genetically controlled differences in
the physiological environment in the intestine, including for example pH in the
stomach and the duodenum, gut food transit times, host digestive enzymes etc. pH is
known to damage CPs at low values reflecting acidic conditions (Huet et al., 2006).
Therefore, the ultimate challenge in this area of research was to identify ways in
which the poor responders can be made to be more sensitive to drug treatment. One
possible way was to combine antacid treatment with PLS. For this reason one set of
mice was given cimetidine prior to being treated with the 0.2ml standard dose of
240nmol of PLS, in order to block acid in the stomach which might be inhibiting the
activity of the drug. This experiment was encouraged by the results of (Huet et al.,
2006) who reported that papaya proteinases incubated with pepsin at low pH became
unstable and easily degraded irreversibly by pepsin.
The hypothesis tested here was that the weaker responding strains may have
lower stomach acidity which inactivates the PLX and PLS to a greater extent than in
C3H mice. So it was assumed that most of the PLS might have been affected by the
low pH of the stomach and less was available for exerting worm damage in the small
intestine. However, Experiment 7 showed that blocking stomach acidity by
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concurrent treatment with cimetidine did not improve efficacy in the intermediate
responder strain. In contrast, Stepek et al. (2006a) found that administration of
cimetidine improved the efficacy of PLS against adult female P. muricola worms in
the stomach. In this case cimetidine neutralized the stomach pH, maintaining it at
approximately 7.0, close to the optimal pH for cysteine proteinase activity. But, as
shown here, neutralising stomach acidity did not change the efficacy of a standard
dose of PLS in the small intestine.
It is possible that any inactivation of PLS by acid in the stomach is reversed
in the small intestine and not permanently blocked as has been reported in previous
studies (Huet et al., 2006). Thus the role of cimetidine has little influence after
enzymes have passed the stomach as their activity will be restored due to the increase
in pH. This might be the reason why the activity of the PLS in the small intestine
against H. bakeri in NIH mice did not improve with the administration of the
cimetidine. The recovery of PLS after restoration of neutral pH was clearly seen in
Experiment 8 where the enzyme incubated at pH 1.2 for 2 h showed the same level
of activity as that incubated at pH 7, when transferred subsequently to optimal
incubation conditions used for assessing activity in the colorimetric assay. Hale et al.
(2005) reported a similar result with proteolytic activity of bromelain toward the Z-
Arg-ArgpNA and Bz-Phe-Val-Arg-pNA substrates which was not inactivated by
exposure to low pH conditions (PBS, pH + pepsin) for 2 h at 37
o
C.
It was considered then that differences between strains in the normal variation
in pH along the GI tract might have contributed to the difference in response of the
poor and high responder to PLS treatment. However, the results of Experiment 9
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showed no significant difference in change in pH along the GI tract between the 2
strains. As expected the lowest pH values were observed in the stomach, being
around 3.5 in both strains, slightly lower than that reported by (McConnell et al.,
2008) in fasted BALB/c mice (4.04). An interesting observation was that both strains
of mice had a pH around 6.5 in the small intestine which is almost the same as the
optimum pH for CPs activity for worm damage. However, the mice responded
differently to PLS treatment suggesting that there may be some other factors
affecting the efficacy of PLS in different strains of mice other than pH.
One of the possible factors might be variation between mouse strains in the
transit time of the orally administered PLS along the GIT. It was thought that the
length of exposure of the worms to PLS may also be a crucial factor because in vitro,
the worms were consistently exposed to latex for the whole of the incubation period
lasting up to 2 h. So the ineffectiveness of the PLS in the poor responder strains
might be due to rapid passage of the contents of the enzyme in the small intestine.
However, the results in Experiment 10 indicate that the rate of enzyme passage in the
small intestine between the poor and higher responder mice was similar. In both
strains it took about 90 min to empty all the enzymes from the small intestine. The
same trend of enzyme activity of PLS has been reported earlier by Stepek et al.
(2007a).
Since the result of Experiment 10 showed the enzyme can remain in the small
intestine for more than 1 h, it was hypothesized next that poor responder mice might
be secreting excess trypsin which might be degrading the CPs faster than possibly
lower levels in responder strains. However, the results in Experiment 11 showed that
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the concentration of trypsin in the poor and higher responder was similar. That
means that if trypsin has any effect on the CPs then both strains are likely to be
affected to the same extent.
Another possible factor was worm burden intensity. It was considered
possible that as the worm burden increases the effectiveness of the PLS decreases
due to the higher worm burden. Nevertheless, the results of Experiment 12 indicated
that for the high responder strain, the extent of worm reduction increased with
increased worm intensity. Although in the poor responder there was no clear trend
with respect to efficacy of treatment, the worms seemed to have established better at
higher intensity than at lower intensity.
Although, it has been reported in this chapter that the strain of mice has great
influence on efficacy of PLS, the cause of variation is not yet known. Therefore
further research is required. It is well known that the GI tract of animals provides a
reducing environment for CP activation, so it may be important to try to administer
the pre activated CPs with cysteine to poor responder strain to compare their
response with that of inactivated CPs.
Alternatively, variation in the extent of the mucosal embedding activity of the
adult H. bakeri between mouse strains may serve to protect the worms against the
PLS activity more so in some strains of mice than others. This needs to be
investigated further either by comparing H. bakeri with a free lumen intestinal
residing nematode or by investigating the nature of mucosal layer in poor and high
responder mice.
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CHAPTER 7: FORMULATION AND DELIVERY OF CYSTEINE
PROTEINASES FOR THE TREATMENT OF RUMINANTS
7.0 Summary
This chapter explores potential formulations and delivery systems for cysteine
proteinases (CPs) from papaya latex supernatant (PLS) as an anthelmintic drug for
ruminants. In vitro studies involving both immediate and slow release dosage forms
were conducted. In the slow release experiments, two hydrophilic matrices were
tested, containing xanthan gum and hydroxypropyl methylcellulose (Methocel-
LVCR and Methocel-CR). Methocel-CR provided better results compared to the
others. In the immediate release experiments three disintegrants (Primojel, L-HPC
and Ac-Di-sol) were investigated. Ac-Di-Sol was found to produce faster immediate
drug release tablets. L-HPC and primojel had less effect. Ruminal boluses with a
mean length of 5.5 cm, diameter of 19 mm and a weight of 16 g were prepared by
sticking normal tablets together. This allowed dosing of the correct amount for
treatment of sheep.
7.1 Introduction
The importance of CPs as anthelmintic drugs has been discussed in previous chapters
of this thesis. Since, they are intended to be used in livestock; they need to be
formulated in such a way that they will be effective in eliminating the target
nematode infections. These cause serious economic losses in ruminant animals and
the most affected animals in the livestock farming industry are sheep, cattle and
goats.
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The same methods and techniques used for the development of human drug
dosage forms are applicable to the development of veterinary drug dosage forms
(Klink et al., 1998). Unlike in humans, livestock sector drug formulation involves
developing a dosage form that minimizes the time and cost associated with the mass
treatment of flocks/herds. In addition it has to focus on animal welfare, ease of
administration and human safety. The most common drug delivery routes in
livestock include injections, feed additives, ruminal boluses or horse pills (large
tablets), and topical pour-on medicines. In comparison, drug formulation for
companion animals is dictated by animal owners, and is based on the safety of the
drug and convenience of delivery (Ahmed and Kasraian, 2002).
The majority of anthelmintic drugs available as human dosage forms were
initially developed for use in veterinary practice in this way. Yet, some types of
dosage forms have restricted use and are only suitable for use either in humans or
certain animal species. Due to the physiological variations between species, each
veterinary treatment needs to be specifically designed for the animal that is to be
treated. The design aims to maximise the effectiveness of the drug in the target
animal (Rothen-Weinhold et al., 2000).
A series of papers published by Stepek et al and that of Buttle et al. (2011)
have demonstrated that CPs from papaya latex have a strong anthelmintic effect
against GI nematodes in rodents and sheep. The enzymes required 5-7 daily doses to
cause a substantial reduction in worm burden. An extended/controlled drug delivery
system would be the most appropriate method for delivery of the enzymes to
ruminant animals. The main reasons for developing controlled drug release systems
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for ruminants are to reduce the stress that results from restraining, handling and
dosing animals, and to reduce the cost in terms of labour and time. Controlled release
systems are more convenient to administer than repeated dosing, and enable the
quantity of the drug administered to be known, in contrast to the administration of
the drug in drinking water or food. The dosage forms also reduce human exposure to
veterinary compounds that are unsafe to health (Medlicott et al., 2004).
Ruminants (sheep, goats and cattle) are livestock of great economic
importance that spend much of their life grazing in open fields. Thus they impose
great challenges for daily drug dosing. A controlled drug delivery system is the most
appropriate form for these animals which have unique physiological features that
provide important opportunities for these drug delivery systems. Their stomach is
composed of four chambers, the rumen, the reticulum, the omasum and the
abomasum. The rumen is the largest compartment and it can be viewed as a large
fermentation tank (Cardinal, 1985). The mean feed particle retention time in the
rumen of cattle is 60 - 80 hours and that of sheep is 25 – 40 hours depending on the
nature of the diet (Baggot, 1988). This region can therefore offer opportunities for
long-acting drug delivery systems, provided that a suitable method is employed to
prevent the device from either being regurgitated along with food or moving down
the GI tract. This can be achieved by using heavy devices with sufficient density if
the bolus is not heavy enough to settle down or by producing devices that expand in
physical dimensions on entry into the rumen (Rothen-Weinhold et al., 2000).
Different methods of controlled drug delivery in ruminants have been
discussed in chapter one including erodible systems, reservoir and matrix devices.
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The release rates from these systems are variable and therefore suitable for nutrients
or mineral supplements. Reservoir and matrix devices provide better control of the
delivery rates and are more reliable for active ingredients with relatively high
aqueous solubility. This technology may also be applicable to papaya latex
supernatant (PLS) which is very soluble in aqueous solutions.
Based on previous study PLS has been demonstrated to have high efficacy
against sheep GI nematodes particularly Haemonchus contortus which had 98%
reduction in worm burden (Buttle et al., 2011). The treatment required a total amount
of 15 g of PLS which was administered in oral solution for 4 daily doses. However,
this dosing was too involving and posed a risk to the animals. There is a need to
minimize the number of doses if possible to 1 or 2 doses while maintaining the total
amount of dose of 15 g. This can be achieved through the use of extended drug
release.
Therefore this chapter is concerned with testing the hypothesis that the
release of CP can be controlled and either slowed through the use of hydrophilic
matrices or accelerated through the use of disintegrants. Although hydrophilic
matrices are applied to small molecules it was expected that they would have the
same effect with a protein drug. The concept is that CP incorporated in a ruminal
bolus would settle in the sheep rumen, dissolving its contents into the rumen fluid
and slowly releasing the enzyme to other parts of the lower gut. Thus the rumen will
act as a reservoir for slow release of the medicine in the GIT. Two hydrophilic
matrix polymers, xanthan gum (XG) and hydroxypropyl methylcellulose (HPMC)
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were assessed based on their ability to induce slow release while maintaining the
enzyme activity.
XG was selected based on its remarkable ability to produce a large increase in
the viscosity by adding a small amount of gum. This allows a large quantity of drug
to be incorporated into the tablet. It is also reported to be very stable under a wide
range of temperatures and pH (Talukdar et al., 1996) and its mechanism of drug
release is through polymer hydration.
HPMC is by far the most common cellulose ether used in swellable-soluble
matrices. It is a water-soluble hydrophilic, non-ionic cellulose ether that gels and is
stable over a wide range of pH 3.0–11.0 and is enzyme resistant (Li et al., 2005). It
is also low in toxicity and tablet matrices are easy to manufacture. HPMC is
available commercially under the trade name METHOCEL (Dow Chemical
Company, USA). The mechanism of drug release is through surface erosion of
hydrated matrix.
It was also thought that if extended release using simple hydrophilic matrix
tablets cannot provide sufficient slow release, then the tablets will be wrapped as a
roll in cardboard tubes. The main idea was actually to reduce the rate of tablet
hydration through a physical barrier which would eventually be degraded and fall
apart in the rumen with time and therefore more prolonged release. This may be a
convenient way of administering a large dose.
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Since it is not known at this stage whether the slow release system will
provide the optimum desired drug release rate, it was necessary to have alternative
formulations equivalent to a liquid dosage form but with minimum drug
administration problems. In this case fast release tablets with three types of
disintegrants Primojel, L-HPC and Ac-di-Sol were evaluated to determine their
effectiveness in inducing fast release of CPs from these tablets.
In the work described in this chapter the enzyme was incorporated into
different hydrophilic polymer matrices and disintegrants then made into tablets with
a 19 mm diameter. Seven to eight tablets were then stuck together to form a roll of
tablets of more than 15 g by weight. Throughout the text that follows, this roll is
referred to as a ‘ruminal bolus’ or simply ‘bolus’ and it was used for in vitro drug
slow and fast release assessment.
7.2 Experimental design and Results
7.2.1 Experiment 1: Effect of xanthan gum on drug slow release
This experiment was carried out as a pilot study to determine the slow release
profiles of the drug alone from a hydrophilic matrix tablet. Previous dosing
experiments on sheep had shown PLS had very hydrophilic macromolecules which
took some time to dissolve at high concentrations (Buttle et al., 2011). This would
indicate whether hydrophilic matrices are able to provide slow release of CPs. Since
the experiment was just a pilot, the tablets were manufactured using a normal tablet
punch die of 9 mm and the tablets were formulated using different proportions of
xanthan gum. The formulation contained 0%, 10%, 15%, 20%, 25% and 30% of
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xanthan gum. In each category, one tablet was assessed for drug release by
determination of the amount of protein release in dissolution tests.
7.2.2 Experiment 1: Results
The results indicate the tablet made of PLS alone released the drug very quickly;
within 10 minutes the tablet was completely dissolved (Fig 7.1). However tablets
made with xanthan gum had slower drug release and the effect intensified with
increase in amount of xanthan gum. Although some tablets had completely dissolved,
the amount of drug release was low which suggested that xanthan gum might be
affecting the enzyme availability. Also the results show that tablets prepared above
20% inclusion level of xanthan gum did not change the drug release profile (Fig 7.1).
Figure 7.1: Effect of different levels of XG on drug release profile over time
Tablets made with different concentrations of xanthan gum. Dissolution test was
done using USP apparatus 2, 100 rev.min
-1
and 900 ml of 50 mM phosphate buffer
with pH 6.8, 37±0.5
o
C. The results show that as the amount of xanthan gum in the
hydrophilic matrices increases the rate of drug release decreases.
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7.2.3 Experiment 2: Screening of more hydrophilic matrix polymers
Since the drug released from tablets loaded with xanthan gum was lower than
expected even for the tablets which were completely dissolved we thought it is better
to try other hydrophilic matrices for comparison. Hydroxypropyl methylcellulose
(HPMC) was selected including both methocel-LVCR and Methocel-CR. Methocel-
CR is of high viscosity and methocel-LVCR is of low viscosity. These matrices were
then mixed with papaya latex powder and made into tablets. At this time the tablet
punch size was changed instead of 9 mm we used 19 mm. This size was the
maximum diameter for preparation of sheep boluses to facilitate the delivery of the
dose of PLS needed for effective therapy. Three formulations with different
proportions of matrices were prepared: the first one contained xanthan gum, the
second methocel-CR and third methocel-LVCR. Each set of matrices contained 0,
10%, 15%, 20%, 25% and 30% of hydrophilic polymer (Table 7.1). Throughout the
study dissolution tests were carried out in triplicate.
Table 7.1: Composition of tablets used for controlled release rate
Ingredients(% w/w) Formulation 1 Formulation 2 Formulation 3
Drug (PLS) 69.5-99.5 69.5-99.5 69.5-99.5
Xanthan gum 0-30 - -
Methocel-CR - 0-30 -
Methocel-LVCR - - 0-30
Magnesium Stearate 0.5 0.5 0.5
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7.2.4 Experiment 2: Results
The results indicate that as the amount of polymer was increased, drug release
became slower and a similar profile was seen in all the 3 types of polymer (Fig. 7.2).
The exception was that above 20% the high viscosity grade of HPMC did not change
the drug release profile with an increase in the amount of polymer.
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Figure 7.2: Effect of various hydrophilic matrices on drug release profile over
time
Tablets made with different concentrations of A) Methocel-LVCR B) Methocel-CR
and C) xanthan gum. Dissolution test was done using USP apparatus 2, 100 rev.min
-1
and 900 ml of 50 mM phosphate buffer with pH 6.8, 37±0.5
o
C. Mean±SD (n=3). The
results show that as more amount of hydrophilic matrix was used the rate of drug
release decreased.
0
20
40
60
80
100
0 30 60 90 120 150 180 210 240 270 300
%
C
u
m
u
la
ti
ve
D
ru
g
re
le
as
e
Time in Minutes
NoHPMC 10% 15% 20% 25% 30%
A
0
20
40
60
80
100
0 30 60 90 120 150 180 210 240 270 300
%
C
u
m
u
la
ti
ve
D
ru
g
re
le
as
e
Time in minutes
B
0
20
40
60
80
100
0 30 60 90 120 150 180 210 240 270 300
%
C
u
m
u
la
ti
ve
d
ru
g
re
le
as
e
Time in minutes
C
181
7.2.5 Experiment 3: Enzyme active site titration for slow release tablets
Having demonstrated that hydrophilic matrix tablets do show a slow release of
proteins from these formulations, it was then necessary to demonstrate that following
tabletting and release that the enzyme in solution was in an active form. Therefore
this experiment was carried out by dissolution testing tablets with 30% polymer in
900 ml of phosphate buffer and a tablet with no polymer. The experiment was done
in triplicate for consistency and the solutions were left overnight to ensure that all the
tablets had been completely dissolved. The following day enzyme activity was
determined by active site titration by titrating a fixed concentration of enzyme
against varying concentrations of its inhibitor E-64. The same experiment was
carried out with PLS powder to determine if tabletting had an effect.
7.2.6 Experiment 3: results
The percentage of active enzyme present in tablets made of different polymer
hydrophilic matrices was calculated as shown in appendix 5. It was found that tablets
loaded with PLS alone contained 14.7% of active enzyme, while tablets loaded with
PLS + 30% xanthan gum had 11.6% active enzyme, on the other hand tablets loaded
with PLS + 30% methocel-CR had 14.5% active enzyme and tablets loaded with PLS
+ methocel-LVCR had 12.6% active enzyme. Based on these results, methocel-CR
was found to have retained more of the active enzyme than any other matrix, almost
the same amount as that of the tablet loaded with PLS alone. Therefore methocel-CR
was selected for the ruminal bolus slow drug release experiment. The results also
showed that both powder and tablets had almost similar amount of active enzymes
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14.9% and 14.7% respectively. However the experiment compared the powder and
tablet composed of only PLS.
7.2.7 Experiment 4: Use of disintegrants to enhance fast drug release
At this moment it was not clear whether the slow drug release would provide better
results for delivery of the intended dose to sheep for 4 days. Therefore there was a
need to carry out an alternative experiment which involved a fast drug release
system. This would be one way to enable an instant delivery of some drug dose in
addition to slow delivery at some later time points because even the tablets made
with PLS alone had slow drug release when compared with normal small drug
molecules. It was thus necessary to accelerate the release by using disintegrants. In
this case three disintegrants (Primojel, L-HPC and Ac-Di-Sol) were chosen based on
their properties as explained in Chapter 1. Three formulations were prepared and
made into tablets. Then the dissolution test was carried out to determine which
disintegrant had the greatest impact on accelerating the drug release profile.
Table 7.2: Composition of tablets used for fast release studies
Ingredients (% w/w) Formulation 1 Formulation 2 Formulation 3
Drug (Papaya latex) 97.5 94.5 89.5 97.5 94.5 89.5 97.5 94.5 89.5
Ac Di-Sol 2 5 10 - - - - - -
Primojel - - - 2 5 10 - - -
L-HPC - - - - - - 2 5 10
Magnesium Stearate 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
183
7.2.8 Experiment 4: Results
The compositions of the tablets used in this experiment are shown in Table 7.2.
Formulation 1 contained 2%, 5%, or 10% of Ac-Di-Sol, Formulation 2 contained
2%, 5%, or 10% of Primojel and Formulation 3 contained 2%, 5%, or 10% of L-HPC
disintegrants. Drug release rate was expected to increase with increased percentage
of disintegrants. The results in Figure 7.3 showed that 2% disintegrant in all
formulations had no effect, but 5% and 10% disintegrants successfully accelerated
the drug release rate when compared with the control tablets which contained no
disintegrant. Of all 3 formulations Ac-Di-sol had the greatest effect, thus it was
selected for further investigation.
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Figure 7.3: Effect of different disintegrants on drug release profile over time
Matrices made with different concentrations of disintegrants A) 2% B) 5% and C)
10%. Matrices were dissolution tested using USP apparatus 2, 100rev.min
-1
in 900ml
of 50 mM phosphate buffer with pH 6.8, 37±0.5
o
C. Mean±SD (n=3). Results showed
that 2% disintegrant was ineffective, but that 5% and 10% disintegrant successfully
accelerated the drug release rate when compared with tablets with no disintegrant. Of
the three disintegrants, Ac-Di-sol had the greatest effect.
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7.2.9 Experiment 5: Amount of Ac-Di-Sol required for fast drug release rate.
Based on the above experiment Ac-Di-Sol was found to have the best result in
accelerating fast release. However it was not known what amount was enough to
provide the maximal release rate. Therefore this experiment was carried out to
determine the required concentration of Ac-Di-Sol in the tablets. The experiment was
started with 5% Ac-Di-Sol because 2% had already shown to have no effect in
Experiment 4. Therefore tablets loaded with PLS and 5 -10% of Ac-Di-Sol were
manufactured and then assessed for in vitro dissolution test.
7.2.10 Experiment 5: Results
Although the results in Figure 7.4 showed little increase in drug release rate with
variation in composition of Ac-Di-Sol from 5-10%, 10% of Ac-Di-Sol could provide
the fastest release rate. Thus the 10% Ac-di-Sol was considered to be enough to
provide the required fast release rate as we did not want to go beyond 10%
disintegrant as it would decrease the amount of PLS which could be incorporated
into the tablets.
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Figure 7.4: Effect of Ac-Di-Sol content on the drug release profile with time
Tablets made with different concentrations of Ac-Di-Sol disintegrant (5-10%) were
tested for dissolution in USP apparatus 2, 100 rev.min
-1
and 900 ml of 50 mM
phosphate buffer with pH 6.8, 37±0.5
o
C. Mean±SD (n=3). Results indicated little
increase in drug release rate with increase in the amount of Ac-Di-Sol.
7.2.11 Experiment 6: Effect of Ac-Di-Sol on enzyme activity
Since Ac-Di-Sol was selected to provide fast drug release rate, it was also necessary
to assess how this disintegrant affected the activity of the enzyme. To achieve this,
an experiment was carried out by dissolving 3 tablets loaded with PLS+10%
disintegrant and another 3 tablets loaded with PLS alone into 900 ml of phosphate
buffer. The solutions were left overnight at 4
0
C to provide sufficient time for any
reaction between the disintegrant and the enzymes to take place. The solutions were
then tested for enzyme activity as explained in the materials and methods section.
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7.2.12 Experiment 6: Results
The same procedure as used in Experiment 3 was also used here to calculate the
percentage enzyme activity. The results indicated that tablets with 10% Ac-Di-Sol
had 21.2% active enzymes compared with 28.7% active enzymes present in tablets
made with no disintegrants. This means that Ac-Di-Sol disintegrant was able to
retain more than 74% active enzyme.
7.2.13 Experiment 7: Effect of methocel-CR and Ac-Di-Sol bolus drug release
rate
This experiment was intended to utilize the whole dose of 15 g of PLS. This has been
recommended by Buttle et al. (2011) as a suitable dose to eliminate nematodes in
sheep, however it requires 5 days of treatment. Thus the purpose of the experiment
was to try to minimize the number of treatments from 5 to a treatment at a single
dosing point, possibly with a number of different boluses. The experiment was
carried out with 3 formulations. Formulation 1 comprised tablets loaded with PLS +
15% methocel-CR, formulation 2 composed of PLS + 10% Ac-Di-Sol and
formulation 2 had tablets loaded with PLS alone which was used as control. The
amount of 15% methocel-CR loaded in the tablet was chosen based on the fact that
the amount had provided better results in Experiment 2. While 10% Ac-Di-Sol was
considered to be enough to enhance fast release there was still some possibility of
adding more, but our interest was to minimize the amount of excipient in order to
incorporate more PLS. Then 7-8 normal tablets loaded with PLS + 15% methocel-
CR, PLS+10% Ac-Di-Sol disintegrant and those loaded with PLS only were stuck
together to form a roll of tablets referred to as a ruminal bolus. Then the in vitro
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dissolution studies were performed as explained in the materials and methods
section. The bolus had an average size of 19 mm in diameter, 5.5 cm in length and
average weight of 16 g.
7.2.14 Experiment 7: Results
The results in Figure 7.5 indicated that the bolus with 15% methocel-CR matrix had
a slower release rate than bolus with 10% Ac-di-Sol disintegrant and that with PLS
alone. Surprisingly the tablets with Ac-Di-Sol disintegrant showed the same effect as
that of PLS alone. Both completely dissolved within 1.5 h, implying that Ac-Di-Sol
had little effect on drug. Moreover the drug released by Ac-di-Sol had only 75% drug
release after complete dissolution when compared with 100% released from bolus
loaded with PLS alone. On the other hand the bolus with 15% methocel-CR released
only 30 % of its drug content after 3 h of dissolution, and the tablet remained
undissolved.
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Figure 7.5: Drug release profile over time from ruminal bolus
Tablets loaded with PLS alone, PLS + 10% Ac-Di-Sol and PLS + 15% Methocel-CR
were tested for Dissolution using USP apparatus 2, 100 rev.min-1 and 16 litres of 50
mM phosphate buffer with pH 6.8, 37±0.5
o
C. Mean±SD (n=3). Results indicated that
bolus loaded with PLS + 10% Ac-Di-Sol has the faster drug release and bolus with
PLS + 15% Methocel-CR had the lowest release as expected.
7.2.15 Experiment 8: Effect of methocel-CR on bolus slow drug release
Since methocel-CR was shown to release only 30% of the drug after 3 h of
dissolution in Experiment 7 and most of the tablet was not dissolved. There was a
need to determine how long it would take for the bolus to have a complete
dissolution. The experiment was intended to determine the exact time the methocel-
CR was able to induce the slow drug release rate from the bolus. The boluses were
manufactured in the same way as in Experiment 7. Two formulations were prepared;
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Formulation 1 had tablets loaded with PLS alone while formulation 2 had tablets
made with PLS + 15% methocel-CR. The boluses were tested for dissolution. Since
the boluses did not have a complete dissolution within the same day then the
experiment was left to run overnight until 9:00 am in the next day starting from
10:00 am in the previous day. Thus total time used in dissolution test was about 23
hours.
7.2.16 Experiment 8: Results
The results in Figure 7.6A indicated that the bolus loaded with PLS alone had a
complete dissolution within 1 h while the bolus loaded with PLS + 15% methocel-
CR matrix had a slower release rate; even after 7 h it had released only 40% of its
drug (Figure 7.6B). This led to the dissolution system to be left on overnight and
when tested after 23 h of dissolution it was found that more than 95% of the drug has
been released. Although it is not easy to tell the exact time when the maximum drug
release in the slow release bolus was achieved, it can be extrapolated and estimated
to be around 18 h.
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Figure 7.6: Effect of Methocel-CR on bolus slow drug release
Tablets loaded with PLS alone and PLS + 15% Methocel-CR were tested for
dissolution using USP apparatus 2, 100 rev. min
-1
and 16 litres of 50 mM phosphate
buffer with pH 6.8, 37±0.5
o
C. Mean±SD (n=3). Results indicated that bolus loaded
with PLS alone had released its drug completely within 1 h while bolus loaded with
PLS + 15% Methocel-CR had only released 40% of its drug after 7 h of dissolution.
7.2.17 Experiment 9: Physical properties of tablets
Finally it was necessary to assess the properties of the bolus produced. However due
to logistical reasons it was not possible to determine the properties of bolus as a
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whole, thus the physical properties of bolus was assessed based on its individual
tablets used to prepare them. The physical properties of the manufactured tablets
were assessed as described in the Materials and Methods and the results are
summarized in Table 7.3.
Table 7.3: Physical properties of the 3 formulations of the tablets
Tablet Weight (g) Hardness (kg) Friability (%)
PLS 2.25±0.03 13.78±0.39 2.8±0.03
PLS + Ac-di-Sol 2.18±0.03 13.61±0.40 1.4±0.01
PLS + Methocel-CR 1.99±0.04 19.79±0.26 1.5±0.01
Mean±SD (n =10)
The formulated matrix tablets met the European pharmacopoeia requirement of
uniformity of weight (not exceeding 5% of the average weight) and tablet hardness
was also within acceptable limits. Only tablets loaded with PLS alone were tested for
disintegration time and all the tablets disintegrated within 15 minutes. However all
tablets prepared from the 3 formulations failed the friability test as their friability was
higher than 1%, the highest acceptable limit. It can also be seen in these results
(Tablet 7.3) that tablets formulated without polymer were twice as friable as tablets
from other formulations. This is probably because polymers might have contributed
to the compaction of tablets making them less friable.
7.3 Discussion
Results in this chapter have shown that both hydrophilic polymers XG and HPMC
(Methocel-CR and Methocel-LVCR) had the same effects in providing slow release
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of the CP enzymes from tablets. As expected the drug release rate decreased with
increase in the matrix concentration up to 20%, whilst above this level, polymer
content had very little effect on the drug release profile. These results are in
agreement with previous studies (Ford et al., 1985, Velasco et al., 1999, Ford et al.,
1991) which reported that one of the most important factors affecting the rate of
release of a drug from polymer matrices is the drug: polymer ratio. An increase in
polymer concentration may cause an increase in the viscosity of the gel as well as the
formation of a gel layer with a longer diffusion path. This decreases the effective
diffusion coefficient of the drug and therefore a reduction in the drug release rate.
Based on the results, a 15% polymer level was considered to be the optimum
amount required for slow release of CP. This amount is less than the amount
recommended by the manufacturer of 20-50% inclusion level in the tablets for slow
drug release rate. This may be due to the fact that CPs are large molecules and their
size and hydrophilicity may have been an impediment to fast release.
Xanthan gum and HPMC have a similar chemical structure but xanthan gum
has some advantages over HPMC which include absence of an initial burst, high
drug retarding ability and better flowability. However, the most common cited
limitation of its use is the ionic influence on drug release behaviour (Talukdar et al.,
1996). On the other hand HPMC is by far the most common cellulose ether used to
form hydrophilic matrices probably due to the fact that it has fast gel formation of a
strong viscous gel to control drug release. The major disadvantage with HPMC is
that drug release from this matrix does not follow time independent kinetics.
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Since both polymer matrices had the same effect on slow drug release
profiles they were then assessed on their ability to retain enzyme activity. It was
found that xanthan gum had a negative influence on enzyme activity, in comparison
with HPMC which had no influence on enzyme activity. The enzymes in tablets
loaded with HPMC remained active at a similar level to that observed in tablets
loaded with PLS only. Among the two HPMC excipients, methocel-CR had no effect
on the enzyme activity at all probably due to the fact that this polymer has a higher
viscosity which might have a strong effect on drug diffusion out of the polymer
matrix. Thus it was selected for further investigation.
The possible reasons for low enzyme activity in the tablets with xanthan gum
might be due to the formation of protein-polysaccharide complexes. Xanthan gum is
a bacterial coat polysaccharide and it has been reported that protein can form
complexes with polysaccharides by either hydrogen bonding or by covalent bonding.
The interaction of hydrogen bonds has been demonstrated in the formation of
coacervates between gelatin and pectin (Schmitt et al., 1998). Covalent bonding has
been reported by the chemical reaction of amino groups of the proteins and
carboxylic groups from the polysaccharides (Stainsby, 1980). This bonding is said to
be irreversible and very stable to pH and ionic strength changes (Hill and Mitchell,
1995). Most of the anionic polysaccharides like potato starch, pectin, xanthan gum,
carrageenans and others can combine with proteins to form either covalent,
electrostatic, hydrophobic or non-polar complexes depending on the structure and
chemical properties of the components of the potential complexes (Lii et al., 2003).
Some studies have reported complex formation between xanthan gum and gelatine or
ovalbumin (Schmitt et al., 1998, Lii et al., 2002). The reaction is due to the presence
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of the anionic carboxylic group of the ȕ-D glucuronic acid moiety in xanthan gum
which potentially forms either ionic or covalent complexes with proteins.
In further work, tablets formulated with 2% of the three disintegrants (Ac-di
Sol, LHPC and primojel) were shown to have no effect on the rate of drug release
rate from tablets. In fact the 2% inclusion was selected based on the amount
recommended by the manufacturers which is between 2-4%. The failure of the 2%
incorporation into the tablets to have any impact on the drug release rate may be due
to the fact that CP is a protein and might have a self inducing slow release effect
when compared to small molecule drugs. For the tablets formulated with a high
concentration of disintegrants (5% and 10%), Ac-Di-Sol was shown to have a higher
effect than L-HPC and primojel in accelerating fast drug release. The same results
have been reported by Zhao and Augsburger (2005) who found that dissolution of
aspirin was faster in tablets with Ac-Di-Sol than tablets with primojel. However
when further investigated with a ruminal bolus, this disnitegrant was found to have
less effect than expected, something that needs further research. The poor
performance of Primojel may be due to its chemical nature which is a
carboxymethylated potato starch which commonly forms complexes with proteins.
Probably in this study it behaves similarly with CP resulting in a lower amount of CP
being released into the dissolution medium.
The results also indicate that the effect the Ac-Di-Sol disintegrant on drug
release rate increases with an increase in concentration of the disintegrant and 10%
was considered enough for fast drug release rate although the effect was not clearly
manifested with the ruminal bolus. The enzyme activity of the tablets loaded with
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this disintegrant was found to possess only 74% active enzyme compared with the
tablet with no disintegrant which had 100% active enzyme of the drug release. The
possible reason could be the same as that of the primojel, that some of the enzyme
might have become involved in complex formation with the disintegrant.
These tablets are being prepared for sheep treatment and in order for
treatment to be successful the tablets need to be settled in the rumen and releasing the
drug slowly to the lower part of the GI tract. To assimilate this mechanism, 7-8
tablets were stuck together so that the whole dose of 15 g PLS can be administered at
once. Three types of formulations were used, these including tablets with 15%
Methocel-CR, 10% Ac-di-Sol and tablets with PLS alone. This range of formulations
were chosen because it was unclear how the larger bolus tablets would behave, and
we anticipated that we would need both immediate availability of some drug with the
remaining drug released slowly over a number of days.
Among the three formulations, boluses containing 15% Methocel-CR were
found to have a slower drug release rate than boluses with Ac-di-Sol and PLS alone.
It was observed that the drug was released through erosion and the 15% of the matrix
seemed to be sufficient to induce slow release, 5% lower than the amount
recommended by the manufacturer (20-50%). This may be due to either the large
size of the bolus as bigger size tablets require less polymer content because of their
lower surface area to volume ratio (and long diffusion pathway), or due to large
protein size of the CPs thus contributing to slow release. While the 10% of Ac-Di-
Sol considered to be necessary was above the recommended amount by the
manufacturer of 2-4% this again may be due to the need to overcome the self induced
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slow release by the CPs. However, it might need more of the disintegrants than is
considered here for best results.
Finally the formulated ruminal boluses met the European pharmacopoeia
requirement of uniformity with the exception of friability which exceeded the
recommend amount of weight loss. There is a common problem with most medicinal
plant extract tablets not meeting all the relevant quality standards. Some studies have
even reported friability up to 15%. For example tablets made from AM-1 (a freeze
dried decoction of powdered root extracts of shrubs used as anti-malaria in Nigeria)
had friability of 15% even after using 5%w/w starch gel binder, the friability still
remained above the highest acceptable limit (Builders et al., 2011).
The in vitro experiments have found that HPMC (in particularly Methocel-
CR) with a concentration of 15% is enough to provide a slow drug release rate
although not to the target of 3 - 4 days so further experimentation is required to
produce formulations with an even slower rate of release. This can be achieved by
administering the matrices in cardboard tubes or by wrapping the matrices together
with rice paper that would create a dosage form with a greater volume:surface area
ratio resulting into more prolonged drug release.
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CHAPTER 8: GENERAL DISCUSSION AND CONCLUSIONS
8.0 Summary
This chapter gives a general overview of the combined results of chapters 3-7 and
their significance. It highlights the major findings and suggests areas for further
future work. For more detailed and specific consideration of the results, the reader
should refer to the results and discussion sections of the individual chapters in this
thesis.
8.1 General discussion
Although the anthelmintic efficacy of plant derived cysteine proteinases have been
extensively studied (Stepek et al., 2006b, Satrija et al., 1994, Stepek et al., 2005,
Stepek et al., 2007a, Buttle et al., 2011), there still remained a need to assess in more
detail some of the possible variables/factors that may influence the efficacy of PLS
against GI nematodes in rodent models. It was important to carry out such
investigations to gain a broader understanding of the possible sources of variation in
efficacy and to improve formulation and delivery systems of the enzymes for use in
humans and livestock.
First, we initiated this project by purifying and concentrating the cysteine
proteinase enzymes (CPs) in spray dried papaya latex using different methods to
determine which of them would provide high yields of CPs. The best method was
then adapted as a standard preparation of CPs to be used in in vitro and in vivo
studies. It was found that concentration by dialysis provided a high yield of active
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enzyme in PLS. We were also interested to find out which storage condition will
provide long term stability of the CPs in the PLS. The results of our experiments
demonstrated clearly that CPs can remain more active at low temperature (-20
o
C and
-80
o
C) and freeze-thawing cycles have no effect on the enzymes’ activities. The
effect of temperature on enzyme activity has been widely documented (Balls and
Thompson, 1940). At higher temperatures it is said that the free Sulphydryl groups in
CPs are oxidized to the disulphide form or even sulphinic, sulphonic or sulphenic
acid, all of which represent essentially irreversible oxidation states (Arakawa et al.,
2001). The stability of CP enzymes in cold temperature may have been enhanced by
the concentration of the PLS and the latex acting as cryoprotectants. It has been
reported that in many proteins, increasing protein concentration helps to increase the
stability of proteins during freeze-thawing (Carpenter and Crowe, 1988). Also we
were not sure if the enzymes would survive under the typical motility assay
conditions employed in our experiments. To answer this question PLS were
incubated in Hanks’ buffer saline solution at 37
o
C for 2 h, under typical motility
assay conditions, and we found that the enzymes remained stable throughout the
entire period of the experiment without losing activity.
To obtain more understanding of the anthelmintic efficacies of kiwi fruit
extract (actinidain), pineapple fruit extract (fruit bromelain) and stem bromelain, a
number of in vitro and in vivo experiments were carried out. A previous in vitro
study (Stepek et al., 2005) with kiwi fruit extract failed to identify any anthelmintic
effect although the enzymes in kiwi fruit are known to belong to the same group of
the papain family. Nevertheless, it was important to repeat these experiments under
more standardized conditions to establish firmly whether this enzyme, actinidain,
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actually has any potential as a novel anthelmintic. To confirm this, worms were
incubated in kiwi fruit extract and examined by scanning electron microscopy (SEM)
for any sign of cuticle damage. We found that actinidain in kiwi fruit had little
anthelmintic effect: only initial signs of cuticle damage were observed towards the
end of the experiments. The biggest problem which we encountered with this enzyme
was that of low active enzyme concentration. Our target was to try to concentrate the
enzyme at least up to a 200 µM concentration so that it would be comparable to that
of PLS. At this particular concentration PLS provides better results in the worm
motility reduction assays compared to lower concentrations. However, the working
concentration we managed to achieve from kiwi fruit extracts was only 50 µM, a
concentration at which even the PLS has been shown to have a poor effect on
motility (Stepek et al., 2005). Based on this result it was not possible to conclude
with any degree of certainly about the relative potency of the anthelmintic effect of
actinidain. Further research is needed, either by devising novel ways to extract the
enzymes from kiwi fruit to achieve a higher yield of active enzyme, new methods to
concentrate the active enzyme more efficiently or alternatively prolonging the
incubation time of the worms in the enzyme to enhance the extent of the damage. If
the enzyme does require prolonged exposure to worms to achieve a comparable
effect to that associated with PLS, it is unlikely to have much future as a novel
anthelmintic, because peristaltic movements of gut contents are likely to flush the
enzyme through the sections of the gut where worms reside before the enzyme has
sufficient opportunity to exert its damage to the cuticle of the resident parasites.
Other enzymes which were assessed for anthelmintic effects included
Bromelain, from both pineapple fruit and stem. Like kiwi fruit extract, with
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pineapple fruit extract we only achieved a relatively low active enzyme concentration
with a maximum concentration of 300 µM, far lower than that obtained with stem
bromelain which we were able to concentrate even more effectively than PLS,
achieving concentration levels of 8000 µM. In motility assay assessments stem
bromelain and PLS were set at the same concentration (200 µM) expecting that the
both would have the same level of inhibitory effect on worm motility. However the
results indicated that stem bromelain had a significantly poorer effect on motility of
the worms, even less than that of pineapple fruit extract at a 150 µM concentration.
In vivo trials with both stem bromelain and pineapple fruit extract were disappointing
showing much lower efficacy compared to PLS. It was not clear why some CPs have
anthelmintic effects while others have a poorer or no effect. This opens an avenue for
future research to investigate the cause of their variations. One likely explanation is
that each of these enzymes target a slightly different sequence of amino acids in the
target proteins, and it may be that the cuticular proteins of the nematodes used in this
project did not have complementary amino acid sequences for the ineffective CPs.
Another major aspect considered in this thesis centred on the factors
influencing the anthelmintic efficacy of PLS against GI nematodes in a mouse model
system (Chapter 5 and 6). The preparation and delivery of any anthelmintic in an
experimental system entails many variables which need to be explored and
standardised to achieve best results. Many of the likely sources of variation have not
yet been thoroughly assessed.
The first factor to be examined was the effect of fasting. It was important to
assess this factor because in earlier studies with CPs, a period of food deprivation
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was routinely employed before administration, but there was no systematic
evaluation as to whether or not this does actually benefit the anthelmintic efficacy.
So an experiment was carried out with 2 groups of mice where the first group was
fasted for 5 h prior to treatment with PLS and the second group was treated without
being fasted. The results (Chapter 5) demonstrated clearly that PLS was equally
effective in reducing worm burdens whether the animals were fasted before treatment
or not. This led to the conclusion that fasting has no beneficial effect on the efficacy
of PLS and it was found that by avoiding fasting some of the adverse side-effects of
treatment were reduced or even avoided entirely. Moreover, since food deprivation,
even for limited periods of time, can cause stress and discomfort to animals, the non-
fasted animals would have experienced less trauma during these trials. However, to
some extent these results were surprising, as it was expected that the presence of
food would reduce the activity of the enzyme by dilution in gastrointestinal chyme
and competition with other potential substrates for the enzyme. The maintenance of
efficacy of PLS in the presence of food suggests that there must be other
compensating factors influencing activity, which need to be further investigated. One
of the possible explanations is that the presence of food increases food residence time
thus offering more time for the CPs to make and maintain contact with the worms,
leading to increased worm damage.
The second factor which was examined in this study was the sex of the host.
Male and female mammals are known to differ markedly in the hormones that
control their sex and reproductive cycles and these in turn have marked effects on
their physiology. The cause of the differences in response to medication between
males and females seems to be caused by steroid sex hormones (oestrogen,
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testosterone and progesterone) which can induce or inhibit the secretion of
Cytochrome P450 enzymes in the liver (Cristofol et al., 1998), enzymes which are
involved in metabolism of exogenous toxic substances (Kubota et al., 2011,
Finnstrom et al., 2002). However, the results (Chapter 6) clearly indicated that
variation in anthelmintic efficacy of PLS was not due to host sex. Host sex has also
been reported to have no influence even in conventional synthetic anthelmintics
(monepantel) (Hosking et al., 2010a).
Another factor which was considered to cause variations in response to
treatment among different strains of mice was host genotype. This factor was
considered due to the fact that under natural conditions animals of different breeds or
species vary in response to medication. Such variation may range from failure to
respond to a drug to life-threatening adverse reactions (Bosch, 2008). To determine
whether the efficacy of PLS treatment is host genotype dependent a range of mouse
strains were compared including both inbred and outbred strains. It was found that
efficacy of PLS varied significantly between mice of different genotype. At the doses
used, the treatment was most effective in C3H mice and least effective in NIHS, CD1
and BALB/c mice in reducing worm burdens.
Different causes of variations in response to treatment were hypothesized and
tested. One of the possible causes of variations in efficacy of PLS between strains of
mice was hypothesized to be host weight. Throughout the study mice were treated
with a standard dose of 240 nmol of PLS in a volume of 0.2 ml regardless of their
variations in body weight. The concentration of PLS was not adjusted in accordance
to the exact weight of individual mice and since some strains are heavier than others,
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it could have been that the heavier strains actually received a lower dose of drug on a
per kg basis. We carried out an experiment to compare the efficacy of PLS between
mice treated with the standard dose of 240 nmol per mouse regardless of their body
weight and those treated based on body weight-adjusted dose (8 µmol per kg body
weight). We found that there was no variation in response to treatment between the
two treatment groups of mice. This result means that administration of a standard
dose to mouse strains varying in body weight without compensating for body weight
was an unlikely explanation for the cause of variation in efficacy of PLS between
mouse strains.
Since CPs are particularly sensitive to pH, variation between mouse strains in
gut pH was investigated but no significant differences in pH changes were detected
along the GI tract when the poor (BALB/c) and high responder mice (C3H) were
compared. Both strains had the lowest pH values (3.5) in the stomach and pH value
around 6.5 in the small intestine, which is within the optimum pH range of CPs
activity for worm damage. Lack of variation in pH values between the two strains of
mice suggests that there must be some other factors affecting the efficacy of PLS in
different strains of mice other than acid or pH.
It was also thought that the length of exposure of the worms to PLS may be a
crucial factor because in in vitro experiments (Chapter 4), worms were consistently
exposed to latex for the whole of the incubation period lasting up to 2 h. So the
ineffectiveness of the PLS in the poor responder strains was hypothesized to be
caused by the rapid passage of the contents of the enzyme in the small intestine. We
carried out an experiment (Experiment 10 of Chapter 6) to compare the amount of
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enzymes in different regions of the intestine at different time intervals after dosing
and it was found that there was no significant variation in the rate of enzyme passage
between the poor and higher responder mice.
Since the results indicated that PLS can remain in the small intestine for more
that 1h, it was then hypothesized that poor responder mice might be secreting excess
trypsin which might be degrading the CPs faster than possibly lower levels in
responder strains. However, when compared the amount of trypsin secreted into the
small intestine of poor and higher responder mice, as measured by enzyme
concentration, was found to be very similar in the 2 strains. That means that if trypsin
has any effect on the CPs then both strains were likely to be affected to the same
extent.
Another factor that was hypothesized to be the source of some of the
variation in response to treatment was worm infection intensity. In this study it was
considered that in response to increasing worm burdens the effectiveness of the PLS
should fall. Nevertheless, the results of Experiment 12 (Chapter 6) indicated that for
the high responder strain, the extent of worm reduction increased with increased
worm intensity, although in the poor responders there was no clear trend with respect
to efficacy of treatment, the worms having established better at higher intensity than
at lower intensity.
The main challenge in this study was to identify ways in which the poor
responders might be made to be more sensitive to drug treatment. One possible way
was to combine antacid treatment with PLS. For this reason one group of mice was
206
given cimetidine prior to treatment with PLS, in order to block acid in the stomach
which might be inhibiting the activity of the drug. The hypothesis tested here was
that the weaker responding strains may have lower stomach acidity which inactivates
the PLS to a greater extent than in high responder mice (C3H mice). So it was
assumed that most of the PLS might have been affected by the low pH of the
stomach and less was available for exerting worm damage in the small intestine.
However, Experiment 7 (Chapter 6) showed that blocking stomach acidity by
concurrent treatment with cimetidine did not improve efficacy in the intermediate
responder strain (NIH).
In the work described in this thesis, when investigating the causes of variation
in host response to treatment with PLS, we focused exclusively on the physiological
aspects of the host, neglecting the potential impact of the variation which might arise
by possible different behaviour patterns of the parasite in different hosts. One of the
parasitic behavioural aspects which still needs to be investigated is the extent of the
mucosal embedding activity of the adult H. bakeri between mouse strains, which
may serve to protect the worms against the PLS activity more so in some strains of
mice than others. This can be investigated either by comparing H. bakeri with a free
lumen intestinal residing nematode or by investigating the nature of the mucosal
layer in poor and high responder mice.
It is also well known that the GI tract of animals provides a reducing
environment for CPs activation. Based on this fact we assumed then that CPs were
equally activated in all strains of mice after oral administration with PLS. This
assumption may be unrealistic, considering the genetic variation between different
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strains of mice. It might be that the poor responder mice failed to provide a full
activation environment for CPs thus providing little chance for the enzymes to
damage the worm cuticle. It is therefore important for future work to try to
administer the pre-activated CPs to poor responder strain and to compare their
response with that of inactivated CPs.
One of the objectives of this study was to explore the possibilities of
formulating PLS as an anthelmintic drug to be used in ruminants. To achieve this in
vitro studies were conducted. These studies involved both immediate and slow
release drug dosage forms simulating the physiological conditions in the GI tract of
the animal. In the slow release experiments, two hydrophilic matrices were tested,
the xanthan gum and hydroxypropyl methylcellulose (HPMC) (both Methocel-
LVCR and Methocel-CR). It was found that Methocel-CR provided better results
compared to the others. In the immediate release Ac-Di-sol was found to produce the
faster immediate drug release rate. Although Methocel-CR was able to provide a
slow drug release rate, it was not slow enough to meet our target of 4 days. Further
future work is required to produce formulations with slower release rate. This might
be achieved by administering the matrices in cardboard tubes or by wrapping the
matrices together with rice paper that would create a dosage form with a greater
volume: surface area ratio resulting in more prolonged drug release. When Ac-Di-
Sol was used to enhance fast release rate in the bolus the result (Chapter 7) was
inconclusive and this also requires further investigation. One difficulty in this area of
research is that it is extremely difficult to devise suitable formulations (with respect
to volume and size) for experimental testing in mouse models. Therefore, if these
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formulations are to be tested it will have to be in small ruminants such as sheep in the
first instance, rather than in mice.
Finally we tested the anthelmintic efficacy of PLS on an equine GI nematode,
Strongylus vulgaris. Strongyles have been reported to be the most pathogenic
parasites of horses exerting a significant economic impact wherever horses are being
raised and maintained, and allowed to graze on contaminated pastures (McCraw and
Slocombe, 1976). Moreover, the problem has been worsened due to the development
of resistance to most of the available chemotherapies. Therefore, it was important to
test the effective of PLS as an alternative novel anthelmintic. Preliminary in vitro
results (Chapter 4) revealed that PLS was highly effective against these nematodes.
This provides a new opportunity for future investigation including in vivo
experiments.
8.2 Conclusions
In summary we can conclude that freezing PLS either at -20
0
C or -80
0
C provided
long term storage of more than 1 year without major loss of activity and freeze-thaw
cycles had no effect on enzyme activity. Moreover motility assay conditions have no
detrimental effect on enzyme activity over the specified period of assessment.
It has been clearly demonstrated that allowing animals to fast before drug
treatment has no beneficial effect on the anthelmintic efficacy of PLS. The study has
also indicated that there is considerable variation in response to treatment with PLS
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between different strains of mice. However the cause/s of variation is/are not yet
known, which opens the door for much possible further research.
The in vitro experiments for drug formulation have provided a better result
with HPMC (in particularly Methocel-CR) which can be used to induce slow drug
release rate although not slow enough to achieve our nominated estimated target of
3-4 days, and this emphasizes the need for further research in this area also. On the
other hand 10% concentration of Ac-Di-Sol was sufficient to provide a fast release
rate for individual tablets but its effect on the bolus was insignificant. Moreover, the
preliminary in vitro results on the efficacy of PLS against equine GI nematodes shed
some light for the potential development of PLS as an equine anthelmintic drug.
Finally the empirical findings in this study provide useful information for
improvement of formulation and delivery of these naturally occurring plant-derived
enzymes for treatment of intestinal worm infections in humans and livestock, while
achieving maximum efficacy and minimal side-effects. I hope that in the years
ahead my findings can be exploited to develop and refine plant derived proteinases as
novel therapies for the treatment of intestinal worm infections.
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APPENDICES
Appendix 1: Paper published from the work in this thesis
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Appendix 2: General Solutions
a) 4 x Assay Buffer Solution
Na2HPO4.12H2O 8.28g
NaH2PO4.H2O 21.49g
Dissolved in 300 ml distilled water and made up to a final volume of 500 ml
with water and adjusted the pH to 6.85 with NaOH.
b) Activating Buffer
4 x Assay buffer + 16 mM L-cysteine (made fresh each day of experiment)
c) Hanks’ Buffer Saline Solution with Phenol red
Stock solution 1
NaCl 168.0 g
KCl 8.0 g
KH2PO4 4.0 g
0.2% Phenol red 200 ml
Made up to 2 litres with distilled water
Stock solution 2
CaCl2.2H2O 3.92 g
MgCl2.6H2O 2.0 g
Made up to 2 litres with distilled water
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Working Hanks:
110 ml of solution 1 were added to 110 ml of solution 2 and made up to 1
litre with water. The pH was adjusted to 7.2 with 1M of NaOH.
d) Hanks’ buffer Saline solution without phenol red
Stock solution 1
NaCl 42.0 g
KCl 2.0 g
KH2PO4 0.5 g
Na2HPO4 (anhydrous) 0.5 g
Dissolved in 500 ml of distilled H2O
Stock solution 2
CaCl2.2H2O 0.925 g
MgCl2.6H2O 0.5 g
Dissolved in 500 ml distilled H2O
Working Hanks:
55 ml of stock 1 were added to 55 ml of stock 2, made up to 500 ml with
water and the pH was adjusted to 7.2 with few drops of NaOH
e) Stopping Buffer Solution
Sodium chloroacetate 5.82 g
Sodium acetate (anhydrous) 8.2 g
Made up to 500 ml with distilled water and the pH was adjusted to 4.3 with
acetic acid
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f) Phosphate Buffered Soluition for Drug Dissolution Test
NaH2PO4.2H2O 31.2 g in 1 litre of dH2O (Stock1)
NA2HPO4.12H2O 71.7 g in 1 litre of dH2O (stock2)
25.5 ml of stock 1 were added to 24.5 ml of stock 2 and made up to 100 ml
with distilled water.
g) 0.15M Phosphate Buffer for SEM:
Na2HPO4 8.52 g in 400 ml dH2O
NaH2PO4.H2O 2.07 g in 100 ml dH2O
400 ml NaH2PO4 added to 100 ml NaH2PO4 to obtain pH of 7.2
h) Gutaraldehyde 2.5%
2.2 ml glutaraldehyde + 19.8 ml phosphate buffer (usually x 2).
Appendix 3: Amount of active enzymes in different storage conditions
Conditions 1 week 4 weeks 24 weeks 48 weeks
room temp 23.3 (27.6) 20(23.5) 14(16.5) 1.1 (1.3)
4
0
C 80(94.1) 70(82.4) 50(58.8) 23.8(27.9)
-20
0
C 75(88.2) 70(82.4) 70(82.4) 70(82.4)
-80
0
C 80(94.1) 68(80) 70(82.4) 67.5(79.4)
Figures outside the bracket are amount of active enzymes in nmol and those in
bracket are percentages of the amount of active enzymes remaining.
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Appendix 4: Active site titration curves for determination of active enzymes in
PLS
a) PLS processing
PL Solution before centrifuge 1:100
PLS after centrifuge 1:100
Dialysed PLS 1:100
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b) PLS storage at various temperature conditions
Day 0 1:100
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c) Effect of freeze-thaw cycles
d) PLS stability in motility assays
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e) Stability of post freeze-dried PLS at ambient temperature (AT) and 4
o
C
Day 0
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Appendix 5: Calculations of percentage active enzyme in tablets
The figures in this appendix show each point representing the mean absorbance
readings at 410 nm of titration of a fixed concentration of enzyme against varying
concentrations of the inhibitor E-64. The percentage amount of active enzyme
present in each tablet was then calculated as follows. Since 20ȝM of E-64 was added
at increment of 10ȝL then 0.2nmol of E64 was added per increment. Because molar
inhibition ratio is 1:1, the baseline point represents the amount of E64 which is
equivalent to the amount of active enzyme present in 100µl of the enzyme solution.
Thus results show that the amount of active enzyme in 100µl is 0.9nmols for tablet
with no matrix (Fig. 2A), 0.65nmols for tablet with Methocel-CR (Fig. 2C), and
0.55nmols for both tablets with Methocel-LVCR and xanthan gum (Fig. 2 B and D).
Since the molecular weight of the enzymes in papaya latex is 25,000g then 1nmol
would be 25ȝg and 0.9nmol contains 22.5ȝg (amount of active enzyme in 100ȝL).
However the initial weight of the tablet was 1.4g (1400mg) dissolved in 900ml then
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total amount of enzyme in 100ȝL is 153.2ȝg (excluding 0.5% of excipient).
Therefore, the percentage active enzyme in the tablet was 14.7% (22.5/153.2 x 100).
Based on this procedure the percentage amount of active enzymes present in the
other tablets was also calculated and found to be 11.6%, 14.5% and 12.6% for
xanthan gum, Methocel-CR and Methocel-LVCR respectively.
Figure 5: Active site titration curves of PLS with and without Ac-di-Sol
disintegrant
Tablets loaded with A) PLS alone and B) PLS and 10% Ac-Di-Sol. Each tablet was
dissolved in 900ml of phosphate buffer then left overnight and tested for enzyme
activity. The graph represents the mean±SEM (n=3) absorbance readings at 410 of
titration level of the inhibitor E64 against a fixed concentration of enzyme. The
results indicate that tablet made with 10% Ac-Di-Sol retained 74% enzyme activity
when compared with tablet made with PLS alone.
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